
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:7671f822-d79f-417c-933b-726aad053802,g:6e474740-7dbf-48ca-96d5-f59417a615fa,d:f1c5a63ddb584a0db5ee835d7440b255--><meta http-equiv="Content-Type" content="text/html">


<title>sesn-20211231</title><div style="display:none"><ix:header><ix:hidden><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityCentralIndexKey" id="fact-identifier-0" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF80LTEtMS0xLTI3NzQz_b1cafb70-0236-46f1-927a-370b6de93ff0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001485003</ix:nonnumeric></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="fact-identifier-1" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF82LTEtMS0xLTI3NzQz_c84400d1-661a-4620-9218-07b869194b37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="fact-identifier-2" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF83LTEtMS0xLTI3NzQz_32bcc5a1-6f95-4f5e-80b7-25f21a6959fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AmendmentFlag" id="fact-identifier-3" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV80L2ZyYWc6ZDlkMzZkMWMxNzhhNDU1Mjk0NjE1ZWI0NjViYzk5OWYvdGFibGU6ZTM4YWUxMWU1NDQyNDllMTlmMmMxN2QzNTE3ZjY1MTgvdGFibGVyYW5nZTplMzhhZTExZTU0NDI0OWUxOWYyYzE3ZDM1MTdmNjUxOF84LTEtMS0xLTI3NzQz_dfe63572-2a68-4e09-81e4-5e258c5a6c54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="sesn-20211231.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i92f97507a36b49449af460f15366dc07_I20220221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8984440967a74e3abe0feaafbe79712a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0bf44be67ed84033b15e86e3de2e9088_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c1773348a6144f8927754151f83c6b2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707ab57c26dd479d83f5e95b7b236b54_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i56d90314fd70472fa324352884486d5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8c7f863b2f43bb922132621a9e5cda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc289b8985ac49eb80e78ca2748e4a96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d96180f8d6e4e14983b270d1c6668aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06678b0cf6c04477b759eb44801366df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iededb75b8b3d41909c578b96949d296b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b663c4ccd24528baa91746670f2709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92612297cd0642f585229a45cac68bd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548b9f86fcd54ebe9243040061933762_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8c9ad583a050492ebb28f616a7b10aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdadfe711654c368dce057e84bccbf9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbcc2cd80c644c9bba710067ba49b410_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>sesn:patient</xbrli:measure></xbrli:unit><xbrli:context id="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5fb4126fec9d47d299096c36c0f06713_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i533b84da1d2441468aadec080d52600b_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>sesn:unit</xbrli:measure></xbrli:unit><xbrli:context id="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecee94376694fc393e30898f2ff86a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028ccf70c10c4129a5d10bd536d297b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de469ec0aa540adac05ef95232f5a15_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a34442b9744cb6ae08c574b84b89b9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4609a0afbc594078808154f146946ab1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2453680b1ee48d49d18b917c46773a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b5f8ea9c52413084c453c81936288b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6d609604934e33aa33ca5fc59ce894_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i537b107b17f34737a20ec184a594ae82_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i695006bd273747aeb95e43b893e8b867_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib942d47e8aca410e959ff68b5d97942f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3d4b0f71404387b7089a237b8a5500_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9280baa377514c5b8f3b86112af15bc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8e07a02a314fe58d21f5e73b65454b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2904e8fab3f54e409e119eb43ab1f654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5309a9a57784300b6ab55b4dbfaa087_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f21fbe1815427897b0c6ef0565f88f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33449a16f50d42fda82fa03444b362a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294acb7d2420400b8155b9d8ca59ecac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a8c65717624d59b77914baa103c3bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i461f7c863e8845a1bf3aecbdde6819d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccafbadd781745f8a66ce65217af032c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i208c2cdd76674e1490701e0cd5f02c0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia21f2148bbe744ea9737cdc30b3b639e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34539641171840f78745ef893c090fa7_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib230fbf43aab492384091cb48ddd7af2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea35f777e5264bc1a11c1a5275407d2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9439e6445a46079edce40b074a4cb1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4126ae783347adb9e0ab895ddfa18d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if671dcdd4df94af4a5b9fb93620a325b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e5f96e4bd74651b225f0392286c025_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12322603449433985e3779be27b8eab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d622315903d4829a4f582cfffed067f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425fb86623034e39aa2df73efd925f25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe412d00cd048258c144cd9ed556654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f1e110f756945ed9233483c148b8a4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia43faec616e1467283e341842cd9d4ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i81e534a3b6984e9ca7a46fb4761feeec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>sesn:term</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ie35eeadb1df94fb4940973f807cc6e7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d207bdc8bb44456958770de74b1eabe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">sesn:MassachusettsAndPennsylvaniaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68866b76b55f41f7a5558f5272486883_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16b4c01413da485fa2ac23775d55bed5_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65be1969c492411ba4743fe748508e67_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-11-01</xbrli:startdate><xbrli:enddate>2019-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibfb861283e22418081b9e629463e783d_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-02-01</xbrli:startdate><xbrli:enddate>2021-02-28</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i072f60a137e94674991638220c6ed9ec_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-01</xbrli:startdate><xbrli:enddate>2021-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-06-01</xbrli:startdate><xbrli:enddate>2019-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifd395e5e95f84b618c6884bc4356ae1a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0d8f6abc7e49829c395d208a3436f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id916d4f7441d4a088be2fca47e276005_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc1156bb975047729b334bf2e3fa2fc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3950633399b7426dbfabb5690ebcde85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75020eb264af4e39a21665962a79801e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f92707265b84c70ae5a42f1daae1378_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e1aa3b61664f47b00658c43dfd99fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7858b2eb979a432a96faff9ead49ee39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d44dfab69545dabde220a346b37456_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i877528c6538245119864f9c0c2e52211_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466f369ef0774c33bd619700d8de5551_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringJune2020Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cacad06c024286911346564a7662f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8512f475d73400cabc282795a6d7b65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie688301f8b994be195f31b42f85842e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5371af6c3e495888104af773d10b15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i174b4bb16b14432aaeeb74b47fc49556_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e67736b7d564e33bad48ed099f8786c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic128bae021684a57b2549146b666bae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec6e4d46e284f0594c5222b5698833c_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-10-01</xbrli:startdate><xbrli:enddate>2019-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc016955920f4e64b8ed1852c953e88a_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae3ad21e639847039d2f1b31b55bc122_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:A2018WarrantAmendmentAmendmenttoSecuritiesPurchaseAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-10-01</xbrli:startdate><xbrli:enddate>2019-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5156f45bd4749bab08cc813bedda252_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if90f693a8f7e416ba3582374b0255711_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-06-01</xbrli:startdate><xbrli:enddate>2019-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-05-01</xbrli:startdate><xbrli:enddate>2021-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie05ac20284034cf78dcee6454eac36b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id3fee83c1a8e4b838f1b1364ca7244be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5019c429efc54a3d939b95facb6113a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f275e89a3774f7cbca3fb8965e7a354_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if520d25ca9304b37b3cf574ce10e6659_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8645ab0e887d4a8bbf9664668f155fb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558d72c250fc4f3bb70e9309cb978078_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3408800d9ca34cbc9107500cccfb1efe_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-05-01</xbrli:startdate><xbrli:enddate>2021-05-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i256cad603adc478fbe2bb635d926f6d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i95faf853daed44049bbacea1c98c9719_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4fac383649084445a8d938fea7593c9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="sesn:NetOperatingLossCarryforwardAxis">sesn:IndefiniteMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6573654cd29340309dbe2c811248a720_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda208642281438089144b87cd645d8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6b0fe41f5b4f79ac97691814a89591_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id24bd2e4f3be4ae1b8b83df732484432_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">sesn:NonCapitalLossCarryforwardMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb901b4a5ff4839828a1c82f4bea528_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878819bdb7ce45d78433cd5efbbd8d27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i810bedfc811b413cbc1b773410810321_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7e35e96c504045f9b37880d11d241235_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-08-01</xbrli:startdate><xbrli:enddate>2016-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i672850f3381947678ce8bad19d353cfe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-09-01</xbrli:startdate><xbrli:enddate>2016-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i58f3a5e587554717a5b2e59570cb1b71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592275577a9d4f158b7f51ca29978045_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iced271cdb5d7466d9c7c148965459481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013a145bc60a457a851dd9b22eab7d0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f7872b3f9441f786d65989d956951c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-06-01</xbrli:startdate><xbrli:enddate>2016-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>sesn:period</xbrli:measure></xbrli:unit><xbrli:context id="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-30</xbrli:startdate><xbrli:enddate>2020-07-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i028e8f65759541db8dc7760918e71d52_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-01</xbrli:startdate><xbrli:enddate>2020-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-01</xbrli:startdate><xbrli:enddate>2021-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-11-30</xbrli:startdate><xbrli:enddate>2020-11-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a168b0aa4c647e1997b38ac0934768d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ebdbf98df0844558086fd4461793449_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i34d384e7e18448558f3f9903191a5912_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149c70a89b234c42b784e047bac76480_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-08-05</xbrli:startdate><xbrli:enddate>2021-08-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i544162f98c2149b991bf17fc6d17e544_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">sesn:FacilityinWinnipegManitolaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-08-30</xbrli:startdate><xbrli:enddate>2021-08-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="id7ea168da84a45ce835565576cb8541c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-02-28</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="document"><xbrli:measure>sesn:document</xbrli:measure></xbrli:unit><xbrli:unit id="interview"><xbrli:measure>sesn:interview</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1"></div><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentType" id="fact-identifier-4" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU1_a6c761d5-68cf-42a9-b4fd-faed8f67b32d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="fact-identifier-5" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YTM1Y2EzN2RjNmJhNDZkZmIzY2JjZTExMTkyOTBkM2UvdGFibGVyYW5nZTphMzVjYTM3ZGM2YmE0NmRmYjNjYmNlMTExOTI5MGQzZV8wLTAtMS0xLTI3NzQz_c84a5ab5-a563-43b9-8324-260d98be02d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="fact-identifier-6" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_fcaaccff-09d5-41c6-944d-38736053795e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="fact-identifier-7" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMzI_e7873fde-901b-4d61-8e24-6c478ac53fdb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December&nbsp;31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="fact-identifier-8" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZDQ5NTY0NjEzNWU0NGE2ZDg5MDc2ODBlNTUxY2NhZmUvdGFibGVyYW5nZTpkNDk1NjQ2MTM1ZTQ0YTZkODkwNzY4MGU1NTFjY2FmZV8wLTAtMS0xLTI3NzQz_665c98bd-9886-49ee-bbfc-28ce5b9adce3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&nbsp;<span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityFileNumber" id="fact-identifier-9" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ4_27f8cf8f-da43-42a7-9f73-ddb7fcfeb15b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-36296</ix:nonnumeric></span></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityRegistrantName" id="fact-identifier-10" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU2_62f92caa-d49c-488c-a00c-5ce0e4229385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Sesen Bio, Inc.</ix:nonnumeric></span></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="fact-identifier-11" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTAtMS0xLTI3NzQz_e874d3c3-2832-4288-a249-c96e0c820d36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="fact-identifier-12" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6ZTcyYjU2ZGFlNDhkNDI3ZDg2YWVkYzU1ODM0ZDk0NTkvdGFibGVyYW5nZTplNzJiNTZkYWU0OGQ0MjdkODZhZWRjNTU4MzRkOTQ1OV8wLTEtMS0xLTI3NzQz_eb3b8bb8-4600-4e44-8dbb-3eb3d880e98e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26-2025616</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br>Identification No.)</span></td></tr></tbody></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="fact-identifier-13" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfNA_a773c3f5-b938-438a-b199-ecb2343a65cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245 First Street</ix:nonnumeric></span>, <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="fact-identifier-14" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfOA_b8cf61d2-8655-4c8c-9bd3-340f47b125be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 1800</ix:nonnumeric></span></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="fact-identifier-15" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTE_9b57684f-64a7-40ed-9cbd-543c31abb206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Cambridge</ix:nonnumeric></span>, <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="fact-identifier-16" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTAtMS0xLTI3NzQzL3RleHRyZWdpb246ODA5YmViZjkzM2IxNDM2ZGI0YTRjNGRjNWY1NWQzNDJfMTU_2f4ca687-9b17-4a55-a3ca-0fd87f5f1dbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MA</ix:nonnumeric></span></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="fact-identifier-17" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6NzM4ZDk0ODQ0ZjM3NDUwYzhkOTNmNzFlODZhNGZmN2YvdGFibGVyYW5nZTo3MzhkOTQ4NDRmMzc0NTBjOGQ5M2Y3MWU4NmE0ZmY3Zl8wLTEtMS0xLTI3NzQz_1a2b7128-bfc9-4f63-9770-6d0777d9b378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">02142</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant’s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:CityAreaCode" id="fact-identifier-18" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zNTQ_f2535667-b01b-48f7-af7f-3e630019618d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">617</ix:nonnumeric></span>)&nbsp;<span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:LocalPhoneNumber" id="fact-identifier-19" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU3_c979bd1b-4156-429a-a7fd-76005eac7013" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">444-8550</ix:nonnumeric></span></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:Security12bTitle" id="fact-identifier-20" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTAtMS0xLTI3NzQz_c81bb2cc-7b3a-48af-b584-404fe7af72a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, $0.001 par value</ix:nonnumeric></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:TradingSymbol" id="fact-identifier-21" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTEtMS0xLTI3NzQz_7adb4571-21ef-4baa-8ebe-ccefc9e1c0d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SESN</ix:nonnumeric></span></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="fact-identifier-22" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6Zjc2ZGZhZTBmOTQ2NDRhZjk3MGM1ODA5MzVkYTQzMTkvdGFibGVyYW5nZTpmNzZkZmFlMGY5NDY0NGFmOTcwYzU4MDkzNWRhNDMxOV8xLTItMS0xLTI3NzQz_bf36588e-c49d-4b3d-84fe-c9e0889784c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Nasdaq Global Market</ix:nonnumeric></span></span></td></tr></tbody></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&nbsp;12(g) of the Act:&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-23" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU4_88753fa5-8075-444f-91cb-b7ddd1d8f103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span> ☒</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Act. Yes ☐ <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="fact-identifier-24" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjU5_fa9b099f-96bb-4f9f-8c2f-42f60a5bd0b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span> ☒</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days. <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="fact-identifier-25" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjQ5_74b4a2c7-ecbc-4270-8547-99876a796b8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span> ☒ No ☐</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-26" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUy_dabd669a-3947-4afd-ba9f-1a68902cf177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span> ☒ No ☐</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer," “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tbody><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="fact-identifier-27" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTAtMS0xLTQ1ODk4_06a99ac2-7f5c-482c-b2be-56f0e4225d06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Large accelerated filer</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☒</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&nbsp;reporting&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="fact-identifier-28" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8wLTMtMS0xLTI3NzQz_67a6cd17-d59f-49aa-9e45-6ef3dee348ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="fact-identifier-29" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGFibGU6YjAxMTE5NGY5YmFmNGY5NThiNTgwNzhhMDQ1MmMwYTEvdGFibGVyYW5nZTpiMDExMTk0ZjliYWY0Zjk1OGI1ODA3OGEwNDUyYzBhMV8xLTMtMS0xLTI3NzQz_5b1fec30-ad64-4d0e-b6e3-9d54a9cf535c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="fact-identifier-30" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18zMjUw_39384eab-cfbc-4aac-a40f-7f1c8c860f3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="fact-identifier-31" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4NQ_678a1f04-ef23-46e7-9caf-a58cdcc6cf82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the closing price of the common stock on the Nasdaq Global Market on June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<span><ix:nonfraction unitref="usd" contextref="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-32" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzYy_0836b742-a1f0-4baf-9b93-e5b311f7dc80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">870.7</ix:nonfraction></span>&nbsp;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <span><ix:nonfraction unitref="shares" contextref="i92f97507a36b49449af460f15366dc07_I20220221" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-33" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18yNzc4_3bb00bd5-780a-416b-b9b8-7b5a417a8531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199,463,645</ix:nonfraction></span> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&nbsp;21, 2022</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="fact-identifier-34" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xL2ZyYWc6MTEzODYwMTRjNDQ2NDVjN2IyNDkxNTMzOTQ5N2YzNGMvdGV4dHJlZ2lvbjoxMTM4NjAxNGM0NDY0NWM3YjI0OTE1MzM5NDk3ZjM0Y18xMjA5NDYyNzkwOTI4Ng_9a693323-2ff3-443a-8e84-4bbf582acbdc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant’s Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders ("2022 Proxy Statement"), which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December&nbsp;31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:17pt;margin-top:12pt"><span><br></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form 10-K for the Fiscal Year ended December&nbsp;31, 2021</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_10" tabindex="18">ii</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Factors Summary </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_10" tabindex="18">v</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&nbsp;I</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_16" tabindex="18">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_19" tabindex="18">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresolved Staff Comments.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22" tabindex="18">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Properties.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22" tabindex="18">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22" tabindex="18">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22" tabindex="18">6</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_22" tabindex="18">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&nbsp;II</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_28" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[Reserved.]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_28" tabindex="18">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management’s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_31" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34" tabindex="18">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34" tabindex="18">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_34" tabindex="18">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_37" tabindex="18">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_40" tabindex="18">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_40" tabindex="18">88</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&nbsp;III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Compensation.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Accountant Fees and Services.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">8</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_43" tabindex="18">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&nbsp;IV</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&nbsp;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits and Financial Statement Schedules.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_49" tabindex="18">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K Summary.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_52" tabindex="18">92</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_55" tabindex="18">SIGNATURES</a></span></div></td></tr></tbody></table></div><div style="margin-top:1pt"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to "Sesen," the “Company,” “we,” “us,” and “our” include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future product research or development, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “goals,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” "contemplate," “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the issues identified in the complete response letter (“CRL”) we received from the US Food and Drug Administration (“FDA”) regarding our Biologics License Application (“BLA”) for Vicineum™ for the treatment of bacillus Calmette-Guérin (“BCG”)-unresponsive non-muscle invasive bladder cancer (“NMIBC”); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the concerns identified in the European Medicines Agency’s (“EMA”) Withdrawal Assessment Report related to our marketing authorization application (“MAA”) for Vysyneum™ (the “EMA Withdrawal Report”);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we have a clear understanding of what additional information regarding chemistry, manufacturing and controls ("CMC") is required for potential resubmission of a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, including an additional Phase 3 clinical trial, and that any such future clinical trials can proceed while addressing CMC issues raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation to discuss the study protocol for an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive carcinoma in situ (“CIS”) of the bladder in patients previously treated with adequate or less than adequate BCG in a Type C Meeting with the FDA scheduled for March 28, 2022 (“Type C Meeting”);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to address questions related to clinical matters raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to use the information from the Type A Meetings following the CRL we received regarding our BLA for Vicineum to determine the appropriate path forward with regulators;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to the FDA following the issuance of the CRL by the FDA, and if approved by the FDA, our ability to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resume pursuing regulatory approval of Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union) of BCG-unresponsive NMIBC in the European Union when there is more clarity from the FDA on next steps for Vicineum in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the FDA to understand next steps for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the EMA to understand next steps for Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the European Union;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future loss and accumulated deficit levels;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulties and expenses associated with obtaining and maintaining regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union and other non-US jurisdictions, and the labeling under any approval we may obtain;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position and estimated cash burn rate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we will have sufficient future cash flows from additional geographic regions outside the US to support the value of our goodwill and EU indefinite-lived, acquired in-process research and development ("IPR&amp;D");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any remeasurement of contingent consideration liability in the future;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any potential impairment to our goodwill and indefinite-lived intangible asset in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to raise substantial additional capital to fund our operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our pre-clinical studies and clinical trials in the United States and other non-US</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on third parties, including contract research organizations (“CROs”) in the conduct of our pre-clinical studies and clinical trials, including an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to Qilu Pharmaceutical Co., Ltd. (“Qilu”) for the production of Vicineum drug substance and drug product, and our reliance on Qilu to perform under our agreement with Qilu;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic operating plan to sublicense Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to business development partners in all regions outside the US, including the European Union, to earn a potential combination of upfront, milestone, and royalty payments, and the business development partner to bear the majority of regulatory and commercialization costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics (“TFPT”) platform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that Vicineum may work via a dual mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that there may be potential for a synergistic effect when Vicineum is given in combination with checkpoint inhibitors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount and timing of milestone and royalty payments pursuant to our out-license agreements and OUS business development partnership agreements, including our license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), (the “Roche License Agreement”) and our exclusive license agreement with Qilu for the development, manufacture and commercialization of Vicineum in China, Hong Kong, Macau and Taiwan ("Greater China");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to regain compliance with Nasdaq’s minimum bid price requirement;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to seek additional OUS business development partnerships; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies and products that are or become available.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the issues raised in the CRL we received from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not determine a viable path forward for continued clinical development of Vicineum, which would prevent us from resubmitting a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not achieve profitable operations or access needed capital;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays or difficulties related to the continued clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including delays in clinical trial sites receiving the supplies and materials needed to conduct clinical trials, difficulties </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or treating patients in active trials due to COVID-19 or otherwise;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including an additional Phase 3 clinical trial for Vicineum, or any of our other product candidates, may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other non-US regulatory authorities or otherwise produce favorable results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not obtain marketing approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may not gain market acceptance for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market opportunity for Vicineum may be limited to those patients who are ineligible for established therapies or for</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whom prior therapies have failed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience issues or delays with third-party disposition, labelling and packaging of clinical supply of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors may discover, develop or commercialize products before, or more successfully than, we do;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to comply with all regulatory requirements or experience unanticipated problems with our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may recognize impairment of our goodwill and indefinite-lived intangible asset; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not meet the Nasdaq minimum bid price requirement during any compliance period or in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be granted relief from delisting from Nasdaq if necessary; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described in “Item 1A. Risk Factors” and “Item 5. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are investigational biologics undergoing clinical development and have not been approved by the FDA, EMA or other comparable non-US regulatory authorities. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. A Type C Meeting has been scheduled with the FDA for March 28, 2022 in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the “Company,” “Sesen,” “we,” “us,” and “our” include Sesen Bio, Inc. and its subsidiaries.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summarizes the principal factors that make an investment in us speculative or risky, all of which are more fully described in “Item 1A. Risk Factors” below. This summary should be read in conjunction with “Item 1A. Risk Factors” and should not be relied upon as an exhaustive summary of the material risks facing our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the exception of specified regulatory, development and commercial milestones under our out-licensing and OUS business development partnership agreements, we currently have no source of revenue and may never become profitable.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of Vicineum </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our lead product candidate, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we are unable to obtain marketing approval for or successfully commercialize our lead product candidate, either alone or through an out-license or an OUS business development partnership, or experience significant delays in doing so, our business could be materially harmed. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If additional clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-US regulatory authorities or do not otherwise produce favorable results, we will be unable to complete the development and potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We  may not be able to develop a more sensitive bioanalytical assay which is needed for the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may cause undesirable side effects, serious adverse events or have other properties that could delay or halt clinical trials, delay or prevent its regulatory approval, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to obtain regulatory authority approval of any proposed names for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and any failure or delay associated with such naming approval may adversely impact our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing approval process is expensive, time-consuming and uncertain. As a result, we cannot predict when or if we, or any licensees or partners, will obtain marketing approval to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or any other product candidate.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to obtain marketing approval in non-US jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in non-US jurisdictions.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will depend on Qilu for the development and commercialization of Vicineum in Greater China.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on third parties to formulate and manufacture Vicineum, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our products or result in higher product costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and affect the prices we may obtain.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 coronavirus could adversely impact our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could materially adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and certain of our officers have been named as defendants in three pending securities class action lawsuits and three related shareholder derivative lawsuits have been filed. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to regain compliance with the listing requirements of the Nasdaq Global Market, our common stock may be delisted from the Nasdaq Global Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_16"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;1. &nbsp;&nbsp;&nbsp;&nbsp;Business.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. In October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA’s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a Type A Meeting with the FDA to discuss questions related to CMC raised in the CRL (the “CMC Type A Meeting”). During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum (the “Clinical Type A Meeting”), which the FDA confirmed will be required for a potential resubmission of a BLA. The trial design may include these elements:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators’ choice of intravesical chemotherapy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trial may include both patients who have received adequate BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients who have received less than adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA encouraged us to submit the final results from the Phase 3 VISTA trial for Vicineum with a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the items we expect to be discussed in the Type C Meeting is the patient population for the additional Phase 3 clinical trial, which may be different than the patient population studied in previous clinical trials for Vicineum for the treatment of NMIBC in two primary ways. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, the additional Phase 3 clinical trial may include patients with only non-muscle invasive carcinoma in situ (CIS) of the bladder, and may not include patients with only papillary disease of the bladder. This change would lead to a smaller overall patient population than previously studied, as some of our past clinical trials of Vicineum in NMIBC have included patients with CIS or high-grade papillary disease of the bladder. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the additional Phase 3 clinical trial may include patients who have received less than adequate BCG in addition to those who have received adequate BCG, per the FDA’s guidance. Receipt of less than adequate BCG could be due to (i) failure of, or intolerance to, a BCG therapy prior to reaching the FDA’s definition of adequate BCG or (ii) supply shortages of BCG, among other reasons. This change would lead to a larger patient population than previously studied, as past clinical trials of Vicineum in NMIBC only included patients who had previously been treated with adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential changes related to the additional Phase 3 clinical trial for Vicineum will be discussed at the upcoming Type C Meeting with the FDA scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our TFPT Platform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current product candidates are based on our proprietary TFPT platform and are focused on addressing areas of unmet medical need in cancer. Our novel TFPTs have been designed to overcome the efficacy and safety challenges of existing ADCs and are being developed for both local and systemic-administration. Our TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through our proprietary recombinant one-step, microbial manufacturing process. Our TFPT platform uses protein binding antibody fragments, which include Fabs, single chain variable domains ("ScFvs"), and non-covalent scFv dimers ("diabodies"), derived from the domains of antibodies that confer antigen recognition. We select antibody fragments for our product candidates depending upon the target therapeutic indication. We target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and that also have limited expression in normal cells. For local administrations, we utilize an immunogenic cytotoxic protein payload designed to both target cancer cells and promote a heightened local immune response against the tumor. For systemic-administrations, we use deBouganin, a plant-derived, protein payload of reduced immunogenic potential that we believe can be repeatedly administered via infusion without the generation of an efficacy-limiting immune response against the payload.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Locally-administered TFPTs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our TFPTs with immunogenic cytotoxic protein payloads for tumors that can be targeted locally rather than systemically. Local administration allows for the TFPT to reach the tumor without being cleared by the immune system, which enables us to maximize the concentration of TFPTs directly to tumors. Our locally-administered TFPT Vicineum, which is our lead product candidate in development for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, contains a targeting antibody binding domain that is designed to bind to EpCAM, a protein over-expressed in many cancers. This binding domain is genetically fused to a truncated form of exotoxin A ("ETA"), which is an immunogenic cytotoxic protein payload that is produced by the bacterial species Pseudomonas. This product candidate is designed to bind to EpCAM on the surface of cancer cells. The TFPT-EpCAM complex is subsequently internalized into the cell and, once inside the cell, the TFPT is cleaved by a cellular enzyme to release the cytotoxic protein payload, thus enabling cancer cell killing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe that our TFPTs designed for local administration may not only directly kill cancer cells through targeted delivery of a cytotoxic protein payload, but also potentiate an anti-cancer therapeutic immune response. This immune response is believed to be triggered by the immunogenic cell death of the cancer cells due to our payload's mechanism of action and the subsequent release of tumor antigens and the immunologically active setting created by the nature of the cytotoxic protein payloads. We believe that this immune response may also enhance the action of checkpoint inhibitors, that require a pre-existing immune response for maximum efficacy.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced locally-administered TFPT product candidate is Vicineum, in development for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and recurrent, locally advanced or metastatic EpCAM-expressing squamous cell carcinoma of the head and neck ("SCCHN"). This TFPT is not, however, suitable for systemic-administration over multiple doses because the body’s immune system would recognize and eliminate foreign proteins, such as ETA, prior to their reaching targeted cancer cells.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemically-administered TFPTs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also utilize our TFPTs with a de-immunized payload where systemic-administration is required. Our systemically-administered TFPTs are built around deBouganin. Since the body’s immune system naturally recognizes and attempts to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eliminate foreign proteins, we designed our systemically-administered TFPTs with a deBouganin payload to avoid inducing an immunogenic response. DeBouganin is constructed by mutating the immunogenic T-cell epitopes from bouganin so that they are not recognized as foreign by the immune system. However, we also believe that deBouganin may enhance the action of checkpoint inhibitors as a result of the promotion of a local tumor immune response following the death of cancer cells. Our systemically-administered product candidate is VB6-845d for the treatment of multiple types of EpCAM-positive solid tumors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Differentiated Approach to Targeted Therapies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our TFPT platform will address many challenges experienced with existing ADCs. The basic construct for our TFPTs and existing ADCs is similar as each is comprised of a targeting domain that specifically binds to cancer cells and delivers a cytotoxic payload. However, existing ADCs have been associated with limitations that we believe are addressed by our TFPTs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Existing ADC Approaches to Treating Tumors </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;We believe existing ADCs have the following fundamental efficacy and safety challenges:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Deliver insufficient drug to tumors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Existing ADCs utilize full-length antibodies, which, due to their large size, have a reduced ability to penetrate tumors, thereby potentially reducing their efficacy.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Inability to kill a broad array of cancer cells within a tumor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsets of cancer cells within tumors may have mechanisms to resist and not be responsive to the cytotoxic payloads, or small molecule chemotherapies, used in existing ADCs.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Off-target toxicities due to unstable chemical linkage between targeting antibody and cytotoxic payload. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing ADCs utilize chemical linkage strategies to join antibodies to small molecule cytotoxic payloads. While in the circulatory system, these chemical linkages can break and release free cytotoxic payloads in the circulation. These free small molecule cytotoxic payloads are not targeted and cannot discriminate between dividing cancer cells and non-cancerous cells, thus resulting in increased off-target toxicities.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Limited combination therapy potential. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events may limit the potential utility of existing ADCs in combination therapies with immune checkpoint inhibitors which have their own adverse events, including immune-related adverse events.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Complex and challenging manufacturing process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The multi-step manufacturing process of existing ADCs creates a non-homogeneous product that limits efficacy and drives greater costs than those estimated for our manufacturing process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantages of our TFPT Platform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;We believe our TFPTs offer the following key advantages:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Deliver a greater amount of drug to tumors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TFPTs are designed using smaller targeting proteins that have an increased ability to exit the circulatory system and have binding properties designed to enable deeper penetration into targeted tumors, and we believe this will increase efficacy.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Ability to kill a broader array of cancer cells within a tumor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel cytotoxic payloads consist of proteins rather than small molecule cytotoxic payloads. We believe the larger size of our cytotoxic protein payloads helps circumvent multi-drug resistance mechanisms that can make certain cancer cells resistant to small molecule cytotoxic payloads. By contrast to existing ADCs, which employ cytotoxic payloads that inhibit cellular replication and are effective at killing rapidly proliferating cancer cells, our cytotoxic protein payloads inhibit protein synthesis and are designed to kill not only rapidly proliferating, but also slowly growing cancer cells including tumor progenitor cells/cancer stem-like cells.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Increase safety due to a more stable linkage between targeting protein and cytotoxic payload. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our single protein molecules are designed to remain intact until they reach the inside of the cancer cell and to not release free cytotoxins into the circulatory system, thereby minimizing off-target toxicity.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Promote a therapeutic immune response. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the potent TFPT toxin-mediated killing of cancer cells in this immunologically active setting leads to the efficient presentation of cancer antigens to the immune system, thereby promoting an anti-tumor cellular immune response. Our locally-administered TFPTs utilize an immunogenic cytotoxic payload that we believe promotes a heightened immune response in the local tumor environment.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Potential combination with checkpoint inhibitors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the potential effect of checkpoint inhibitors, which are antibodies that promote the action of anti-tumor T-cells by blocking inhibitory ligand/receptor interactions that include PD-1 and PD-L1, may be enhanced when used in combination with other agents. We believe that, by mediating specific killing of tumor cells and promoting anti-tumor immune responses, our TFPTs, while potentially effective on their own, may complement checkpoint inhibitors. In particular, we believe that the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use of our cytotoxin payload ETA, which induces immunogenic cell death, may facilitate the presentation of tumor cell surface antigens following the death of cancer cells, thereby providing a tumor immune response to enhance the action of checkpoint inhibitor therapies.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Utilize a simpler and more efficient manufacturing process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary recombinant one-step manufacturing process creates a homogeneous product that we believe will improve efficacy and result in lower manufacturing costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to designing, engineering, developing and commercializing TFPTs to identify and address oncology indications that suffer from a high unmet medical need. The key elements of our strategy are as follows:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Obtain regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum to the FDA for the treatment of BCG-unresponsive NMIBC, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022 in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Maximize the commercial potential Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We own exclusive, worldwide rights to Vicineum and we have out-licensed the rights to Vicineum in Greater China, the Middle East and North Africa region (“MENA”) and Turkey. If Vicineum receives marketing approval from the FDA for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we plan to pursue commercialization strategies that maximize the value of Vicineum in the United States by partnering with a contract sales organization. Based on our market research, we believe Vicineum has an innovative profile with a high possibility that patients, healthcare professionals and payors will be advocates for its use for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which we believe represents a significant commercial opportunity. We believe that we will be able to effectively communicate differentiating characteristics and key attributes of Vicineum to patients, physicians and payors, with the goal of establishing favorable reimbursement as well as a favorable formulary status in targeted urology practices. Additionally, we believe that our plans to partner with a contract sales organization should allow us to address the urologists-initiated treatment market for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States in an efficient and effective way. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expand on the value of Vicineum through strategic partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we intend to build a North American specialty urology sales force to market the product in the United States. Outside the United States, we will continue to seek additional business development partners with urology expertise by selectively partnering with pharmaceutical and biopharmaceutical companies when we believe that a partner could bring additional resources and expertise to maximize the value of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. In 2020 and 2021, we entered into license agreements to support such commercialization efforts outside the United States for Greater China, MENA and Turkey.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Explore opportunities in combination therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We plan to continue discussions with potential partners that utilize technologies whose mechanism of action could be complementary to our TFPT platform. These technologies include, but are not limited to, checkpoint inhibitors, immune modulators and other immuno-oncology agents. In June 2017, we entered into a Cooperative Research and Development Agreement (“CRADA") with the National Cancer Institute ("NCI") for the development of Vicineum in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab for the treatment of NMIBC. Vicineum is believed to work via a dual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells. Because of this second mechanism, there may be potential for a synergistic effect when given in combination with checkpoint inhibitors. Under the terms of the CRADA, this hypothesis is being tested by the NCI in Phase 1 clinical trial in patients with BCG-unresponsive NMIBC to evaluate the safety, efficacy and biological correlates of Vicineum in combination with durvalumab (“NCI Trial”). On September 10, 2021, preliminary results from an interim analysis of 12 patients in the NCI Trial (“Interim Analysis”) were presented at a conference hosted by the American Urological Association. Enrollment in the Phase 1 clinical trial is ongoing. Based on the Interim Analysis, the combination of Vicineum and durvalumab has been generally well-tolerated with no new safety signals emerging (no Grade 4 or 5 treatment-related adverse events) and has a similar safety profile compared to both agents used individually. The Interim Analysis also indicated a 3-month complete response rate of 42% (5/12) and a 12-month complete response rate of 17% (2/12). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of Vicineum for the treatment of SCCHN and of VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, the commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for Vicineum for the treatment of SCCHN and for VB6-845d.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we are focused exclusively on the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and have deferred further development of our other product candidates. The following table sets forth our current development stage programs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><img alt="sesn-20211231_g1.jpg" style="height:586px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g1.jpg" src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g1.jpg"></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the Treatment of Non-Muscle Invasive CIS of the Bladder in Patients Previously Treated with Adequate or Less Than Adequate BCG</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing Vicineum, oportuzumab monatox, for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Vicineum is given via intravesical administration directly into the bladder. Vicineum utilizes an immunogenic cytotoxic protein payload that is a truncated form of ETA produced by the bacterial species </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Vicineum also includes an anti-EpCAM ScFv targeting domain that is required to deliver the ETA into EpCAM-expressing cancer cells. The toxicity to non-cancerous bladder cells is minimized due to their not having EpCAM over-expressed on their surface. In August 2018, we received Fast Track designation from the FDA for Vicineum for the treatment of BCG-unresponsive NMIBC. The FDA has conditionally accepted the proprietary brand name VICINEUM™ for our product candidate, oportuzumab monatox.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most cancers that form in the bladder are transitional cell carcinomas that derive from the transitional cell lining of the bladder. Transitional cell carcinoma of the bladder can be characterized as either high-grade or low-grade. Low-grade bladder cancer often occurs</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the lining of the bladder, but rarely invades the muscular wall of the bladder or spreads to other parts of the body and is unlikely to be fatal. High-grade bladder cancer commonly occurs in the bladder, has a strong tendency to invade the muscular wall of the bladder, spread to other parts of the body and is more likely to result in death. Bladder cancer is also divided into muscle-invasive and non-muscle invasive, based on invasion of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">muscularis propria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is the thick muscle deep in the bladder wall. Muscle-invasive disease is more likely to spread to other parts of the body.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three forms of high-grade NMIBC: Ta, a papillary tumor in the innermost layer of the bladder lining; T1, a papillary tumor that has started to grow into the connective tissue beneath the bladder lining; and CIS, flat lesions of the transitional cell lining of the bladder. Papillary tumors are generally low-grade with low risk of progression, although about two to nine percent are high-grade, with a moderately high risk of progression to muscle-invasive bladder cancer. Evaluable CIS tumors are always high-grade, with a worse prognosis than papillary tumors, as such CIS tumors are more aggressive, with a higher probability of progression to muscle-invasive disease. Furthermore, the incidence of CIS in conjunction with Ta or T1 tumors results in a higher risk of recurrence and progression. About 75% to 85% of bladder cancers are non-muscle invasive. Of these, Ta tumors account for about 70%, T1 tumors account for about 20% and CIS lesions account for about 10%.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to World Cancer Research Fund International figures, bladder cancer is the tenth most common cancer diagnosed worldwide and the second most common malignancy of the genitourinary system, which refers to cancers of the urinary system of men and women and the reproductive organs of men.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, there were an estimated 573,000 new cases of bladder cancer diagnosed and 213,000 deaths worldwide, according to data from the Global Cancer Observatory. The 5-year global prevalence of bladder cancer, or the number of individuals with bladder cancer in a 5-year period, is estimated at 1.7 million individuals. The most recent data from the NCI's Surveillance, Epidemiology and End-Result Program ("SEER") estimated that approximately 84,000 new cases of bladder cancer would be diagnosed in 2021 and there would be approximately 17,000 deaths due to bladder cancer in the United States during 2021. Based on a 2014 publication in Current Opinion in Urology, among cancers in the United States, bladder cancer has the highest per-patient treatment costs, with an estimated overall cost of approximately $4.0 billion annually and has the highest overall cost among the elderly. Based on our assessment of the market, the treatment paradigm has remained the same since those figures were generated, and we believe the cost of care has increased.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMIBC makes up 75% to 85% of all bladder cancers. The high recurrence rate and ongoing invasive monitoring requirement of bladder cancers are the key contributors to the economic and human toll of this disease. Bladder cancer occurs predominantly in older patients (about nine of the ten people with bladder cancer are over the age of 55 years). The median age at diagnosis is approximately 73 years of age. Overall, the five-year survival rate for bladder cancer in the United States is 77%. While the five-year survival rates are 98% for stage zero and 88% for stage one NMIBC, once the cancer becomes invasive, the rates drop dramatically with five-year survival rates of 63%, 46% and 15% for stage two, three and four muscle invasive bladder cancers, respectively. We are targeting patients with non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our initial target market includes the approximately 6,000 patients in the US diagnosed annually, including those patients with non-muscle invasive CIS of the bladder previously treated with adequate or less than adequate BCG. We would expect that, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved by the FDA, patients would receive treatment until the earlier of 2 years and disease recurrence.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Approaches to Treatment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the initial treatment of Ta or T1 is transurethral resection of the bladder tumor ("TURBT") followed by BCG treatment. For CIS, whether or not TURBT is an option, BCG is the standard of care. BCG is a live attenuated strain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium bovis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a diminished virulence in humans. Since BCG works by utilizing an immune/inflammatory mechanism, BCG is generally initiated two to four weeks after TURBT, allowing the urothelium to heal and lowering the risk of systemic infection. When high-grade bladder tumors have been completely resected, BCG is used as adjuvant therapy to prevent recurrence. In patients with residual disease after resection, BCG helps to eradicate residual disease and delay progression. The BCG regimen consists of an induction phase followed by a maintenance phase. The induction phase involves six consecutive once-weekly instillations of the drug into the bladder. The maintenance phase involves three consecutive once-weekly instillations repeated every three to six months for at least one year. The response rate to a single induction phase of BCG is 60% to 70% with an additional 30% to 50% of the non-responders becoming responders following a second induction phase. However, BCG’s failure rate for all responders is estimated to be as high as 50% within the first 12 months of treatment and 90% within five years. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For patients who received BCG and whose disease is now BCG-unresponsive, surgical removal of the bladder, or a radical cystectomy has been recommended due to the risk of progression to muscle invasive disease, which greatly reduces a patient’s prognosis. Radical cystectomy is a complex surgery associated with a mortality rate of 8% within six months of surgery. The surgery also entails a number of short-term risks including bleeding and/or clots, infections, bowel obstruction, bowel perforation, peritonitis and injury to the urethra. More than 25% of radical cystectomy patients require hospital readmission for surgery-related complications within 90 days following surgery. The impact of radical cystectomy is life-altering, with major lifestyle changes, including incontinence and sexual dysfunction, and daily issues related to management of the external bag for urine collection.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Keytruda was approved by the FDA in January 2020 for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy and is the only approval of Keytruda in the NMIBC space. Keytruda has been on the market for the treatment of BCG-unresponsive CIS (+/- Ta/T1) patients since January 2020. In 2009, Endo Pharmaceuticals Inc.'s Valstar (valrubicin) was re-launched in the United States for the treatment of BCG-refractory CIS bladder cancer in patients for whom radical cystectomy is not an option. Valstar is administered directly into the bladder once a week for six weeks. Due to drug resistance and toxicities, Valstar has had limited clinical utility. Other than Keytruda and Valstar, there are no other approved therapies for BCG-unresponsive CIS bladder cancer. However, there are various other intravesical product candidates in development for the treatment of NMIBC, including product candidates developed by FerGene Inc. (Adstiladrin/nadofaragene firadenovec (rAd-IFN/Syn3)), AADi, LLC (ABI-009), ImmunityBio (Anktiva/N-803 in combination with BCG), Theralase Technologies Inc. (TLD-1433), Janssen (Erdafitinib and TAR-200) and CG Oncology (CG0070). In addition, systemically-administered checkpoint inhibitors are being evaluated for the treatment of NMIBC including products developed by Bristol-Myers Squibb (Opdivo alone or in combination with BCG +/- BMS986205), F. Hoffmann-La Roche AG (Tecentriq) and AstraZeneca (Imfinzi). Another route of administration for checkpoint inhibitor is currently being evaluated by Pfizer with the subcutaneous administration of Sasanlimab (PF-06801591) for the treatment of BCG-unresponsive NMIBC patients. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Update</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a CMC Type A Meeting with the FDA. During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that any of these future trials can proceed while addressing CMC issues raised in the CRL. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Clinical Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA encouraged us to include the Vista Trial data in a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA previously conditionally accepted the name Vicineum for our product candidate, oportuzumab monatox, in the United States, this approval is subject to further and final review by FDA upon potential resubmission of a BLA. If the FDA objects to our proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">European Union</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we submitted a MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC under the EMA’s centralized procedure. On March 31, 2021, we were informed that the Committee for Medicinal Products for Human Use of the EMA had conditionally accepted the proprietary brand name Vysyneum for our product candidate, oportuzumab monatox, in the European Union. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA’s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the EMA previously conditionally accepted the name Vysyneum for our product candidate, oportuzumab monatox, in the European Union, this approval is subject to further and final review by the EMA upon potential resubmission of the MAA. If the EMA objects to our proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the EMA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”) pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, to develop, manufacture and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in Greater China. The Investigational New Drug application (“IND”) for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the partnership agreement between Sesen Bio and Qilu Pharmaceutical, the trial is being run at the sole cost of Qilu Pharmaceutical.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region (20 countries in the Middle East and North Africa). No submission for registration has taken place in any of the countries as approvals are contingent on FDA or EMA approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with EİP Eczacıbaşı İlaç Pazarlama A.Ş., to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. No submission for registration has taken place in either region as approvals are contingent on FDA or EMA approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Review</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 we disclosed that our Board of Directors (the “Board”) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the “Review”). The Review took place over the course of five months, involved full cooperation from our management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. It is now complete. As a result of the Review, the Board continues to fully support our current management team and believes no changes or amendments relating to our prior disclosures to the Securities and Exchange Commission (“SEC”) or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. We intend to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Proposed Phase 3 Clinical Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prior Phase 3 Clinical Trial – VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, through our subsidiary Viventia, commenced our single-arm, multi-center, open-label Phase 3 clinical trial ("VISTA Trial') in patients with BCG-unresponsive NMIBC who have received adequate BCG and whose disease is now BCG-unresponsive, and for whom the then-current standard of care was a radical cystectomy in the third quarter of 2015 in the United States and Canada. Based on safety and efficacy data observed with the longer 12-week induction in our Phase 2 clinical trial, the FDA agreed to our plan to employ more frequent dosing in the VISTA Trial, in which the primary endpoints were complete response ("CR") and duration of response ("DoR") in patients with CIS whose disease is BCG-unresponsive. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA’s guidance. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary and secondary endpoints for the VISTA Trial were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dose</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 mg of Vicineum (in 50 mL of saline)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total enrollment</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 patients, including 93 CIS patients whose disease is BCG-unresponsive</span></div></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary endpoints</span></div></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive; and</span></td></tr><tr style="height:23pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kaplan-Meier estimate of DoR for BCG-unresponsive CIS patients who experience a CR at 3 months (post-induction).</span></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with CIS were considered to have a CR if at the time of any disease status evaluation (per protocol every 13 weeks or any unscheduled evaluation) there was no evidence of high-grade disease (CIS, high-grade Ta or any grade T1 disease) or disease progression (e.g., to muscle invasive disease). Low-grade disease was not considered a treatment failure in these patients, and they could remain on study treatment following TURBT.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:7pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.134%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.485%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="7" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secondary endpoints</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Event-free survival in all patients;</span></td></tr><tr style="height:30pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CRR at 6, 9, 12, 15, 18, 21 and 24 months in patients with CIS whose disease is BCG-unresponsive;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to cystectomy in all patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to disease recurrence in papillary patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PFS in all patients;</span></td></tr><tr style="height:15pt"><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OS in all patients; and</span></td></tr><tr style="height:27pt"><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Safety and tolerability of Vicineum therapy in all patients.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exploratory endpoint</span></div></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate biomarkers that may be associated with response or disease progression or treatment failure, which may include, for example, EpCAM status, tumor subtype morphology, furin levels in tumor cell endosomes, presence of a glycosaminoglycan coat and presence of receptors that could impede a host anti-tumor immune response, such as PD-L1.</span></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment (under 2018 FDA guidance on treatment of NMIBC, adequate BCG is defined as at least one of the following (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course):</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and DoR for BCG-unresponsive CIS patients who experience a CR.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate†:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></tbody></table></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">†Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%), all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1 and 2 Clinical Trials</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 Clinical Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We initiated an open-label, dose-escalating Phase 1 clinical trial of Vicineum for the treatment of BCG-unresponsive NMIBC in September 2004 at 22 sites in Canada. We enrolled 64 patients with high-grade Ta or T1 tumors with or without CIS (17 of which had CIS) and who had previously received at least one treatment of BCG. The Phase 1 clinical trial was designed to assess safety and determine the maximum tolerated dose, and the recommended Phase 2 dose. The secondary objective was to explore the anti-tumor activity of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eight dose levels were initially evaluated, ranging from 0.1 to 10.56 mg, and given once weekly for six consecutive weeks. Each dose was administered by instillation and held for two hours prior to voiding. Safety data from each dose cohort was evaluated after three weeks of treatment before proceeding to the next dose cohort. A maximum tolerated dose was not reached; therefore, additional escalations through 13.73 mg, 17.85 mg, 23.20 mg and 30.16 mg were undertaken. No dose-limiting toxicities were reported and no maximum tolerated dose was reached in these additional dose-escalations. Vicineum was generally well-tolerated at each of these escalated doses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CR was defined in this Phase 1 clinical trial as non-positive urine cytology and either normal cystoscopy or abnormal cystoscopy with negative biopsy. Of the 64 patients enrolled, only 61 were considered to be evaluable for efficacy as two patients were excluded from the analysis due to an absence of BCG treatment prior to this Phase 1 clinical trial, and there was one unrelated death for whom no final tumor assessment was obtained. Evidence of clinical efficacy, as defined by a CR, was achieved by 24 of the 61 randomized patients (39%). Only three of the 17 patients (18%) treated in the 0.1-&lt;1 mg/dose range were CRs. In contrast, seven of the 14 patients (50%) treated in 1.0-&lt;10 mg/dose range and 14 of the 30 patients (46.7%) treated in the ≥10 mg/dose range experienced CRs at the three-month assessment. Of the patients with CIS, five of the 17 patients (29%) achieved a CR, while non-recurrence was observed in seven of the 16 patients with T1 (43.8%) and 12 of the 28 patients with Ta (42.8%). This Phase 1 clinical trial was completed in April 2006.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 Clinical Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on our Phase 1 clinical trial conducted in Canada, we submitted the IND for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA in August 2005, and we initiated an open-label Phase 2 clinical trial of Vicineum in March 2007 at 20 sites in Canada and the United States. We enrolled 46 patients with CIS (with or without Ta or T1) who had previously received at least one treatment of BCG. Of the 46 patients enrolled, 27 patients (58.7%) had received at least two treatments of BCG. The Phase 2 clinical trial was designed to determine the tolerability and explore the potential for clinical benefit from Vicineum. Clinical benefit was defined in this Phase 2 clinical trial as a CR or no evidence of disease at the three-month evaluation. A CR was defined in this Phase 2 clinical trial as no histological evidence of disease and negative urine cytology. Any cases with no histological evidence of disease on initial biopsy but atypical or suspicious urine cytology were also considered CRs only if they remained negative after being evaluated with repeat biopsy, directed and random. A patient was considered to have a durable CR if that patient obtained a CR and remained disease-free for a period of at least 12 months from initiation of treatment. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dosing regimen for our Phase 2 clinical trial included an induction phase followed by a maintenance phase, consisting of three weekly treatments and then nine weeks of no treatment repeated every three months for at least one year. There were two treatment groups in this Phase 2 clinical trial. Treatment Arm A consisted of 23 patients, of which 22 were ultimately evaluable as one patient violated eligibility requirements early in this Phase 2 clinical trial. Twenty-two patients in the induction phase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received six consecutive once-weekly instillations of 30 mg of Vicineum. At the three-month assessment, patients with residual disease but no disease progression-where disease progression was defined as being muscle invasive-were eligible for either a second induction phase or a maintenance phase, which consisted of three consecutive once-weekly instillations repeated every three months for at least one year. Of the 13 patients who did not achieve a CR at the three-month assessment, nine patients elected additional treatment. From these nine, two became CRs after receiving maintenance dosing. Treatment Arm B was added to evaluate a longer induction cycle using the same dose. In Treatment Arm B, 23 patients in the induction phase received 12 consecutive once-weekly instillations of 30 mg Vicineum. At the three-month assessment, the combined CR rate for both treatment arms was 40%. At the 12-month assessment, the CR rate in Treatment Arm A was 13%, but 17% in Treatment Arm B. Of those patients who did not achieve a CR at the three-month assessment, 73% had either a reduction in tumor size or did not experience further tumor growth.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data below shows the percentage change in surface area of cancer within the bladder, based on bladder mapping data utilizing cystoscopy in 40 patients. The following charts demonstrate the responses in this Phase 2 clinical trial in Treatment Arm A and Treatment Arm B:</span></div><div style="margin-bottom:6pt;text-align:center"><img alt="sesn-20211231_g2.jpg" style="height:342px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g2.jpg" src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g2.jpg"></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:12pt;text-align:center"><img alt="sesn-20211231_g3.jpg" style="height:425px;margin-bottom:5pt;vertical-align:text-bottom;width:638px" data-src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g3.jpg" src="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-20211231_g3.jpg"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Phase 2 clinical trial was completed in September 2009.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near the completion of this Phase 2 clinical trial in 2009, Valstar was re-launched in the United States for the treatment of BCG-refractory CIS bladder cancer in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. However, because physicians were not widely prescribing Valstar to their patients and it was not an approved therapy in Europe, this disrupted our originally designed clinical path of a head-to-head pivotal Phase 3 clinical trial of Vicineum against Valstar. Due to the uncertainty of the standard of care in this space, our efforts were put on hold until a clear clinical path was established. In May 2013, the FDA co-sponsored a public workshop where it evaluated potential trial designs for the development of therapies for NMIBC and specifically provided regulatory guidance supporting the idea that a single-arm clinical trial could provide sufficient evidence of benefit if the results were robust. The panel suggested it is acceptable to include high-risk papillary patients without CIS in a clinical trial with CIS patients because the clinical management and outcome if left untreated is considered to be the same. In September 2014, we conducted an end of Phase 2 meeting with the FDA and, consistent with our interactions with the FDA during this meeting, refocused our resources to commence an open-label, non-randomized Phase 3 clinical trial of Vicineum in BCG-unresponsive NMIBC, which ended up being our Phase 3 VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety data</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our safety data from 110 patients in our Phase 1 and Phase 2 clinical trials support further development of Vicineum for the treatment of NMIBC BCG failures. There were no Grade 4 or Grade 5 serious adverse events that were considered by the clinical investigators to be related to Vicineum during the Phase 1 and Phase 2 clinical trials of Vicineum for the treatment of NMIBC BCG failures. There was one Grade 5 serious adverse event, or death, which was determined by the clinical investigator to be unrelated to Vicineum. The most common reported treatment-related adverse events were an abnormally frequent passage of small amounts of urine, blood in the urine and painful urination, the majority of which were considered to be mild or moderate in severity. No patients discontinued treatment due to a Vicineum-related adverse event during the Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan. We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (“MENA”) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing Vicineum for the prevention and treatment of cancers including, but not limited to, NMIBC and various sub-types of NMIBC (the “Field”) in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize Vicineum in the Field in Greater China. A joint development committee was established between us and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to Vicineum in Greater China. We and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which we will manufacture or have manufactured and supply Qilu with all quantities of Vicineum necessary for Qilu to develop and commercialize Vicineum in the Field in Greater China until we have completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for Vicineum has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a licensed product-by-licensed product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party’s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to us in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8&nbsp;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9&nbsp;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in the MENA region (20 countries in the Middle East and North Africa). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement. </span></div><div><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with EIP pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the license agreement, we are entitled to receive an upfront payment of $1.5 million. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the Treatment of SCCHN</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum (formerly referred to as Proxinium in publications, focused on this clinical setting), is also being developed as a treatment for patients with recurrent, locally advanced or metastatic EpCAM-expressing SCCHN who have received at least one prior platinum-based chemotherapy regimen. To treat SCCHN, Vicineum is administered via injection directly into the targeted tumor, or intratumoral injection. Vicineum for the treatment of SCCHN has received Orphan Drug Designation from the FDA and the EMA and Fast Track designation from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our two Phase 1 clinical trials encompassing 44 patients treated with Vicineum, a complete resolution or reduction in size of injected tumors was observed in 16 of the 30 evaluable patients (53%) with EpCAM-expressing tumors as assessed by the investigators’ clinical measurements, the investigators' overall assessment including qualitative changes and assessment of available radiologic data. An additional 27% of evaluable patients had stable disease and, therefore, the results indicate an overall tumor control rate of approximately 80%. In addition, three out of the four patients with CRs of injected tumors had regression or complete resolution of adjacent non-injected lesions. Vicineum was generally well-tolerated during the clinical trials. Dose-limiting toxicity in the Phase 1 clinical trials was transaminase elevation in liver enzymes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our clinical trials involving Vicineum for the treatment of SCCHN, we also observed some stabilization, partial reduction and complete resolution of non-injected tumors. We believe that TFPT mediated killing of cancer cells occurs via a mechanism known as ICD, which is known to enhance the presentation of neoantigens to the immune system. We believe that this, combined with the immunogenic nature of our cytotoxic protein payload creates a heightened immune response, wherein naive cytotoxic T-cells are stimulated by antigen presenting cells, such as dendritic cells, presenting tumor cell surface antigens following the death of cancer cells. We believe that this anti-tumor response may complement checkpoint inhibitor therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our clinical trials involving Vicineum for the treatment of SCCHN, there were no Grade 5 serious adverse events that were considered by the clinical investigator to be related to Vicineum. The serious adverse events (Grade 3 and Grade 4) that were reported in the clinical trials of Vicineum for the treatment of SCCHN and were considered to be possibly, probably or definitely related to treatment consisted of abnormal tumor growth, anorexia, cancer pain, decrease in red blood cells, difficulty swallowing, elevated calcium levels, facial pain, fatigue, high blood sugar, influenza like illness, injection site pain, liver function abnormalities, low albumin level, low sodium concentration, nausea, rash, swelling, tumor hemorrhage and tumor necrosis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the combined Phase 1 (VB4-101 and VB4-101A) and Phase 2 (VB4-845-01-IIA) studies, seven subjects died during the clinical trials of Vicineum for the treatment of SCCHN, but none of the deaths were deemed to be Vicineum-related. Out of the four patients who discontinued treatment due to liver function test abnormalities, 2 subjects were in study VB4-101 and 2 were subjects were in VB4-101A). Four subjects withdrew from the clinical trials. Three of the four subjects withdrew at their request and one of the four subjects withdrew at the request of the investigator.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 (VB4-845-01-lllA) VB4-845-01-lllA was a randomized, multicentre therapeutic confirmatory study evaluating the safety and efficacy of Vicineum plus BSC versus BSC alone in the treatment of patients with advanced SCCHN who had received at least 1 anti-cancer treatment regimen for advanced disease. One hundred and sixty-six of the approximately 292 patients were enrolled at 75 sites. The primary endpoint for the study was overall survival. A total of 166 patients had been randomized into the study. Of the 166 patients, 82 were randomized to the Vicineum treatment plus BSC arm and 84 patients were randomized to the BSC arm.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VB4-845-01-IIIA was terminated early due to a corporate decision unrelated to safety or efficacy. At the time of study termination, survival data was available for 133 of 142 patients that had been randomized. A total of 66 were enrolled on the BSC arm and 67 enrolled in the Vicineum plus BSC treatment arm. Of the 66 BSC patients enrolled in the BSC arm, there were 43 documented deaths in this treatment arm; the date of death was known for 36 patients and unknown for 7. Of the patients treated with Vicineum, 41 deaths were documented with the date of death known for 37 patients and unknown for 4. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim safety data was available for 132 of 139 patients that had been randomized. One hundred and eleven patients reported at least 1 AE. Thirty-six patients reported 205 adverse events (AEs) that were treatment related. Most of the treatment-related AEs were mild to moderate in severity. Of the 205 treatment-related AEs reported, there were 23 Grade 3 events and 2 Grade 4 events. There were no Grade 5 related AEs reported. The 2 related Grade 4 events were 2 occurrences of tumour necrosis in 1 patient; both were considered probably related to the treatment. Most related AEs resolved on their own and did not require additional treatment. Others were treated with concomitant medications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four patients in the Vicineum plus BSC group reported Grade 3 increases in both ALT and AST. One patient reported a Grade 3 increase in ALT and another patient reported a Grade 3 increase in AST. All of the Grade 3 increases in ALT/AST occurred in the Vicineum plus BSC group. No Grade 4 increases in ALT/AST were reported. In 1 patient, Vicineum was discontinued due to liver function test abnormalities, in 1 patient Vicineum was interrupted due to liver function test abnormalities and in the last patient Vicineum was discontinued due to disease progression.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of Vicineum for the treatment of SCCHN in order to focus our efforts and our resources on our ongoing development and, if approved, the commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for the development of Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or exclusively license worldwide rights to our Vicineum for the treatment of SCCHN intellectual property portfolio that provides for an unextended patent term until 2036. See ‘‘Our Intellectual Property’’ below for additional details.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VB6-845d</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors. VB6-845d is a TFPT consisting of an EpCAM targeting Fab genetically linked to deBouganin, which is administered by intravenous infusion. DeBouganin acts by inhibiting protein synthesis and helps circumvent multi-drug resistance mechanisms. EpCAM is over-expressed on the cell surface of many solid tumors, including breast, colorectal, gastric, lung, ovarian and prostate. EpCAM overexpression has been shown to be involved in promoting malignant progression. In addition, EpCAM overexpression is associated with increased tumor grade, disease progression, increased proliferative phenotypes and diminished survival. EpCAM is also a cancer stem cell marker. A Phase 1 clinical trial conducted with VB6-845, the prior version of VB6-845d, revealed no clinically relevant immune response to the deBouganin payload. Five of seven patients (71.4%) maintained stable disease (meaning no change in tumor size from baseline) after one completed cycle of treatment (four weeks). Two patients had decreases in target tumor size, and one subject who continued treatment through a third cycle (12 weeks) maintained stable disease. Interim safety data from our Phase 1 clinical trial was consistent with expectations for the study population of patients with advanced solid tumors and the anticipated effects of targeted biological therapies containing immunogenic sequences.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the antibody responses directed against the Fab seen in our Phase 1 clinical trial conducted in Russia and in the country of Georgia, we de-immunized the Fab portion of VB6-845 to create VB6-845d. In April 2016, we submitted an IND to the FDA in preparation of initiating a Phase 1/2 clinical trial of VB6-845d in patients with EpCAM-positive cancers in the United States.&nbsp;The IND was withdrawn in July 2016 after we received initial feedback from the FDA indicating that they had identified hold and non-hold deficiencies that needed to be addressed.&nbsp;In December 2016, we submitted a request for a pre-IND meeting to&nbsp;seek input on the manufacturing,&nbsp;nonclinical and clinical plans for VB6-845d prior to resubmitting an IND. In February 2017, the FDA provided guidance on our manufacturing and nonclinical plans for VB6-845d. Overall, we believe that our pre-clinical data and the interim Phase 1 clinical data support further clinical investigation of VB6-845d to explore whether it may fulfill the significant unmet medical need in the treatment of patients with EpCAM-positive solid tumors. Specifically, we believe that VB6-845d has potential to be a first-in-class TFPT capable of providing clinical benefit in these difficult to treat patient populations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our TFPTs utilizing our de-immunized deBouganin payload may be enhanced if combined with checkpoint inhibitors. We believe that deBouganin’s potential effect on cancer cells could promote an immunogenic response that may enhance the action of checkpoint inhibitors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deferred further development of VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We are also exploring collaborations for VB6-845d.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or exclusively license worldwide rights to our VB6-845d intellectual property portfolio that provides for an unextended patent term until at least June 2025 and, method of treatment patents and applications for VB6-845d are granted, until at least 2036. See ‘‘Our Intellectual Property’’ below for additional details.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMC</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2020, we and Leiden University Medical Center (“LUMC”) agreed to the co-development of an imaging agent (the “Imaging Agent”) that is comprised of an antibody fragment of Vicineum™, and an imaging molecule supplied by LUMC. The Imaging Agent is designed to delineate tumor from normal tissue during surgery so that the tumor margin is clearly visible, thereby helping to ensure clear margins after surgical excision of cancerous tissue. A Phase 1/2 clinical trial of the Imaging Agent was successfully completed by LUMC with favorable tolerability and demonstrated tumor detection, which we believe further supports the targeting specificity of Vicineum. We signed an agreement with LUMC whereby we have an option to obtain an exclusive, worldwide license to any intellectual property related to the Imaging Agent. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBI-031 - Out-License Agreement with Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into the Roche License Agreement, pursuant to which we granted Roche an exclusive, worldwide license, including the right to sublicense, to our patent rights and know-how related to our monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by us (collectively, the “Licensed Intellectual Property”). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (the “Roche Licensed Product”) and pursue ongoing patent prosecution, at its cost. At the time of the Roche License Agreement, EBI-031, which was derived using our previous AMP-Rx platform, was in pre-clinical development as an intravitreal injection for diabetic macular edema and uveitis.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received from Roche an upfront license fee of $7.5 million in August 2016 upon the effectiveness of the Roche License Agreement following approval by our stockholders, and Roche agreed to pay up to an additional $262.5 million upon the achievement of specified regulatory, development and commercial milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5 million is payable to us for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5 million in development milestones, the next of which is $30.0 million for initiation of the first Phase III study, (ii) $50.0 million in regulatory milestones and (iii) $75.0 million in commercialization milestones. In September 2016, Roche paid us the first development milestone of $22.5 million as a result of the IND application for EBI-031 becoming effective on or before September 15, 2016.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, a $20 million milestone was achieved due to Roche initiating a Phase II clinical trial. We invoiced Roche $20 million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $20 million was received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional amounts of up to $65.0 million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two “option periods” during which Roche may elect to make a one-time payment to us and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing ("Initiation") in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay us $135.0 million within 30 days after Roche’s exercise of such buy-out option and receipt of an invoice from us, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay us, within 30 days after Roche’s exercise of such buy-out option and receipt of an invoice from us, $265.0 million, which amount would be reduced to $220.0 million if none of our patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either we or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to us or by providing written notice if we are debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. We may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of 12 months where Roche is not conducting sufficient development activities with respect to the products made from the Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Roche reported that it started a multi-center, non-randomized, open-label, multiple ascending dose Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intravitreal EBI-031 monotherapy in patients with diabetic macular edema. Further, Roche reported that once determined, an extended cohort will be dosed with the optimal dose of EBI-031 while another arm of the trial will test EBI-031 in combination with Lucentis (ranibizumab) following intravitreal administration in patients with diabetic macular edema.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Roche reported that it started enrollment of two Phase 2 clinical trials in patients with diabetic macular edema (“DME”). The first clinical trial, BP43445 (NCT05151731), is a multicenter, randomized, double-masked, active comparator-controlled trial to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of EBI-031 administered intravitreally in patients with DME. The second clinical trial, BP43464 (NCT05151744), is a combination trial to assess the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of EBI-031 with ranibizumab (an anti-vascular endothelial growth factor inhibitor) compared with ranibizumab alone in DME patients. For both trials, only one eye will be chosen as the trial eye and the duration of the trial will be 52 weeks.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or exclusively license approximately 13 families of patents and applications, which generally relate to our TFPT-based product candidates and evolving our platform of targeting agents, cytotoxins (such as deBouganin) and linker technologies. As our product candidates evolve through clinical development, we continue to monitor advancements and bolster patent coverage where possible.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidate - Vicineum </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclusively license two families under a license agreement with the University of Zurich ("Zurich") (the "Zurich License Agreement") which, among other things, include composition of matter claims directed to EpCAM antibody chimeras, EpCAM antibody chimera-cytotoxin conjugates, and their potential use in treating bladder and head and neck cancer. These families claim all or portions of Vicineum, as well as methods of treating bladder and head and neck cancer consist of issued patents in the United States, Europe, Canada, China, Israel and Japan and also include pending applications in the United States. The expiry dates of the patents in this family are April 2024 and June 2025, subject to any applicable patent term adjustment or extension that may be available on a jurisdictional basis. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Zurich portfolio, we own two issued US patents related to Vicineum. The expiry date of these patents is February 2029, subject to any applicable patent term extension that may be available on a jurisdictional basis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have patent families relating to treatment regimens using Vicineum that include issued patents in the United States, Australia and Japan and patent applications in Canada, Europe and Hong Kong. These patents will expire in 2036. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a license agreement with Micromet AG ("Micromet") (the "Micromet License Agreement"), now part of Amgen, Inc., which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA Ireland Limited ("XOMA") (the "XOMA License Agreement") which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. See "Our Vicineum License Agreements" below for additional information.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBI-031 and our Legacy Product Candidates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wn the following families of patents and patent applications related to EBI-031 and our legacy product candidates. As of February&nbsp;28, 2022, our patent portfolio includes the following patents and applications related to our legacy product candidates:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of anti-VEGF therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a provisional application directed to compositions and methods for increasing the retention of RGD therapeutic agents in the eye which, if converted and granted, is expected to expire in 2038.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of our knowledge based on correspondence received on February 25, 2022, the followi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng families are owned by us, and licensed to Roche pursuant to the Roche License Agreement dated June 10, 2016:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents covering the IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including IL-6 antibody EBI-029, filed in the United States, Australia, China, Japan, Korea, New Zealand, Russia and South Africa, that expire in November 2033; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications covering the IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including IL-6 antibody EBI-029, filed in Brazil, Canada, Europe, India, Mexico, United States and Singapore, and, if granted, are expected to expire in 2033; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents covering IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including the IL-6 antibody EBI-031, in Australia, Austria, Belgium, Bulgaria, Chile, China, Columbia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Indonesia, Ireland, Italy, Japan, Lithuania, Macau, Malaysia, Mexico, Morocco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Slovakia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United States and United Kingdom, that expire in November 2035; </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications covering IL-6 antagonistic anti-IL6 monoclonal antibodies and active fragments thereof, including the IL-6 antibody EBI-031, having applications pending or to be filed in Algeria, Bahrain, Brazil, Canada, Costa Rica, Europe, Egypt, India, Israel, Korea, New Zealand, Oman, Peru, Philippines, Qatar, Saudi Arabia, Singapore, Thailand, United Arab Emirates, United States and Vietnam, and, if granted, are expected to expire in 2035; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications in China, Europe, Japan and the United States, each corresponding to a United States provisional application covering the IL-6 antibody EBI-031 formulation, which, if granted, are expected to expire in 2037.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Vicineum License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview and Exclusivity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with the University of Zurich ("Zurich") which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same. These patents cover some key aspects of Vicineum. Upon receipt of the CRL regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, we became obligated to pay $0.5&nbsp;million in a milestone payment to Zurich. We are also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by us to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. For the year ended December 31, 2020, we recorded an expense of $0.3&nbsp;million for the achievement of the development milestone related to the submission of our BLA for Vicineum with the FDA. For the year ended December 31, 2021, we recorded an expense of $0.5&nbsp;million for the regulatory milestone related to receipt of the CRL from the FDA in August 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights, at our sole expense, while Zurich is afforded reasonable opportunities to review and comment on such activities. If appropriate, we shall apply for an extension of the term of any licensed patent where available, for example, in at least the United States, Europe and Japan. In the event of any substantial infringement of the patent rights, we may request Zurich to take action to enforce the licensed patents against third parties. If the infringing activity is not abated within 90 days and Zurich has elected not to take legal action, we may bring suit in our own name (and in Zurich’s name, if necessary). Such action will be at our own expense and Zurich will have the opportunity to join at its own expense. Recoveries from any action shall generally belong to the party bringing the suit, but (a) in the event that we bring the action and an acceptable settlement or monetary damages are awarded, then Zurich will be reimbursed for any amount that would have been due to Zurich if the products sold by the infringer actually had been sold by us, or (b) in the event a joint legal action is brought, then the parties shall share the expense and recoveries shall be shared in proportion to the share of expense paid by the respective party. Each party is required to cooperate with the other in litigation proceedings at the expense of the party bringing the action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Zurich License Agreement expires as of the expiration date of the last patent to expire within the Zurich patent rights. We are currently projecting an expiration date for the United States licensed patents in June 2025, subject to any applicable patent term extension that may be available on a jurisdictional basis. Zurich has the right to terminate the Zurich License Agreement if we breach any obligation of the agreement and fail to cure such breach within the applicable cure periods. We have the right to terminate the Zurich License Agreement at any time and for any reason by giving 90 days written notice to Zurich.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants us nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. These patents cover some key aspects of Vicineum. Under the terms of the License Agreement with Micromet, as of December 31, 2021, we may be obligated to pay up to €2.4&nbsp;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&nbsp;million at exchange rates in effect on December 31, 2021). We are also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, we are required to pay to Micromet an annual license maintenance fee of €50,000 (approximately $56,625 at exchange rates in effect as of December 31, 2021), which can be credited towards any royalty payment we owe to Micromet. We recorded an expense of €0.7&nbsp;million ($0.9&nbsp;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of our BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. We recorded an expense of €0.5&nbsp;million ($0.6&nbsp;million) related to the submission of the MAA to the EMA for Vysyneum™ in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Micromet, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by Micromet, we may be required, upon the request of Micromet and at Micromet’s expense, to provide reasonable assistance to Micromet with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Micromet License Agreement expires as of the expiration of any royalty obligations under the License Agreement. Either party has the right to terminate the Micromet License Agreement if the other party fails to comply with any of its material obligations under the Micromet License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with XOMA Ireland Limited ("XOMA") which grants us non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. These patents and related know-how cover some key aspects of Vicineum. Under the terms of the License Agreement with XOMA, we are required to pay up to $0.25&nbsp;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, we anticipate that these milestones may be triggered by Vicineum’s clinical development pathway. We are also required to pay a 2.5% royalty on the net sales for products incorporating XOMA’s technology, which includes Vicineum. We have the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Rights</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XOMA, at its sole expense, is responsible for the patent filing, prosecution and maintenance activities pertaining to the patent rights. In any patent enforcement action initiated by XOMA, we may be required, upon the request of XOMA and at XOMA’s expense, to provide reasonable assistance to XOMA with respect to such enforcement action.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the XOMA License Agreement expires as of the expiration of any royalty obligations under the XOMA License Agreement. Either party has the right to terminate the XOMA License Agreement if the other party fails to comply with any of its material obligations under the XOMA License Agreement and fails to cure such non-compliance within the applicable cure periods.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a 31,100 square foot manufacturing, laboratory, warehouse and office facility in Winnipeg, Manitoba. We have three 15-liter fermenters, one 30-liter fermenter, one 150-liter fermenter, one 500-liter fermenter and one 1,500-liter fermenter. Our classified fermentation suite and post-production processing capabilities were dedicated to producing our pre-clinical study and clinical trial batches of Vicineum. In September 2017, we completed the manufacturing of all Vicineum necessary for our Phase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 VISTA Trial and for our CRADA with the NCI. In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to outsource future Vicineum clinical and commercial to third-party manufacturers.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fujifilm and Baxter </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the “Fujifilm MSA”) for the manufacturing process and technology transfer of Vicineum drug substance production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter (the “Baxter CSA”) for the manufacturing process and technology transfer of Vicineum drug product production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (“PPQ”) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be highly comparable to our supply of Vicineum produced at our Winnipeg facility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work ("SOW #11") with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2022 and 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use Vicineum produced by Fujifilm and Baxter for any future clinical trials of Vicineum, including the additional Phase 3 clinical trial, and, if approved, for commercial supply.</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is highly competitive, subject to rapid and significant technological change and has a strong emphasis on developing proprietary products. While we believe that our next generation TFPT platform, knowledge, experience and scientific resources provide us with competitive advantages, we face competition from both large and small pharmaceutical and biotechnology companies, academic institutions and other research organizations; specifically with companies, institutions and organizations that are actively researching and developing products that attach proprietary cell-killing payloads to antibodies for targeted delivery to cancer cells. Our competitors include, but are not limited to:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">NMIBC: Merck &amp; Co., Inc. (Keytruda/pembrolizumab and BCG) (approved drugs), Endo Pharmaceuticals Inc. (Valstar/valrubicin) (approved drug), FerGene Inc. (Adstiladrin/nadofaragene firadenovec (rAd-IFN/Syn3)), Medical Enterprises Ltd. (Synergo RITE plus mitomycin C), Aadi, LLC (ABI-009), ImmunityBio (Anktiva/N-803 in combination with BCG), CG Oncology. (CG0070), Theralase Technologies Inc. (TLD-1433 photodynamic compound), Bristol-Myers Squibb (Opdivo/nivolumab with or without BCG or BMS-986205), F. Hoffmann-La Roche AG (Tecentriq/Atezolizumab), AstraZeneca (Imfinzi/durvalumab with or without BCG or External Beam Radiotherapy), Eli Lilly and Company (Gemcitabine) and Telormedix SA (Vesimune); Pfizer, Inc. (Sasanlimab);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SCCHN: Bristol-Myers Squibb Company (Opdivo/nivolumab) (approved drug), Eli Lilly and Company, and Merck (Erbitux, pembrolizumab) (approved drugs);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple types of solid tumors: Amgen Inc. (Panitumumab) (approved drug), Bayer AG and Onyx Pharmaceuticals (Sorafenib) (approved drug), Bristol-Myers Squibb Company, Eli Lilly and Company, and Merck (Erbitux) (approved drug), F. Hoffmann-La Roche AG (Bevacizumab) (approved drug), Genentech, Inc. (Bevacizumab, Erlotinib and Trastuzumab) (approved drugs), Pfizer, Inc. (Sunitinib) and Trion Research GmbH (Removab); and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition to competition from alternative treatments, we may also face competition from products that are biosimilar to, and possibly interchangeable with, our product candidates. Biosimilar products are expected to become available over the coming years. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then and insurers or other third-party payors may encourage or even require the use of lower priced biosimilar products. Even if our treatments receive market authorization, they may not be listed on the formularies of payors (public or private insurers) or reimbursed. This may impact the uptake of the drug as a treatment option for patients and/or the price at which the drug can be sold at. Further, if the drug is reimbursed it may be at a narrower indication than the full scope of market authorization.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical studies, conducting clinical trials, obtaining regulatory approval and marketing than we do. These competitors are also active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Moreover, specialized biologics, biopharmaceutical and biotechnology companies may prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or cheaper than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our product’s entry. We believe the factors determining the success of our programs will be the drug design, effectiveness against multi-drug resistance mechanisms, efficacy, safety, price and convenience of our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biologics company, we are subject to extensive regulation by the FDA, and other national, supranational, state, provincial and local regulatory agencies. We are also subject to extensive regulation by similar governmental authorities in other countries in which we operate. In the United States, the Federal Food, Drug, and Cosmetic Act ("FDCA") and the Public Health Service Act ("PHSA") and their implementing regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, post-approval monitoring and reporting, labeling, storage, record keeping, distribution, import, export, advertising and promotion of our product candidates. Although the discussion below focuses on regulation in the United States, we anticipate seeking approval to market our products in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope to that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the EU are addressed in a centralized way through the European Commission following the opinion of the EMA, but country-specific regulation in the individual European Union Member States ("EU Member States") remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent compliance with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate supranational, federal, state, provincial, local and non-US statutes and regulations require the expenditure of substantial time and financial resources, and we may not be successful in any given jurisdiction.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">US Government Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, drug products are regulated by the FDA under the FDCA and other laws, including, in the case of biologics, the PHSA. Drug products are also subject to other federal, state and local statutes and regulations. A failure to comply with any applicable requirements during the product development, approval, or post-approval periods may lead to administrative or judicial sanctions, including, among other things, the imposition by the FDA or an institutional review board ("IRB") of a hold on clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, or administrative, civil and/or criminal investigation, penalties or prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, all of our product candidates are regulated by the FDA as biologics. Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the United States. Manufacturers of biologics may also be subject to state and local regulation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps required before a biologic may be marketed in the United States generally include:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of pre-clinical studies, animal studies and formulation studies, some in compliance with the FDA’s current Good Laboratory Practices ("GLP") regulations, and the Animal Welfare Act administered and enforced by the United States Department of Agriculture;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND to support human clinical testing, which must become effective before human clinical trials may commence;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an IRB before each trial may be initiated at each clinical site;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled clinical trials under protocols submitted to the FDA and reviewed and approved by each IRB, conducted in accordance with federal regulations and current Good Clinical Practices ("GCP") to establish the safety, purity and potency of the biologic for each targeted indication;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission of a BLA to the FDA;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facilities at which the biologic is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of a BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-clinical Studies</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the pre-clinical studies must comply with federal regulations and requirements, including, as applicable, GLP and the Animal Welfare Act. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The FDA evaluates the IND to determine whether there is an adequate basis for starting the product candidate in initial clinical trials, and the IND must become effective before human clinical trials may be commenced. Additional pre-clinical studies may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If during this 30-day period the FDA does not raise any concerns or issues that must be addressed prior to the commencement of clinical trials or does not impose a clinical hold, the IND becomes effective 30 days following the FDA’s receipt of the IND and the clinical trial proposed in the IND may begin.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators. Clinical trials are subject to extensive regulation and must be conducted in compliance with (i) federal regulations, (ii) GCP standards, which set safeguards to protect the rights and health of patients and establish standards for conducting, recording data from, and reporting results of clinical trials, and (iii) protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if any. Non-US studies conducted under an IND generally must meet the same requirements that apply to studies being conducted in the United States. The informed written consent of each study patient must be obtained before the patient may begin participation in the clinical trial. The study protocol, study plan, and informed consent forms for each clinical trial must be reviewed and approved by an IRB for each clinical site, and the study must be conducted under the auspices of an IRB for each trial site. Investigators and IRBs must also comply with FDA regulations and guidelines, including those regarding oversight of study patient informed consent, complying with the study protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial program for a product candidate is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases are as follows:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 involves the initial introduction of a product candidate into humans. Phase 1 clinical trials are typically conducted in healthy human subjects, but in some situations are conducted in patients with the target disease or condition. These clinical trials are generally designed to evaluate the safety, metabolism, pharmacokinetic ("PK") properties and pharmacologic actions of the product candidate in humans, the side effects associated with increasing doses and, if possible, to gain early evidence of effectiveness. During Phase 1 clinical trials, sufficient information about the product candidate’s PK properties and pharmacological effects may be obtained to inform and support the design of Phase 2 clinical trials. The total number of participants included in Phase 1 clinical trials varies, but is generally in the range of 20 to 80;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 includes the controlled clinical trials conducted to obtain initial evidence of effectiveness of the product candidate for a particular indication(s) in patients with the target disease or condition, to determine dosage tolerance and optimal dosage, and to gather additional information on possible adverse side effects and safety risks associated with the product candidate. Phase 2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population, usually involving no more than several hundred participants; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical trials are clinical trials conducted in an expanded patient population at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product candidate has been obtained and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the product candidate and to provide an adequate basis for regulatory approval. Phase 3 clinical trials usually involve several hundred to several thousand participants. In most cases, the FDA requires two adequate and well controlled Phase 3 clinical trials to demonstrate the efficacy of the product candidate, although a single Phase 3 clinical trial with other confirmatory evidence may be sufficient in certain instances.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decision to suspend or terminate development of a product candidate may be made by either a health authority body, such as the FDA, by an IRB, or by a company for various reasons and during any phase of clinical trials. The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. In some cases, clinical trials are overseen by a data safety monitoring board ("DSMB"), which is an independent group of qualified experts organized by the trial sponsor to evaluate at designated points in time whether or not a trial may move forward and/or should be modified. These decisions are based on unblinded access to data from the ongoing trial and generally involve determinations regarding the benefit-risk ratio for study patients and the scientific integrity and validity of the clinical trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are requirements for the registration of certain clinical trials of product candidates on public registries, such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the submission of certain information pertaining to these trials, including clinical trial results, after trial completion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, a sponsor submits extensive information about the product candidate to the FDA in the form of a BLA to request marketing approval for the product candidate in specified indications.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologics License Applications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain approval to market a biologic in the United States, a marketing application must be submitted to the FDA that provides data establishing the safety and effectiveness of the product candidate for the proposed indication. The application includes all relevant data available from pertinent pre-clinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a product candidate, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product candidate to the satisfaction of the FDA. For example, in November 2016, the FDA issued a draft guidance document on developing new drugs and biologics for treating BCG-unresponsive NMIBC and finalized this guidance in February 2018. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, the fees payable to the FDA for reviewing an original BLA, as well as annual program fees for approved products, can be substantial, subject to certain limited deferrals, waivers and reductions that may be available. The FDA has 60 days from receipt of a BLA to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, in which case the BLA will have to be updated and resubmitted. The FDA’s PDUFA review goal is to review 90% of priority BLA applications within </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months of filing and 90% of standard applications within 10 months of filing, but the FDA can and frequently does extend this review timeline to consider certain later-submitted information or information intended to clarify or supplement information provided in the initial submission. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not complete its review or approve a BLA within these established goal review times. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, and potent for its intended use, and whether the product is being manufactured in compliance with cGMP. The FDA may also refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured or the facilities that are significantly involved in the product development and distribution process and will not approve the product candidate unless cGMP compliance is satisfactory. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the Pediatric Research Equity Act, certain BLAs must include an assessment, generally based on clinical trial data, of the safety and effectiveness of the biological product in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either at a company’s request or by its own initiative, including waivers for certain products not likely to be used in a substantial number of pediatric patients. Products with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process required.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a CRL. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. If and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of a BLA, the FDA may issue an approval letter. The FDA’s PDUFA review goal is to review such resubmissions within two or six months of receipt, depending on the type of information included. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval and deny approval of a resubmitted BLA. FDA approval of any application may include many delays or never be granted. An approval letter authorizes commercial marketing of the product candidate with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy ("REMS") to help ensure that the benefits of the product outweigh the potential risks. REMS can include Medication Guides, communication plans for healthcare professionals, and also may include elements to assure safe use ("ETASU"). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the biologic. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the biologic’s safety, purity, or potency, which can be costly.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or a supplemental BLA before the change can be implemented. A supplemental BLA for a new indication typically requires clinical data similar to that in the original application, and the FDA generally uses the same procedures and actions in reviewing a supplemental BLA as it does in reviewing a new BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance. In addition, new or modified government requirements, including from new legislation, may be established that could delay or prevent regulatory approval of our product candidates under development or affect our ability to maintain product approvals we have obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Market Exclusivity</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), the FDA can approve products that are biosimilar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required by a full BLA. To be biosimilar, a biological product must be highly similar to an already-licensed FDA biological product, or reference product and can have no clinically meaningful differences in safety, purity and potency from the reference product. An interchangeable biosimilar product must meet additional standards for interchangeability and, if approved, may be substituted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the reference product. At this juncture, it is unclear whether any product biosimilar deemed ‘‘interchangeable’’ by the FDA, in fact, will be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After an innovator has marketed its product for four years, a manufacturer may file an application for approval of a ‘‘biosimilar’’ version of the innovator product. However, although an application for approval of a biosimilar may be filed four years after approval of the innovator product, qualified innovative biological products receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA under the PHSA. The BPCIA also provides a mechanism for innovators to enforce the patents that protect innovative biological products and for biosimilar applicants to challenge the patents. Such patent litigation may begin as early as four years after the innovative biological product is first approved by the FDA. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be licensed by the FDA until the end of the exclusivity period. The first biologic product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against any other determinations of interchangeability to the reference product for the lesser of (i) one year after first commercial marketing of the interchangeable biosimilar product, (ii) 18 months after approval of the interchangeable biosimilar product if there is no legal challenge, (iii) 18 months after the resolution in the interchangeable biosimilar product applicant’s favor of a lawsuit challenging the reference product’s patents, and (iv) 42 months after approval of the interchangeable biosimilar product if a lawsuit is ongoing within the 42-month period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of the BPCIA are conceptually similar to those of the Hatch-Waxman Act, which established abbreviated pathways for the approval of generic drugs. The FDA has published several guidance documents providing direction on developing and obtaining approval of biosimilar product candidates. The guidance documents to date explain, among other things, that the FDA will approve a biosimilar product if there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency. A determination of biosimilarity may be based upon: (1) analytical studies showing that the biological product is highly similar to, with no clinically meaningful differences from, the reference product, (2) animal studies, including toxicity assessments, and/or (3) a clinical trial or trials (including assessment of immunogenicity and PKs) that are sufficient to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is licensed and for which licensure is sought for the biological product. The FDA recommends that sponsors use a stepwise approach to developing the data and information needed to support biosimilarity. At each step, the sponsor should evaluate the extent of residual uncertainty of biosimilarity that remains and incorporate the FDA’s advice for additional studies to address remaining uncertainty. To meet the higher standard for interchangeability the sponsor must demonstrate, in addition to biosimilarity, that the proposed biological product can be expected to produce the same clinical result and, if administered more than once to any given patient, the safety risk and potential for diminished efficacy associated with switching between the proposed biological product and the reference product is not greater than continuing to use the reference product. A biological product that is determined to be interchangeable may be substituted for the reference product without the intervention of the prescribing healthcare provider. In March 2015, the FDA approved the first biosimilar product under the BPCIA, and it has approved other biosimilar products since then. If any of our product candidates is approved by the FDA, the approval of a biosimilar to one of our products could have a material impact on our business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than our products, if approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Purple Book," first published by the FDA in September 2014, lists biological products, including any biosimilar and interchangeable biological products licensed by the FDA under the PHSA. The lists include the date a biological product was licensed under Section 351(a) of the PHSA and whether the FDA evaluated the biological product for reference product exclusivity under Section 351(k)(7) of the PHSA. The Purple Book will also enable a user to see whether a biological product licensed under Section 351(k) of the PHSA has been determined by the FDA to be biosimilar to or interchangeable with a reference biological product. Biosimilar and interchangeable biological products licensed under Section 351(k) of the PHSA will be listed under the reference product to which biosimilarity or interchangeability was demonstrated.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of biologics through standards and regulations for, among other things, direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet. A biologic cannot be promoted before it is approved. After approval, promotion of a biologic can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers are permitted, however, to prescribe products for unapproved uses (also known as ‘‘off-label’’ uses) – that is, uses not approved by the FDA and therefore not described in the product’s labeling – because the FDA does not regulate the practice of medicine. However, FDA restricts manufacturers’ communications regarding unapproved uses. Broadly speaking, a manufacturer may not promote a product for an unapproved use, but may engage in non-promotional, balanced communication regarding unapproved uses under specified conditions. Failure to comply with applicable FDA requirements and restrictions in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this area may subject a company to adverse publicity and enforcement action by the FDA, the United States Department of Justice ("DOJ"), or the Office of Inspector General of the United States Department of Health and Human Services ("HHS"), as well as state authorities. Such enforcement action could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After regulatory approval of a product is obtained, a company is required to comply with a number of post-approval requirements. For example, as a condition of BLA approval, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the product. In addition, as a holder of an approved BLA, a company would be required to report adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of its products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of our product candidates is required to comply with applicable FDA manufacturing requirements contained in the FDA’s cGMP regulations. Biologic manufacturers and other entities involved in the manufacture and distribution of approved biologics are also required to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. The FDA and certain state agencies periodically inspect manufacturing facilities to assess compliance with cGMP and other laws. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery of problems with a product after approval may result in serious and extensive restrictions on a product or the manufacturer or holder of an approved BLA, as well as lead to potential market disruptions. These restrictions may include suspension of product manufacturing until the FDA is assured that quality standards can be met, continuing oversight of manufacturing by the FDA under a ‘‘consent decree,’’ which frequently includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. Other potential consequences include interruption of production, issuance of warning letters or other enforcement letters, refusal to approve pending BLAs or supplements to approved BLAs, product seizure or detention, and injunctions or imposition of civil and/or criminal penalties.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation, correction, and reporting of any deviations from cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that a company may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, such as additional post-market clinical trials to assess new safety risks or distribution-related or other restrictions under a REMS.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Extension</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of the FDA approval of our product candidates, some of our US patents may be eligible for limited patent term extension. The provisions of the Hatch-Waxman Act permit a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office ("USPTO"), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for patent term extension for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other countries also provide for patent term extensions or similar extensions of patent protection for biologic products. For example, in Japan, it may be possible to extend the patent term for up to five years and in Europe, it may be possible to obtain a supplementary patent certificate that would effectively extend patent protection for up to five years.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act ("FCPA") prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any non-US official, political party or candidate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the purpose of influencing any act or decision of the non-US entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring such companies to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Union and other International Government Regulation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in countries outside of the United States prior to the commencement of clinical trials or marketing of a product in those countries. Some countries outside of the United States have a similar process that requires the submission of a CTA much like the IND prior to the commencement of human clinical trials. In the EU, for example, a CTA must be submitted to the competent authorities of the EU Member States where the clinical trial is conducted and to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country’s requirements, clinical trial development may proceed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization Application for Biologic Medicinal Products</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval to commercialize a new product under EU regulatory systems, we must submit a marketing authorization application.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, a marketing authorization for a medicinal product can be obtained through a centralized, mutual recognition, decentralized procedure, or national procedure (single country). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and certain biologic products and optional for certain other products, including medicinal products that are a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public or animal health.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the centralized procedure, the applicant can submit a single application for marketing authorization to the EMA which will provide a positive opinion regarding the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European Commission takes a final decision to grant a centralized marketing authorization which permits the marketing of a product in all 27 EU Member States and three of the four European Free Trade Association States - Iceland, Liechtenstein and Norway. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the EMA CHMP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the EU, such as the United Kingdom and countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCPs, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable non-US regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising, Promotion and Compliance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of our products will also be subject to EU laws and EU Member States’ national laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. Other EU Member State national legislation may also apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product’s Summary of Product Characteristics ("SmPC"), as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. The SmPC forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion and is prohibited in the EU. The applicable laws at the EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of development (pre- and post-marketing), failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These penalties could include the imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant Orphan Drug Designation to biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States or a disease or condition that affects more than 200,000 individuals in the United States but there is no reasonable expectation that the cost of developing and making the biologic would be recovered from sales in the United States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax credits for certain research and user fee waivers under certain circumstances. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to seven years of market exclusivity, which means the FDA may not approve any other application for a biologic for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. The FDA can revoke a product’s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same biologic for a different disease or condition.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, medicinal products: (a) that are used to diagnose, treat or prevent life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU; or (b) that are used to treat or prevent life-threatening, seriously debilitating or serious and chronic conditions and that, for economic reasons, would be unlikely to be developed without incentives; and (c) where no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists, or, if such a method exists, the medicinal product would be of significant benefit to those affected by the condition, may be granted an orphan designation in the EU. The application for orphan designation must be submitted to the EMA and approved by the European Commission before an application is made for marketing authorization for the product. Once designated, Orphan medicinal product designation also entitles a party to financial incentives such as reduction of fees or fee waivers. Moreover, ten years of market exclusivity is granted following marketing authorization, if the product continues to be designated as an orphan medicinal product upon grant of the marketing authorization. During this ten-year period, with a limited number of exceptions, neither the competent authorities of the EU Member States, the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal products with the same therapeutic indication. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this latter product is demonstrated to be safer, more effective or otherwise clinically superior to the original orphan medicinal product. This period of market exclusivity may be reduced to six years, at the end of the fifth year, if the orphan designation criteria are no longer met, including where it can be demonstrated on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation must be requested before submission of an application for marketing approval or marketing authorization. Orphan drug designation does not convey any advantage in, nor shorten the duration of the regulatory review and approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum for the treatment of SCCHN has received Orphan Drug Designation from the FDA and the EMA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Programs in the United States and Other Jurisdictions</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a product may be granted Fast Track designation if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address unmet medical needs for such condition. With Fast Track designation, the sponsor may be eligible for more frequent opportunities to obtain the FDA’s feedback, and the FDA may initiate review of sections of a BLA before the application is complete. This Rolling Review is available if the applicant provides, and the FDA approves, a schedule for the remaining information. Even if a product receives Fast Track designation, the designation can be rescinded and provides no assurance that a product will be reviewed or approved more expeditiously than would otherwise have been the case, or that the product will be approved at all.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may designate a product candidate as a breakthrough therapy if it finds that the product candidate is intended, alone or in combination with one or more other product candidates or approved products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For product candidates designated as breakthrough therapies, more frequent interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development. Product candidates designated as breakthrough therapies by the FDA may also be eligible for Priority Review. We may apply for breakthrough therapy designation for some of our product candidates. However, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for designation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated approval under FDA regulations allows a product designed to treat a serious or life-threatening disease or condition that provides a meaningful therapeutic advantage over available therapies to be approved on the basis of either an intermediate clinical endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit. Approvals of this kind typically include requirements for confirmatory clinical trials to be conducted with due diligence to validate the surrogate endpoint or otherwise confirm clinical benefit and for all promotional materials to be submitted to the FDA for review prior to dissemination.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant Priority Review designation to a product candidate, which sets the target date for FDA action on the application at six months from FDA filing, or eight months from the sponsor’s submission. Priority Review may be granted where a product is intended to treat a serious or life-threatening disease or condition and, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in safety or efficacy compared to available therapy. If criteria are not met for Priority Review, the standard FDA review period is ten months from FDA filing or 12 months from sponsor submission. Priority Review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Centralized Procedure in the EU, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding ‘‘clock stops,’’ when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated evaluation might be granted by CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, which should be justified and assessed on a case-by-case basis. In this circumstance, EMA ensures that the opinion of CHMP is given within 150 days.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vicineum has received Fast Track and Priority Review designations from the FDA for the treatment of BCG-unresponsive NMIBC and Fast Track designation from the FDA for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some non-US jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any partners, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any partners, may receive for any approved products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services ("CMS"), the agency that administers the Medicare and Medicaid programs, may revise reimbursement and implement coverage restrictions. Any reduction in reimbursement from Medicare, Medicaid or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2010, President Obama signed one of the most significant healthcare reform measures in decades. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the "ACA") substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. The ACA has impacted existing government healthcare programs and has resulted in the development of new programs. For example, the ACA provides for Medicare payment for performance initiatives.&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Among the ACA's provisions of importance to the pharmaceutical industry are the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biological products;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program ("MDRP") to 23.1% for innovator drugs and 13% for non-innovator drugs of the average manufacturer price ("AMP");</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which AMP is calculated and reported by manufacturers for products that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new partial prescription drug benefit for Medicare recipients ("Medicare Part D") coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient products to be covered under Medicare Part D (subsequent legislation increased this amount to 70% effective as of January 1, 2019);</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers’ Medicaid rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, thereby potentially increasing manufacturers’ Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service Act's 340B drug pricing program;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report to CMS annually specifying financial arrangements with physicians and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any ‘‘payments or other transfers of value’’ made or distributed to prescribers, teaching hospitals, and other healthcare providers and reporting any ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations during the preceding calendar year;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a mandatory non-deductible payment for employers with 50 or more full-time employees (or equivalents) who fail to provide certain minimum health insurance coverage for such employees and their dependents;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payments and service delivery models; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the ACA have been subject to judicial challenges, as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, as amended, commonly referred to as the “individual mandate,” effective January 1, 2019. Further, the Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare prescription drug plans, commonly known as the “donut hole,” by raising the manufacturer discount under the Medicare Part D coverage gap discount program to 70%. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. It is unclear how the ACA and its implementation, as well as efforts to repeal, replace, or otherwise modify, or invalidate, the ACA, or portions thereof, will affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, among other things, led to aggregate reductions in Medicare payments for all items and services, including prescription drugs and biologics, to service providers of, on average, 2% per fiscal year beginning April 1, 2013, and due to subsequent legislation, will continue until 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022). On December 10, 2021, President Biden signed a law that provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012 also, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and reform government healthcare program reimbursement methodologies for drug products. For example, Congress is currently considering changes that could affect our overall rebate liability. Changes under consideration include a drug price negotiation program, Medicare Part B and Part D inflation rebates, under which manufacturers would owe rebates if the average sales price or average manufacturer price of a drug were to increase faster than the pace of inflation, and Part D benefit redesign, including a proposed new manufacturer discount program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing and Reimbursement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we obtain regulatory approval. In the United States and in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a biologic may be separate from the process for setting the price or reimbursement rate that the payor will pay for the biologic. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the products approved by the FDA, or comparable non-US regulatory authorities for a particular indication or if a product is included it may not be listed on the formulary for all the indications or it may be listed on a narrower basis than what is approved by the FDA, or comparable non-US regulatory authorities. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA, or other comparable non-US regulatory authorities’ approvals. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2003, the United States Congress enacted legislation creating Medicare Part D, which became effective at the beginning of 2006. Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval. However, to obtain payments under this program, we would be required to sell products to Medicare recipients through prescription drug plans operating pursuant to this legislation. These plans will likely negotiate discounted prices for our products. Federal, state and local governments in the United States continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Future legislation could limit payments for pharmaceuticals such as the product candidates that we are developing or modify manufacturer discounts. For example, Congress is currently considering legislation that would sunset the current Part D discount program and replace it with a new manufacturer discount program, effective 2024. Congress further could enact a Medicare Part D inflation rebate, under which manufacturers would owe rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. Further, there are national, provincial and territorial formularies funded by government healthcare systems, in addition to formularies for private payors (private insurers) and hospitals or hospital groups. Listing on the formularies and price depend on evidence and submissions regarding the cost-benefit of the drug and comparison of the cost-effectiveness of a particular product candidate to currently available therapies and is often subject to negotiations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, once a marketing authorization is granted for a medicinal product the applicant is required to engage in pricing and reimbursement discussions and negotiate with a separate pricing authority in each of the EU Member States. The EU Member States governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of the EU Member States may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU Member States allow companies to fix their own prices for medicinal products but monitor and control company profits. The downward pressure on healthcare costs in general, particularly pharmaceuticals, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products. Furthermore, many EU Member States and other non-US countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. The EU Member States have discretion to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. We may face competition for our products, if approved, from lower priced products in non-US countries that have placed price controls on pharmaceutical products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Technology Assessment ("HTA") of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States. These EU Member States include France, Germany, Ireland, Italy and Sweden. The HTA process in European Economic Area ("EEA") countries is governed by the national laws of these countries. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options available on the market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between EU Member States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">American Society of Clinical Oncology ("ASCO") Value Assessment for Cancer Treatments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2016, ASCO published a framework to assess the value of cancer treatment options. The framework was developed in response to concern that new, expensive cancer treatments may not be supported by adequate medical evidence. The purpose of the framework is to provide a standardized quantification of cancer treatments and assist oncologists and patients in deciding between new cancer treatments and the standard of care. The framework takes into account a medication’s (i) efficacy, (ii) safety and (iii) cost, to derive an overall treatment value. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that the safety and efficacy profiles of our product candidates are potentially better than that of the standard of care and, if approved, we intend to price our products competitively, we do not know how the data will be assessed by ASCO. It is also unknown whether use of this application could adversely affect the assessment of any of our product candidates. If this framework were adopted and utilized by payors and physicians, and if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG were to receive low ratings, this could adversely affect the price and reimbursement of Vicineum, if approved, reduce prescriptions and harm our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our arrangements with third-party payors and customers will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by United States federal and state governments and by governments in non-US jurisdictions in which we conduct our business. We have described below some of the key federal, state and non-US healthcare laws and regulations that may affect our ability to operate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds; knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government; or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. The False </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims Act also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the statute and to share in any monetary recovery. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies’ marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government’s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively, "HIPAA"), among other things, impose criminal and civil liability for knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held in our by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have adopted analogous laws and regulations, including state anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states, regardless of the payor. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual healthcare providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register their sales representatives. Some states prohibit pharmacies and other healthcare entities from providing specified physician prescribing data to pharmaceutical companies for use in sales and marketing. Some states prohibit other specified sales and marketing practices, including the provision of gifts, meals, or other items to certain healthcare providers, and/or offering co-pay support to patients for certain prescription drugs. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. In addition, in order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in some states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to data privacy and security laws and regulations by both the federal government and the states in which we conduct our business. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. Numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, including the California Consumer Privacy Act ("CCPA"), govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that could negatively affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes requirements relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions have corresponding laws and regulations governing the handling of personal information and third-party communications that may be more or less stringent than those of the United States. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our activities are potentially subject to additional regulation by various federal, state and local authorities in addition to the FDA, including CMS, other divisions of HHS (for example, the Office of Inspector General), the DOJ and individual United States Attorney offices within the DOJ, and state and local governments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we participate in the MDRP, we will have certain price reporting obligations to the MDRP, and we may have obligations to report average sales price ("ASP") figures to the Medicare program. Under the MDRP, we would be required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds available for our drugs under Medicaid and Medicare Part B. Those rebates would be based on pricing data reported by us on a monthly and quarterly basis to CMS. These data would include AMP and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the United States in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. On December 21, 2020, CMS issued a final rule that modified MDRP regulations to permit reporting multiple best price figures with regard to value based purchasing arrangements (beginning in 2022); provide definitions of “line extension,” “new formulation,” and related terms with the practical effect of expanding the scope of drugs considered to be line extensions (beginning in 2022); and revise best price and AMP exclusions of manufacturer-sponsored patient benefit programs, including with respect to the potential inapplicability of such exclusions in the context of pharmacy benefit manager “accumulator” programs (beginning in 2023). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law also requires that a company that participates in the MDRP report ASP information each quarter to CMS for certain categories of drugs that are paid under Part B of the Medicare program. Manufacturers calculate ASP based on a statutorily defined formula and interpretations of the statute. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. For calendar quarters beginning January 1, 2022, manufacturers will be required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate Program. In addition, starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologicals, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or single-use packages for units of discarded drug reimbursed by Medicare Part B in excess of 10 percent of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125 percent of the refund amount. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that any company that participates in the MDRP also participate in the Public Health Service’s 340B drug pricing program in order for federal funds to be available for the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. The Health Resources and Services Administration ("HRSA"), which administers the 340B program, issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January 1, 2019. HRSA also has implemented a ceiling price reporting requirement, pursuant to which manufacturers must report the 340B ceiling prices for their covered outpatient drugs to HRSA on a quarterly basis. HRSA then publishes those prices to 340B covered entities. Moreover, under a final regulation effective January 13, 2021, HRSA newly established an administrative dispute resolution (“ADR”) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. HRSA further could terminate a manufacturer’s agreement to participate in the 340B program for a failure to comply with 340B program requirements. In the event that HRSA were to terminate such an agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs that we are able to successfully commercialize.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in order to be eligible to have its products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, a manufacturer also must participate in the Department of Veterans Affairs Federal Supply Schedule ("FSS") pricing program, established by Section 603 of the Veterans Health Care Act of 1992. Under this program, the manufacturer is obligated to make its “covered drugs” (biologics or innovator drugs) available for procurement on an FSS contract and charge a price to four federal agencies - Department of Veterans Affairs, Department of Defense, Public Health Service and Coast Guard - that is no higher than the statutory federal ceiling price. We also expect to participate in the Tricare Retail Pharmacy Program, under which we would pay quarterly rebates to DoD for prescriptions of innovator drugs dispensed to Tricare beneficiaries through Tricare Retail network pharmacies. The requirements under the 340B and FSS programs could reduce the revenue we may generate from any products that are commercialized in the future and could adversely affect our business and operating results. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The Medicaid rebate amount for each covered outpatient drug is computed each quarter based on the manufacturer’s submission to CMS of its current AMP and, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the case of innovator products, best price figures, for the quarter. If we participate in the MDRP and become aware that our reporting for a prior quarter was incorrect, or has changed, we will be obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the MDRP. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we would be required to offer our products to certain covered entities, such as safety-net providers, under the 340B program, and we may be obligated to issue refunds to covered entities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we participate in the MDRP or our products are covered under Medicare Part B, we will be liable for errors associated with our submission of pricing data. We cannot assure you that our submissions, if we participate in these programs, will not be found by CMS to be incomplete or incorrect. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted false AMP, ASP or best price information to the government, we may be liable for civil monetary penalties per item of false information. If we are found to have made a misrepresentation in the reporting of our ASP, the Medicare statute provides for civil monetary penalties for each misrepresentation for each day in which the misrepresentation was applied. Civil monetary penalties also can be applied if we are found to have intentionally charged 340B covered entities more than the statutorily mandated ceiling price. Our failure to submit monthly/quarterly AMP, ASP and best price data on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we would participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs that we are able to successfully commercialize. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including (depending on the applicable law) criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private ‘‘</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’’ actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a non-US country, we may be subject to similar non-US laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and more extensive reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States and by the United Kingdom's Bribery Act 2010. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The national laws of certain EU Member States require payments made to physicians to be publicly disclosed. Moreover, the European Federation of Pharmaceutical Industries and Associations ("EFPIA") Code on disclosure of transfers of value from pharmaceutical companies to healthcare professionals and healthcare organizations imposes a general obligation on members of EFPIA or related national industry bodies to disclose transfers of value to healthcare professionals. In addition, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her competent professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable non-US regulatory requirements, we may be subject to, among other things, warning letters or untitled letters, injunctions, civil, administrative, or criminal penalties, monetary fines or imprisonment, suspension or withdrawal of regulatory approvals, suspension of ongoing clinical studies, refusal to approve pending applications or supplements to applications filed by us, suspension or the imposition of restrictions on operations, product recalls, the refusal to permit the import or export of our products or the seizure or detention of products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental and Safety Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of federal, provincial and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. Our operations involve such hazardous materials and produce such hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by federal, provincial and local regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. Radioactive materials in Canada come under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal jurisdiction. Canada’s Nuclear Safety and Control Act 1997 c.9 contains a general prohibition against any activity, including possession of radioactive material, except in accordance with the terms and conditions set out in a federal license issued by the Canadian Nuclear Safety Commission. The Nuclear Substances and Radiation Devices Regulation does however, exempt licensing requirements for small quantities of radioactive substances that either meet concentrations set out in a schedule to the Regulation or, for radioactive substances not set out in the schedule, that meet certain regulatory criteria. Our operations do not currently require a federal license issued by the Canadian Nuclear Safety Commission. Our operations in Canada may be subject to license approvals, notification requirements and investigation and enforcement for air and water and waste matters.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History and Acquisition of Viventia</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in 2008. We were formerly known as Denovo Therapeutics, Inc. and Newco LS14, Inc. before changing our name to Eleven Biotherapeutics, Inc. in February 2010 and again to Sesen Bio, Inc. in May 2018. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada, the shareholders of Viventia named therein (collectively, the "Selling Shareholders") and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (“Clairmark”), pursuant to which we agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the "Viventia Acquisition"). In connection with the closing of the Viventia Acquisition, we issued 4.0 million shares of our common stock to the Selling Shareholders according to their pro rata share of Viventia’s then-outstanding shares of common stock, which represented approximately 19.9% of our voting power as of immediately prior to the issuance of such shares of common stock. Clairmark is an affiliate of Leslie L. Dan, who served on our board of directors until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition, we are obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the acquisition agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the "Purchased Product"), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) and quarterly earn-out payments equal to two percent (2%) of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Share Purchase Agreement, we, our affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key human capital management objectives are to recruit, retain, manage and motivate our employees. There are a limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense given the numerous pharmaceutical and biotechnology companies looking for similar personnel as well as universities and research institutions. We rely on our executive officers and other key employees to achieve our research, development and commercialization objectives and to successfully implement our business strategy. We also rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to maintaining a diverse and inclusive workplace in which our employees from all backgrounds can fully contribute to the growth and success of our business. We communicate shared values and leadership behaviors, which are expected of all employees. Additionally, every employee has an annual performance review and has opportunities to contribute to corporate goals. We rely on a variety of sources to fill open positions, including job boards and postings on our corporate website.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a demonstrated history of investing in our workforce through comprehensive and competitive compensation and benefits, and a focus on health and employee wellbeing. We have adopted our 2014 Stock Incentive Plan ("2014 Plan") and Employee Stock Purchase Plan (“ESPP”) to enable us and our subsidiaries to recruit and retain highly qualified employees, directors and consultants, provide those individuals with an incentive for productivity, and provide those individuals with an opportunity to share in our growth and value.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we had thirty-five full-time employees and no part-time employees, nine hold Ph.D. degrees and one is a veterinary doctor. This number consists of fifteen employees engaged in administration and twenty employees engaged in research and development (eight in clinical and regulatory, three in supply chain, five in manufacturing/engineering, and four in quality and support). Two of our employees are located in our corporate headquarters in Cambridge, fifteen of our employees are located in our Winnipeg facility, and five of our employees are located in our Philadelphia office. We have no collective bargaining agreements with our employees, and none are represented by labor unions. We have not experienced any work stoppages. We believe our relationship with our employees is satisfactory.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the COVID-19 pandemic, approximately 30% of our employees have continued to work at our Winnipeg facility, where we have adopted health screening, implemented socially distancing and personal protective equipment requirements, enhanced cleaning and sanitation protocols, and modified workspaces to reduce the potential for transmission of the virus. All other employees who do not require access to our facility to perform their work have been working from home during the pandemic. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information and Access to SEC Reports</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 245 First Street, Suite 1800, Cambridge, Massachusetts 02142, our telephone number is (617)-444-8550 and our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports, available free of charge in the “Investors” section of our website as soon as reasonably practicable after we file these reports with the SEC. We routinely post these reports, recent news and announcements, financial results and other important information about our business on our website at www.sesenbio.com. Information contained on our website is not a part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the SEC maintains an Internet website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common shares could decline, and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Risks and uncertainties of general applicability and additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a specialty pharmaceutical company with a limited operating history. Over the past few years, we have focused primarily on developing our lead product candidate, Vicineum. Since our inception, we have received no revenues from sales of our products, have incurred significant operating losses and expect to continue to incur operating losses for the foreseeable future as we continue the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and seek marketing approval from the FDA. We had net losses of $0.3 million, $22.4 million and $107.5 million for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively. We incurred negative cash flows from operating activities of $68.9 million, $30.8 million and $37.5 million for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively. As of December&nbsp;31, 2021, we had cash and cash equivalents of $162.6 million, net working capital (current assets less current liabilities) of $194.0 million and an accumulated deficit of $316.3 million. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our initial public offering ("IPO"), our follow-on public offerings, sales effected in at-the-market ("ATM") offerings and, our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The majority of our revenue to date has been from milestone payments received under our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses for the foreseeable future, and we expect these losses to increase as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States and the European Union;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adapt our regulatory compliance efforts to incorporate requirements applicable to marketed drugs; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek and conduct combination trials of one or more of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to develop additional product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with drug development and commercialization, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform trials in addition to those expected or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">With the exception of specified regulatory, development and commercial milestones under our out-licensing and OUS business development partnership agreements, we currently have no source of revenue and may never become profitable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to become and remain profitable depends on our ability to generate revenue. Although we may be entitled to certain payments under our out-licensing and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, neither we nor any of our business development partners have commercialized any of our product candidates. We do not expect to generate significant revenue from the development of our product candidates unless and until we or one of our business development partners obtain marketing approval for, and commercialize, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our ability to generate revenue from Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG will depend on a number of factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain regulatory approval for, and successfully commercialize, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete and submit applications to, and obtaining regulatory approval from, non-US regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the markets in the territories for which we or our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partners gain regulatory approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to find a suitable contract sales organization ("CSO") to help us market and promote Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain effective medical affairs, sales, marketing and distribution to market and sell Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into and maintain commercially reasonable agreements with wholesalers, distributors and other third parties in our supply chain;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in establishing a commercially viable price for Vicineum, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in defending against potential competition and other developments in our market generally;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture commercial quantities of Vicineum at acceptable cost levels;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain coverage and adequate reimbursement from third-party payors, including government payors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partners' ability to successfully complete development activities, including necessary clinical trials, for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved for commercial sale, Vicineum may not gain market acceptance or achieve commercial success. If our addressable market is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or clinical practice guidelines, we may not generate significant revenue from sales of Vicineum. In addition, we would anticipate incurring significant costs associated with commercializing Vicineum, if approved. We may not achieve profitability soon after generating product sales from Vicineum, if ever. If we are unable to generate product revenues from Vicineum, we will not become profitable and may be unable to continue operations without continued funding.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our development efforts, obtain drug approvals, diversify our offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are devoting substantial financial resources to our ongoing and planned activities, including a new Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and functions associated with operating as a public company. We expect to continue to spend substantial amounts to continue the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and, if approved, commercialize Vicineum. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of continuing the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of the regulatory approval process for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG by the FDA and comparable non-US regulatory authorities, including the potential for the FDA to require that we perform more studies and clinical trials than those we currently expect;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain commercial arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third party licensors under our in-licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available when needed on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we also could be required to:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek out-licensing or commercialization partners to assist in the clinical development or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG in the United States and other markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, limit, reduce or terminate the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly curtail our operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our cash and cash equivalents of $162.6 million as of December&nbsp;31, 2021, will be sufficient to fund our operations into 2024; however, we have based this estimate on assumptions that may prove to be wrong, and our capital resources may be utilized faster than we currently expect.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of shares of our common stock or rights to purchase shares of our common stock, including common stock purchase warrants and stock options, could result in additional dilution of the percentage ownership of our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, licensing and OUS business development partnership agreements, strategic alliances and marketing and distribution arrangements and other commercial arrangements. We do not have any committed external source of funds other than the amounts payable under our out-licensing and OUS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business development partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights as holders of our common stock.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also adopted the 2014 Plan to enable us and our subsidiaries to recruit and retain highly qualified employees, directors and consultants, provide those individuals with an incentive for productivity, and provide those individuals with an opportunity to share in our growth and value. As of December&nbsp;31, 2021, we had an aggregate of 15.8 million stock options and RSUs outstanding under the 2014 Plan, our prior equity plan and inducement awards granted outside of our equity plans. In addition, as of December&nbsp;31, 2021, we had 8.9 million shares of common stock available for grant under our 2014 Plan. Future equity incentive grants and issuances of shares of common stock under the 2014 Plan, or other grants outside of the 2014 Plan pursuant to inducement equity awards, may have an adverse effect on the market price of shares of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through government or other third-party funding, licensing or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnership agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, strategic alliances or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval of Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our lead product candidate, Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we are unable to obtain marketing approval for or successfully commercialize our lead product candidate, either alone or through an out-license or OUS business development partnership, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for sale and have invested a significant portion of our efforts and financial resources in the development of Vicineum. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to address the issues identified in the CRL from the FDA or resubmit a BLA for Vicineum, or address the concerns identified in the EMA Withdrawal Assessment Report or resubmit our MAA for Vysyneum, including because of a lack of capital or otherwise. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the issues identified in the CRL or the concerns identified in the EMA Withdrawal Assessment Report are resolved to the satisfaction of the FDA or the EMA, respectively, the FDA and the European Commission retain the right not to approve a BLA or MAA, respectively, or to require additional information, or to raise additional issues with regard to regulatory approval, which could further delay or prevent its approval or limit product labelling claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prospects are substantially dependent on our ability and the ability of our out-licensing and OUS business development partners to obtain marketing approval for and commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. In addition, either the substance of the issues identified by the FDA in the CRL, or the CRL itself, or the concerns identified in the EMA Withdrawal Assessment Report could have an adverse impact on future efforts to obtain marketing authorization for Vicineum from other non-US regulatory authorities, or on our future efforts to commercialize Vicineum and gain acceptance of Vicineum from third party payors. The success of Vicineum will depend on several factors, including the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing the clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing the issues identified in the CRL we received from the FDA and the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receiving marketing approvals from the FDA, the European Commission or comparable non-US regulatory authorities, including our ability to address the issues identified by the FDA in the CRL or the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining the commercial manufacturing supply and distribution chain for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of our current and future out-licensing or OUS business development partners;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching commercial sales, if and when marketing approval is received;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrating an acceptable safety profile prior to and following any marketing approval;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining marketplace acceptance, if approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining pricing sufficient to realize a meaningful return on our investment; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other therapies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our OUS business development partners are unable to develop, receive marketing approval for, or successfully commercialize Vicineum or experience delays as a result of any of these factors or otherwise, our business could be materially harmed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other non-US regulatory authorities or do not otherwise produce favorable results, we will be unable to complete the development and potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we must complete pre-clinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of Vicineum in humans. In order to address the issues identified in the CRL we received from the FDA for the BLA for Vicineum and the concerns </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identified in the EMA Withdrawal Assessment Report, we will need to complete one or more additional clinical trials. Such trials will require us to incur substantial additional costs and will delay the potential commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Further, the outcome of pre-clinical studies and early clinical trials may not be predictive of the success of later clinical trials, and preliminary results of a clinical trial do not necessarily predict final results. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if such clinical trials are successfully completed as planned, the results may not support approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG under the laws and regulations of the FDA, the European Commission or comparable non-US regulatory authorities. We cannot be certain that additional clinical data will demonstrate Vicineum is both safe and effective for its intended uses to the satisfaction of the FDA, the EMA or comparable non-US regulatory authorities. Pre-clinical and clinical data and analyses are often able to be interpreted in different ways. Even if we view our results favorably, we may be unable to demonstrate safety and efficacy of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG to the satisfaction of the FDA, the EMA or other non-US regulatory authorities. If a regulatory authority has a different view, we may still fail to obtain regulatory approval of Vicineum. This, in turn, would prevent us from commercializing Vicineum and our ability to generate revenues in the future would be materially impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to develop a more sensitive bioanalytical assay which is needed for the additional Phase 3 clinical trial for Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to develop a more sensitive bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay for the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG than was used in our prior VISTA Trial for Vicineum. This bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay will be used to measure levels of Vicineum in the blood. The development of a new bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay for a novel biologic like Vicineum can be complex. There is risk that an adequately sensitive bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay may not be scientifically or economically feasible or that any new bioanalytical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assay developed by us or a third party will not be accepted by the FDA or other comparable regulatory bodies. As a result, further development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may be negatively impacted or delayed, which would have an adverse impact on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed or prevented. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG that we may develop, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon the development of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in these clinical trials may be slower or more challenging than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements, including GCP or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations, trial sites or manufacturing facilities by the FDA or other comparable non-US regulatory authorities could result in findings of non-compliance and the imposition of a clinical suspension or termination;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs/Ethics Committees may delay or not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays or fail to reach agreement with the FDA or a comparable non-US regulatory authority on a trial design that we are able to execute;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including for the same indications as our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trial sites and investigators may deviate from clinical trial protocols or otherwise fail to conduct the trial in accordance with regulatory requirements, and investigators may drop out of the clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trial sites may withdraw from our clinical trials, including as a result of changing standards of care or ineligibility of a site to participate in our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or regulators or IRBs/Ethics Committees or other reviewing entities, including comparable non-US regulatory authorities, may require us to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements including GCP or a finding that the patients are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may be greater than we anticipate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may receive feedback from DSMBs or the FDA, or a comparable non-US regulatory authority, that might require modification to the protocol for the clinical trial or performance of additional studies before clinical trials may continue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as a clinical trial proceeds, or as the results of earlier stage studies or concurrent studies become available, we may determine that we need to modify the protocol and/or other aspects of the clinical trial before it may continue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA, a comparable non-US regulatory authority, or we may decide to, or a DSMB may recommend to, suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of Vicineum or other materials necessary to conduct clinical trials of Vicineum may be insufficient or inadequate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs/Ethics Committees to suspend or terminate the trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue a clinical trial, including the occurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials or increased expenses associated with the services of our CROs and other third parties; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in applicable laws, governmental regulations or administrative actions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their activities, we have limited control over their actual performance. Any delays in completing our clinical trials will increase our costs, slow down our development and regulatory submission process for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and jeopardize our ability to obtain regulatory approval, commence commercial sales and generate revenues, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is ultimately approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials outside of the United States, as we have done historically for Vicineum (both for the treatment of BCG-unresponsive NMIBC and for the treatment of SCCHN) and as we may decide to do in the future, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in countries outside of the United States to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with non-US regulatory frameworks, as well as political and economic risks relevant to such countries.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of Vicineum or other testing, if the results of these trials or tests are not favorable or are only modestly favorable or if there are safety concerns, we may:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, or is subject to a REMS;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have Vicineum removed from the market after obtaining marketing approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our pre-clinical studies or clinical trials will begin as planned, will need to be restructured or will be completed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on schedule, or at all. Significant pre-clinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of patients to participate in these trials as required by the FDA or similar non-US regulatory authorities. We have previously experienced difficulties with clinical trial enrollment and retention, which led to the early termination of our Phase 3 trial of Vicineum for the treatment of SCCHN in 2008, and we may experience difficulties in patient enrollment in our clinical trials in the future for a variety of reasons. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject enrollment is affected by a number of factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the clinical trial in question;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population for the disease;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for statistically significant analysis of the clinical trial’s primary endpoints;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinicians' and patients' perceived risks and benefits of the product candidate under study, including relative to alternative treatments;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any ongoing clinical trials conducted by competitors for the same indication;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our ability to successfully initiate, enroll and complete a clinical trial in any country outside of the United States, should we decide to do so, is subject to numerous risks unique to conducting business in such countries, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in establishing or managing relationships with CROs and physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different or additional standards for the conduct of clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">absence in some countries of established groups with sufficient regulatory expertise for review of the protocols associated with our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring that clinical trial quality is sufficient to meet the standards of the FDA or other regulatory authorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to locate qualified local consultants, physicians and partners; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential burden of complying with a variety of non-US laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for other product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any of our clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG may cause undesirable side effects, serious adverse events or have other properties that could delay or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">halt clinical trials, delay or prevent its regulatory approval, limit the commercial profile of its labeling, if approved, or result in significant negative consequences following any marketing approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects or serious adverse events caused by Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could cause us or regulatory authorities to interrupt, delay or halt respective clinical trials and could result in a restrictive label or the delay or denial of regulatory approval by the FDA or other comparable non-US regulatory authorities. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Grade 4 or Grade 5 serious adverse events that were considered by the clinical investigators to be related to Vicineum during the Phase 1 and Phase 2 clinical trials of Vicineum for the treatment of NMIBC. There was one Grade 5 serious adverse event, or death, which was determined by the clinical investigator to be unrelated to Vicineum. The most common reported treatment-related adverse events were an abnormally frequent passage of small amounts of urine, blood in the urine and painful urination, the majority of which were considered to be mild or moderate in severity. No patients discontinued treatment due to a Vicineum-related adverse event during the Phase 1 and Phase 2 clinical trials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, side effects and serious adverse events or further safety or toxicity issues that we may experience in our clinical trials or in post-marketing experience, if approved, could lead to the FDA's or other comparable non-US regulatory authority's imposition of a REMS or other post-marketing obligations, which could hinder us from generating revenues or achieving profitability. Results of our clinical trials could reveal an unacceptably high severity and prevalence of side effects or serious adverse events. As a result, our clinical trials could be suspended or terminated, and the FDA or comparable non-US regulatory authorities could order us to cease further development or deny approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The related drug-side effects or serious adverse events in our clinical trials could affect clinical trial patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG receives marketing approval, and we or others later identify undesirable side effects or serious adverse events caused by Vicineum, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may suspend or be forced to suspend marketing of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be obliged to conduct a product recall or product withdrawal;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend, vary, or withdraw their approvals of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may order the seizure or recall of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label or a REMS or other post-marketing obligations that could diminish the usage or otherwise limit the commercial success of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be required to pay fines and face other administrative, civil and criminal penalties; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to obtain regulatory authority approval of any proposed names for oportuzumab monatox for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and any failure or delay associated with such naming approval may adversely impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the FDA previously conditionally accepted the name Vicineum, and EMA previously conditionally accepted the name Vysyneum, for our product candidate, oportuzumab monatox, these approvals are subject to further and final review by FDA and EMA upon potential resubmission of our respective applications and at the time of regulatory authority review of such applications. If the FDA or EMA object to any proposed proprietary product name, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable laws, not infringe the existing rights of third parties and be acceptable to the FDA and EMA, as applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The marketing approval process is expensive, time-consuming and uncertain. As a result, we cannot predict when or if we, or any licensees or partners, will obtain marketing approval to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG or any other product candidate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate’s quality, safety, and efficacy. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, especially if additional clinical trials are required, if approval is obtained at all. In October and December 2021, we participated in a CMC Type A Meeting and Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other comparable non-US regulatory authorities may determine that any product candidate that we may develop is not safe, effective or of appropriate quality, is only moderately effective or has undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The different requirements and expectations of the non-US regulatory authorities compared with the FDA may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post approval limitations or restrictions. If we experience delays in obtaining regulatory approvals, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in non-US jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United States would not assure approval of product candidates in non-US jurisdictions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell any product candidate that we may develop outside of the United States, we or our third-party licensees or commercialization partners must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States it is required that the product be approved for reimbursement before the product can be sold in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. For example, on March 5, 2021, we submitted our MAA to the EMA for Vicineum for the treatment of BCG-unresponsive NMIBC under the EMA’s centralized procedure. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC. We have decided to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on the next steps for Vicineum in the United States. Additionally, on October 20, 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA’s standard practice when an MAA is withdrawn. The Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in other jurisdictions, the commercial prospects of our product candidates may be significantly diminished, and our business prospects could decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biologics products is highly competitive. We face competition with respect to Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG from both large and small pharmaceutical, biopharmaceutical and biotechnology companies, academic institutions and other research organizations. There are a number of large pharmaceutical, biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of NMIBC. For instance, in January 2020, the FDA approved Merck &amp; Co., Inc.'s Keytruda (pembrolizumab) as a systemic monotherapy to treat patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. In addition, FerGene Inc. is developing Adstiladrin (nadofaragene firadenovec (rAd-IFN/Syn3) for BCG-unresponsive NMIBC for the United States market. On May 17, 2020, the FDA issued a CRL that indicated outstanding questions regarding CMC = issues of Adstiladrin. In September 2020, CG Oncology (CG0070, a recombinant adenovirus type 5, same type as Adstiladrin) initiated a Phase 3 study for the treatment of BCG-unresponsive patients with expected primary and study completion dates of December 2022 and December 2024, respectively. In December 2020, ImmunityBio (Anktiva/N-803 in combination with BCG) released preliminary Phase 2 data for the CIS cohort and is expected to file its BLA following a meeting with the FDA in the first quarter of 2022. However, the Phase 2 trial did not include a BCG only control arm. In May 2020, the preliminary results of the Phase 2 study of Tecentriq for the treatment of BCG-unresponsive CIS patients were presented at ASCO by the NCI (National Cancer Institute) which sponsored the trial. The data showed that the trial did not meet its primary endpoint and further development of Tecentriq remains uncertain. Finally, another route of administration for checkpoint inhibitors is currently being evaluated by Pfizer with the subcutaneous administration of Sasanlimab (PF-06801591) for the treatment of BCG-unresponsive NMIBC patients. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody fragment and immuno-oncology therapeutics fields. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than product candidates that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to compete may be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic drug products. Generic products are currently being used as part of the standard of care for the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If any product candidate that we may develop achieves marketing approval, we expect that it will be priced at a significant premium over competitive generic products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More established companies may have a competitive advantage over us due to their greater size, cash resources and institutional experience. Compared to us, many of our competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors may obtain regulatory approval of their product candidates before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer, more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could render our product candidates obsolete or non-competitive before we can recover the expenses of development and commercialization.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may face competition from biosimilar products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the BPCIA, abbreviated pathways for approval of biosimilar and interchangeable biological products were created. The BPCIA establishes legal authority for the FDA to review and approve biosimilars for marketing, as well as biosimilars that have been designated as “interchangeable” with a previously approved biologic, or reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a full BLA. This period of regulatory exclusivity runs concurrently with, but is independent of, periods of patent protection for the reference product.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, approved as a biological product under a full BLA should qualify for a 12-year period of exclusivity. However:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the United States Congress could amend the BPCIA to significantly shorten this exclusivity period as has been previously proposed; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a potential competitor could seek and obtain approval of its own BLA during our exclusivity period instead of seeking approval of a biosimilar version.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and its provisions continue to be interpreted and implemented by the FDA and United States courts. As a result, the ultimate impact, implementation and implications of the BPCIA are subject to uncertainty and could compromise the future commercial prospects for our biological products. Moreover, it is not yet clear the extent to which a biosimilar, once approved, may be substituted for any one of our reference products in a way that is similar to traditional generic substitution for pharmaceutical products; this will depend on a number of marketplace and regulatory factors that are still developing at both the federal and state levels of government.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the use of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. If we cannot successfully defend ourselves against claims that Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial patients;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial patients;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced time and attention of our management to pursue our business strategy; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10.0 million CAD in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million CAD, which may not be adequate to cover all liabilities that we may incur. We would need to increase our insurance coverage if we expand our clinical development activities beyond historical levels. We would need to further increase our insurance coverage if Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is approved, and we commence commercialization. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will depend on Qilu for the development and commercialization of Vicineum in Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we entered into the Qilu License Agreement. Under the terms of the Qilu License Agreement, Qilu has an exclusive license to manufacture, develop and commercialize Vicineum in Greater China, including mainland China, Hong Kong, Macau and Taiwan. The timing and amount of any milestone and royalty payments we may receive under the Qilu License Agreement will depend in part on Qilu’s efforts. We will also depend on Qilu to comply with all applicable laws relative to the manufacturing, development and commercialization of Vicineum in Greater China. We do not control the individual efforts of Qilu, and any failure by Qilu to devote sufficient time and effort to the manufacture, development and commercialization of Vicineum could have a material adverse impact on our financial results and operations, such as by a failure of Qilu to meet its obligations to us, including future milestone and royalty payments. In addition, if Qilu were to violate, or was alleged to have violated, any laws or regulations during the performance of its obligations for us, it is possible that we could suffer financial and reputational harm or other negative outcomes, including possible legal consequences. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination, breach or expiration of the Qilu License Agreement could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive milestones and royalties. In such an event, we may be required to devote additional efforts and to incur additional costs associated with pursuing the manufacture, development and commercialization of Vicineum in Greater China. If we breach our obligations under the Qilu License Agreement and are unable to cure such breach, Qilu may terminate the Qilu License Agreement and retain all rights to manufacture, develop and commercialize Vicineum in Greater China with no obligation to make any additional milestone or royalty payments. Qilu has the right to receive a refund of all amounts paid us in the event the Qilu License Agreement is terminated under certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances. In addition, the royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent for Vicineum in a particular region or no data or regulatory exclusivity for Vicineum in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into and may enter into additional OUS business development partnerships or out-license agreements with third parties for the commercialization or development of our product candidates. If our OUS business development partnerships or out-licenses are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought and may seek additional third-party partners or licensees for development and commercialization of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Our current and likely commercialization partners or licensees include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. Our ability to generate revenues from these arrangements depend and will depend on our partners' or licensees' abilities and efforts to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships and licenses involving our product candidates pose a number of risks, including the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees have significant discretion in determining the amount and timing of efforts and resources that they will apply to these partnerships or licenses;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not perform their obligations as expected;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not pursue commercialization and development of our product candidates that receive marketing approval or may elect not to continue or renew commercialization or development programs based on clinical trial results, changes in any such partner’s or licensee’s strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the partners or licensees believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered under the partnership or license with us may be viewed by our partners or licensees as competitive with their own product candidates or products, which may cause partners or licensees to cease to devote resources to the commercialization of our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees could become involved in a business combination, which might deemphasize or terminate the commercialization or development of any product candidate licensed to it by us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with partners or licensees, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming and expensive;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">partners or licensees may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialization partners or licenses may be terminated for the convenience of the partner or licensee and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnership agreements and licenses may not lead to commercialization or development of product candidates in the most efficient manner, or at all. If any partnerships or licenses that we enter into, do not result in the successful commercialization and development of products or if one of our partners or licensees terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the partnership or license. All of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of any current or future OUS business development partners and licensees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one of our partners or licensees terminates its agreement with us, we may find it more difficult to attract new partners or licensees and our perception in the business and financial communities could be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to reach agreements with suitable new partners or licensees on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into partnerships and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on domestic and international third-party CROs to monitor and manage data for our pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and we control only some aspects of their activities. Nevertheless, we are responsible for ensuring that each of our pre-clinical studies and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to assist in conducting our pre-clinical studies in accordance with GLP and the Animal Welfare Act requirements. We and our CROs are required to comply with US federal regulations and GCP, which are international standards meant to protect the rights and health of patients and assure the credibility of clinical trial data that are enforced by the FDA and comparable non-US regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable non-US regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2021, the FDA published a Warning Letter (the “FDA Warning Letter”) issued to a former clinical investigator in our VISTA trial for Vicineum arising from a 2021 FDA inspection related to the review of our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. We discontinued use of the clinical site and the clinical investigator over four years ago when we learned of professional misconduct by the clinical investigator that was unrelated to the VISTA trial. The FDA Warning Letter indicated that the clinical investigator did not comply with applicable statutory requirements and applicable regulations regarding conduct of clinical investigations. The clinical investigator's medical license was temporarily suspended on May 29, 2017, due to inaccurate recordkeeping, which was unassociated with Sesen Bio and the patients in the VISTA trial. We notified the FDA of the misconduct at that time. There was no evidence found that patients were harmed by the clinical investigator’s actions. We included the corresponding patient data from the clinical site in the BLA submission to the FDA, which were thoroughly analyzed and discussed during the BLA review.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Failure to comply with these regulations may require us to repeat pre-clinical studies and clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, non-clinical and pre-clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our pre-clinical studies and clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have relied and will continue to rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party service </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose our relationships with CROs, our product development efforts could be delayed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on domestic and international third-party vendors and CROs for pre-clinical studies and clinical trials related to our product development efforts. Switching or adding additional CROs would involve additional cost and requires management time and focus. Our CROs generally have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements or research projects with us pursuant to such agreements if it can be reasonably demonstrated that the safety of the patients participating in our clinical trials warrants such termination in accordance with the reasonable opinion of the relevant CRO. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may not provide the same type or level of services as the original provider. If any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on third parties to formulate and manufacture Vicineum, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our products or result in higher product costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we completed the manufacturing of all Vicineum necessary for our VISTA Trial and for our CRADA with the NCI. In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process to outsource future Vicineum clinical and commercial to third-party manufacturers. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and, among other things, raised CMC issues pertaining to a recent pre-approval inspection and product quality. At the CMC Type A Meeting held in October 2021, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that such trials can proceed while addressing CMC issues. Therefore, we have no current plans to re-build internal manufacturing capacity for Vicineum and we expect to continue to rely on third-party expertise in this area. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers exposes us to certain risks that we would not be subject to if we manufactured Vicineum ourselves, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development of manufacturing capabilities to produce clinical supply of Vicineum may require our third-party manufacturers to invest substantial additional funds and hire and retain technical personnel who have the necessary manufacturing experience. Our third-party manufacturers may fail to devote sufficient time and resources to develop the capabilities to manufacture Vicineum.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because of the complex nature of Vicineum, our third party manufacturers, or other third parties we rely on, may encounter difficulties in achieving the volume of production needed to satisfy our clinical supply demands, may not be able to achieve such volume at an acceptable cost, may experience technical issues that impact comparability, quality, or compliance with applicable regulations governing the manufacture of biological products, and may experience shortages of qualified personnel to adequately staff production operations.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third-party manufacturers could default on their agreements with us to meet our requirements for supply of Vicineum, or they may terminate or decide not to renew their agreements with us, based on their own business priorities, at a time that is costly or damaging to us. If our third-party manufacturers were to terminate our arrangements or fail to meet our manufacturing demands, we may be delayed in our ability to obtain and maintain regulatory approval of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It may be difficult or impossible for us to find replacement manufacturers on acceptable terms quickly, or at all. Identifying alternate manufacturers may be difficult because the number of potential manufacturers that have the necessary expertise to produce biologics is limited. Additionally, the FDA must approve any alternative manufacturer before we may use the alternative manufacturer to produce clinical supply of Vicineum.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any third-party manufacturer makes improvements in the manufacturing process for Vicineum, we may not own, or may have to share, the intellectual property rights to such improvements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A third-party manufacturer may gain knowledge from working with us that could be used to supply one of our competitors with a product that competes with ours.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers reduces our control over production and supply of Vicineum but does not relieve us of our responsibility to ensure compliance with applicable legal and regulatory standards. The FDA and other non-US </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar non-US standards. Methods of manufacture as well as validation of manufacturing procedures and quality control systems are reviewed by regulatory authorities, such as the FDA and other comparable non-US regulatory authorities, to determine their effect on the quality, purity and potency of product candidates. All such manufacturing procedures, validation programs and quality assessment activities must be properly documented in accordance with regulatory requirements. Any failure by our third-party manufacturers to comply with cGMP or similar non-US standards, including any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. For example, we may be unable to resolve the issues raised in the CRL pertaining to a recent pre-approval inspection and product quality. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a failure by our third-party manufactures to comply with cGMP or similar non-US standards could be the basis for the FDA or any other non-US regulatory authorities to issue a warning or untitled letter, withdraw approvals for product candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import or export of products, injunction, imposing administrative or civil penalties, or pursuing criminal prosecution.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products, or if our licensors are unable to obtain and maintain patent protection for the technology or products that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our and our licensors’ ability to obtain and maintain patent protection in the United States and other countries with respect to Vicineum and our other proprietary technology and product candidates. We and our licensors have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications in jurisdictions of interest at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensors’ patent rights are highly uncertain. Our and our licensors’ pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. In addition, the laws of non-US countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned or licensed patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. In particular, during prosecution of any patent application, the issuance of any patents based on the application may depend upon our ability to generate additional pre-clinical or clinical data that support the patentability of our proposed claims. We may not be able to generate sufficient additional data on a timely basis, or at all. Moreover, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. In addition, invalidation of our patent rights by third parties could jeopardize the anticipated revenue streams from current licensees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on Vicineum and our other product candidates and technologies throughout the world would be prohibitively expensive, and our or our licensors’ intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and practices of countries outside the United States do not protect intellectual property rights to the same extent as federal and state laws in the United States. Moreover, the intellectual property laws of the United States change over time. For example, several United States Supreme Court cases have redefined what is considered to be patentable subject matter. Consequently, we and our licensors may not be able to prevent third parties from practicing our and our licensors’ inventions in all countries inside or outside the United States, or from selling or importing products made using our and our licensors’ inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export infringing products to territories where we or our licensors have patent protection, but where enforcement is not as strong as in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-US jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our or our licensor’s patents or marketing of competing products in violation of our proprietary rights generally in those countries. Proceedings to enforce our patent rights in non-US jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our and our licensors’ patents at risk of being invalidated or being interpreted narrowly and put our and our licensors’ patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of certain countries outside of the US may not protect our rights to the same extent as the laws of the United States, and such laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic and/or biosimilar product manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors’ patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic or biosimilar product manufacturers may develop, seek approval for, and generic versions or biosimilar versions, respectively, of our products. The FDA has published several guidance documents on biosimilar product development. If a biosimilar product is also found to be interchangeable with a reference product, it may be substituted for the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. If any of our product candidates are approved by the FDA, the approval of a biologic product biosimilar to or interchangeable with one of our products could have a material impact on our business. In particular, a biosimilar could be significantly less costly to bring to market and priced significantly lower than our products, if approved by the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including EU countries, have compulsory licensing laws under which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors’ efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections from the USPTO or other applicable non-US intellectual property offices. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections, or have to expend additional resources to secure registrations, such as commencing cancellation proceedings against third-party trademark registrations to remove them as obstacles to our trademark applications. In addition, in the USPTO and in comparable agencies in many non-US jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our license agreements with Zurich, Micromet and XOMA, and if we cannot meet the requirements under the agreements, we could lose important rights to Vicineum, which could have material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license agreement with Zurich. Pursuant to the Zurich License Agreement, we were granted an exclusive license, with the right to sublicense, under certain patents primarily relating, in part, to our targeting agents, EpCAM chimera and immunoconjugates (including aspects of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN) and methods of use, to make, use, sell and import products that would otherwise infringe such patents in the field of the treatment, stasis and palliation of disease in humans. If we fail to meet our obligations under the Zurich License Agreement, Zurich may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Zurich patent rights would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Zurich License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Zurich License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with Micromet, which grants us non-exclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products. If we fail to meet our obligations under the Micromet License Agreement, Micromet may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed Micromet patent rights would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the Micromet License Agreement could result in our loss of rights to practice the patent rights licensed to us under the Micromet License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a license agreement with XOMA, which grants us non-exclusive rights, with certain sublicense rights, to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems. If we fail to meet our obligations under the XOMA License Agreement, XOMA may have the right to terminate our license, and upon the effective date of such termination, our right to use the licensed XOMA patent rights and related know-how would end. To the extent such licensed technology or patent rights relate to our product candidates, we would expect to exercise all rights and remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patent rights licensed to us, but we may not be able to do so in a timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the XOMA License Agreement could result in our loss of rights to practice the patent rights licensed to us under the XOMA License Agreement, and to the extent such patent rights and other technology relate to our product candidates or other of our compounds, it could have a material adverse effect on our commercialization efforts for our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and Vicineum for the treatment of SCCHN.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks or other intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. In a trademark infringement proceeding, we could be enjoined from continued use of a trademark deemed to be infringing and forced to rebrand product packaging, product inserts, market and advertising materials, resulting in a loss of sales and established goodwill in that name or mark. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a trademark. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our partners, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO. The risks of being involved in such litigation and proceedings may increase as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. We may not be aware of all such intellectual property rights potentially relating to our product candidates and their uses. Thus, we do not know with certainty that any product candidate, or our commercialization thereof, does not and will not infringe or otherwise violate any third party’s intellectual property.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants, independent contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and our licensors’ employees, including our senior management, were previously employed at universities, medical institutions or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product candidates that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have licensed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar product manufacturers may develop, seek approval for, and launch biosimilar versions of our products, which could be significantly less costly to bring to market and priced significantly lower than our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors might not have been the first inventor to file patent applications covering certain of our inventions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may design around our intellectual property rights or independently develop similar or alternative technologies or duplicate any of our technologies without infringing or misappropriating our intellectual property rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents with claims that cover our products or even issued patents;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies or product candidates that are patentable; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the intellectual property rights of others may have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If and when we commercialize, our relationships with customers and third-party payors may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by United States federal and state governments and by governments in non-US jurisdictions in which we conduct our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a full discussion of these laws, see the subsection titled “Other Healthcare Laws and Compliance Requirements” in Item 1. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare programs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and affect the prices we may obtain.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some non-US jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any commercialization partners, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any commercialization partners, may receive for any approved products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS, the agency that administers the Medicare and Medicaid programs, may revise reimbursement and implement coverage restrictions. Any reduction in reimbursement from Medicare, Medicaid or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in March 2010, President Obama signed into law the ACA. Among the provisions of the ACA of potential importance to our business and our product candidates are the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription products and biological products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the MDRP to 23.1% for innovator drugs and 13% for non-innovator drugs of the AMP;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which AMP is calculated and reported by manufacturers for products that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient products to be covered under Medicare Part D;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers’ Medicaid rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, thereby potentially increasing manufacturers’ Medicaid rebate liability;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service Act's 340B drug pricing program;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new requirements to report to CMS annually specifying financial arrangements with physicians and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any ‘‘payments or other transfers of value’’ made or distributed to prescribers, teaching hospitals, and other healthcare providers and reporting any ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations during the preceding calendar year;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a mandatory non-deductible payment for employers with 50 or more full-time employees (or equivalents) who fail to provide certain minimum health insurance coverage for such employees and their dependents;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the ACA have been subject to judicial challenges, as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation or implementation. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Code, commonly referred to as the “individual mandate,” effective January 1, 2019. Further, the Bipartisan Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare prescription drug plans, commonly known as the “donut hole,” by raising the manufacturer discount under the Medicare Part D coverage gap discount program to 70%. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. It is unclear how the ACA and its implementation, as well as efforts to repeal, replace, or otherwise modify, or invalidate, the ACA, or portions thereof, will affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, among other things, led to aggregate reductions in Medicare payments for all items and services, including prescription drugs and biologics, to service providers of, on average, 2% per fiscal year beginning April 1, 2013, and due to subsequent legislation, will continue until 2030 (with the exception of a temporary suspension from May 1, 2020 through March 31, 2022). On December 10, 2021, President Biden signed a law that provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012 also, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which regulatory approval is obtained, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which could have a material adverse effect on our financial operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient programs, and reform government healthcare program reimbursement methodologies for drug products. For example, Congress is currently considering changes that could affect our overall rebate liability. Changes under consideration include a drug price negotiation program, Medicare Part B and Part D inflation rebates, under which manufacturers would owe rebates if the average sales price </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or average manufacturer price of a drug were to increase faster than the pace of inflation, and Part D benefit redesign, including a proposed new manufacturer discount program. If healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. We cannot be sure whether additional legislative changes will be enacted in the United States or outside of the United States, or whether regulatory changes, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory environment surrounding information security, data collection, and privacy is increasingly demanding. In the United States, we are subject to a number of data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, such as Section 5 of the Federal Trade Commission Act, govern the collection, use, and disclosure of health-related and other personal information. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may obtain health information from third parties (e.g., healthcare providers who prescribe our products) that are subject to privacy and security requirements in the United States under HIPAA. Although we are not directly subject to HIPAA-other than potentially with respect to providing certain employee benefits-we could be subject to criminal penalties if we knowingly obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Finally, a data breach affecting sensitive personal information, including health information, could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to US data protection laws and regulations, we also may be subject to European and other international data protection requirements, such as the EU General Data Protection Regulation. Our failure to comply with data privacy and security laws and regulations, or changes in the way in which these laws are implemented, could lead to unfavorable outcomes, including increased compliance costs, delays or impediments in the development of new products, increased operating costs, diversion of management time and attention, regulatory liability as a result of government enforcement actions and significant penalties against us, civil liability as a result of claims initiated by data subjects (including claims initiated as class actions) contracting parties or other third parties as a result of non-compliance with data protection laws and/or contractual obligations, and adverse publicity that could negatively affect our operating results, financial condition and our overall and business. Federal regulators, state attorneys general, and plaintiffs’ attorneys, including class action attorneys, have been and will likely continue to be active in this space. Such liabilities could adversely impact our results of operations, financial condition and our overall business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our current and future operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we operate. The FCPA prohibits any United States individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any non-US official, political party or candidate for the purpose of influencing any act or decision of the non-US entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered non-US officials. Certain payments to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on United States exchanges for violations of the FCPA’s accounting provisions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct, including intentional failure to comply with FDA regulations or similar regulations of comparable non-United States regulatory authorities, failure to provide accurate information to the FDA or comparable non-United States regulatory authorities, including the competent authorities of the EU Member States, failure to comply with manufacturing standards we have established, failure to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-United States regulatory authorities, and failure to report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business and Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 coronavirus could adversely impact our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the novel strain of coronavirus, COVID-19. The COVID-19 coronavirus has spread and has caused significant disruptions around the world. We may experience disruptions as a result of the COVID-19 pandemic that could severely impact our business, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties related to the continued clinical development of Vicineum for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including delays in clinical trial sites receiving the supplies and materials needed to conduct clinical trials, difficulties in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or treating patients in active trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in raising additional capital needed for the continued development of Vicineum for non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and if approved, commercialization for Vicineum due to the long-term negative effects of the pandemic on the financial, banking and capital markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators and other important agencies and contractors due to limitations in employee resources, travel restrictions or forced furlough of government employees;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key business activities due to illness and/or quarantine of key individuals and delays associated with recruiting, hiring and training new temporary or permanent replacements for such key individuals, both internally and at our third-party service providers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evolving changes in local regulations as part of a response to the COVID-19 outbreak that may require us to change the ways in which operate, which may result in unexpected costs; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key commercialization, manufacturing, and related activities due to limitations on work and travel imposed or recommended by federal or state governments, employers and others.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global pandemic of COVID-19 continues to evolve. The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the virus. The full impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute our business strategies and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiatives in the expected time frame, will depend on future developments, including the duration of the pandemic and continuing restrictions on travel and transports, and shelter-in-place, social distancing, and similar measures, all of which are uncertain and difficult to predict. The broad-based business and economic disruptions caused by the pandemic could materially affect our business condition, results of operations and cash flows, including our ability to raise additional capital.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could compromise our ability to execute our business plan and harm our operating results. Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could materially adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we rely on information technology networks and systems, some of which are provided, hosted or managed by third parties, to collect, store, process and transmit electronic data. In addition, we handle certain data, including proprietary business information and personal information that is subject to data protection laws and regulations. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have implemented processes, procedures, and controls to help mitigate the risks associated with a cyber security incident, there can be no assurance that these measures will be sufficient for all possible situations. Even security measures that are appropriate, reasonable, and/or in accordance with applicable legal requirements may not be able to protect the networks, systems and information we maintain and those of third parties with which we contract. Unauthorized parties, whether within or outside our company, may disrupt or gain access to our systems, or those of third parties with whom we do business, through human error, misfeasance, fraud, trickery, or other forms of deceit, including break-ins, use of stolen credentials, social engineering, phishing, ransomware, computer viruses or other malicious codes, and similar means of unauthorized and destructive tampering. Even the most well-protected information, networks, systems and facilities remain potentially vulnerable because the techniques used in such attempted cyber security incidents evolve and generally are not recognized until launched against a target. Accordingly, we may be unable to anticipate these techniques or to implement adequate security barriers or other preventative measures, making it impossible for us to entirely mitigate this risk. While we have experienced, and expect to continue to experience, threats and disruptions to our information technology infrastructure, none of them to date has had a material impact on our business or operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, our product research, development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could be delayed, or we could be subject to regulatory and other government investigations, enforcement actions, or incur liability, substantial fines or costs, any of which could materially adversely affect our business, our reputation, results of operations and financial condition. Although we maintain insurance coverage for various cyber security risks, there can be no guarantee that all costs or losses incurred will be fully insured.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our restructuring plan and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unresponsive NMIBC. The restructuring plan included a reduction in our workforce by 18 positions (approximately 35%) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring expenses for the year ended December 31, 2021 were approximately $5.5&nbsp;million, consisting primarily of severance and other employee-related costs of $2.8&nbsp;million and contract termination costs of $2.7&nbsp;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, our restructuring plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and certain of our officers have been named as defendants in three pending securities class action lawsuits and three related shareholder derivative lawsuits have been filed. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend and are uncertain in their outcome.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021 and October 7,2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys’ fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the “Securities Litigation”), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (“Lead Plaintiffs”) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the “Amended Complaint”). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants’ response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D’Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with Sesen Bio, Inc. named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by us concerning our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D’Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys’ fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the “Federal Derivative Litigation”). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intend to vigorously defend against these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management’s attention and resources from other business concerns, which could adversely affect our business. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are not able to estimate the possible cost to us from these actions, as the pending lawsuits are currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuits or the possible amount of any damages that we may be required to pay. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the pending lawsuits or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could adversely affect our business, financial condition, results of operations or stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to regain compliance with the listing requirements of the Nasdaq Global Market, our common stock may be delisted from the Nasdaq Global Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders' equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Global Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, we received notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") that we are not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement by having the closing bid price of our common stock meet or exceed $1.00 per share for at least ten consecutive business days. The notification had no immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq Global Market under the symbol “SESN” at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not regain compliance by July 25, 2022, we may be eligible for an additional 180 calendar day grace period. If we fail to regain compliance during the applicable period, we will receive notification from Nasdaq that our common stock is subject to delisting. At that time, we may then appeal the delisting determination to a Nasdaq hearings panel. Such notification will have no immediate effect on our listing on the Nasdaq Global Market, nor will it have an immediate effect on the trading of our common stock pending such hearing. There can be no assurance, however, that we will be able to regain compliance with Nasdaq’s minimum bid price requirement. If we regain compliance with the Nasdaq’s minimum bid price requirement, there can be no assurance that we will be able to maintain compliance with the continued listing requirements for the Nasdaq Global Market or that our common stock will not be delisted from the Nasdaq Global Market in the future. In addition, we may be unable to meet other applicable listing requirements of the Nasdaq Global Market, including maintaining minimum levels of stockholders’ equity or market values of our common stock in which case, our common stock could be delisted notwithstanding our ability to demonstrate compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from the Nasdaq Global Market may adversely affect our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are delisted from Nasdaq and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or in the “pink sheets.” As a result, we could face significant adverse consequences including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and little or no analyst coverage for us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would no longer qualify for exemptions from state securities registration requirements, which may require us to comply with applicable state securities laws; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities (including pursuant to short-form Registration Statements on Form S-3) or obtain additional financing in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our common stock becomes subject to the penny stock rules, it would become more difficult to trade our shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain our listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock may be deemed a penny stock. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be affected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our Certificate of Incorporation or bylaws.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;1B.&nbsp;&nbsp;&nbsp;&nbsp;Unresolved Staff Comments.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Properties.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a 31,100 square foot manufacturing, laboratory, warehouse and office facility in Winnipeg, Manitoba. We have three 15-liter fermenters, one 30-liter fermenter, one 150-liter fermenter, one 500-liter fermenter and one 1,500-liter fermenter. Our classified fermentation suite and post-production processing capabilities were dedicated to producing our pre-clinical study and clinical trial batches of Vicineum.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we completed the manufacturing of all Vicineum necessary for our Phase 3 VISTA Trial and for our CRADA with the NCI.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with this achievement, we ended our manufacturing activities at our facility in Winnipeg and completed the technology transfer process to outsource future Vicineum clinical and commercial to third-party manufacturers. We operate our Winnipeg facility under a two-year renewable lease expiring in September 2022, and we have a right to renew the lease for one subsequent three-year term.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Cambridge, MA, where we occupy office space under a lease that was executed in October 2016. The initial term of the lease expired in July 2017, with the lease now continuing on a renewable four-month term unless terminated by either party with the requisite notice. The lease is currently extended through</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have office space in Philadelphia, PA, where we occupy office space under a lease executed in December 2017. The initial term of the lease expired in May 2018, which now continues on renewable six-month terms unless terminated by either party with the requisite notice. The lease has been extended through</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities are adequate to meet our current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints seek compensatory damages and costs and expenses, including attorneys’ fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the “Securities Litigation”), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (“Lead Plaintiffs”) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the “Amended Complaint”). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants’ response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D’Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant, but no defendant has yet been served. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D’Arcy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys’ fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the “Federal Derivative Litigation”). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages, and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_28"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Price</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol "SESN" on the Nasdaq Global Market. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&nbsp;21, 2022, there were 17 holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid, and for the foreseeable future do not expect to declare or pay, cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.          &nbsp;&nbsp;&nbsp;&nbsp;[Reserved.]</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_31"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;Management’s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes thereto and other financial information included elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. You should review "Item 1A. Risk Factors" of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA’s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a Type A Meeting with the FDA to discuss questions related to CMC raised in the CRL (the “CMC Type A Meeting”). During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum (the “Clinical Type A Meeting”), which the FDA confirmed will be required for a potential resubmission of a BLA. The trial design may include these elements:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators’ choice of intravesical chemotherapy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trial may include both patients who have received adequate BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients who have received less than adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA encouraged us to submit the final results from the Phase 3 Vista Trial for Vicineum with a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted our request for a Type C Meeting to discuss the study protocol for an additional Phase 3 clinical trial that we plan to conduct for potential resubmission of a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the items we expect to be discussed in the Type C Meeting is the patient population for the additional Phase 3 clinical trial, which may be different than the patient population studied in previous clinical trials for Vicineum for the treatment of NMIBC in two primary ways. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, the additional Phase 3 clinical trial may include patients with only non-muscle invasive carcinoma in situ (CIS) of the bladder, and may not include patients with only papillary disease of the bladder. This change would lead to a smaller overall patient population than previously studied, as some of our past clinical trials of Vicineum in NMIBC have included patients with CIS or high-grade papillary disease of the bladder. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the additional Phase 3 clinical trial may include patients who have received less than adequate BCG in addition to those who have received adequate BCG, per the FDA’s guidance. Receipt of less than adequate BCG could be due to (i) failure of, or intolerance to, a BCG therapy prior to reaching the FDA’s definition of adequate BCG or (ii) supply shortages of BCG, among other reasons. This change would lead to a larger patient population than previously studied, as past clinical trials of Vicineum in NMIBC only included patients who had previously been treated with adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential changes related to the additional Phase 3 clinical trial for Vicineum will be discussed at the upcoming Type C Meeting with the FDA scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The single-arm, multi-center, open-label Phase 3 clinical trial (“VISTA Trial”) completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and duration of response ("DoR") for BCG-unresponsive CIS patients who experience a complete response ("CR").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate†:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">†Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. Final numbers</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are pending. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (“PPQ”) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be highly comparable to supply of Vicineum at our Winnipeg facility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work ("SOW #11") with Fujifilm under the Fujifilm MSA for the manufacturing of commercial batches of Vicineum in 2022 and 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use Vicineum produced by Fujifilm and Baxter for any future clinical trials of Vicineum and, if approved, for commercial supply.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (“MENA”) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9 million of revenue during the three months ended June 30, 2021, for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments to Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in MENA region (20 countries in Middle East and North Africa) (the “MENA License Agreement”). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with EİP Eczacıbaşı İlaç Pazarlama A.Ş., (“EIP”) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5 million. We are in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal Review</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 we disclosed that our Board of Directors (the “Board”) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the “Review”). The Review took place over the course of five months, involved full cooperation from our management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. It is now complete. As a result of the Review, the Board continues to fully support our current management team and believes no changes or amendments relating to our prior disclosures to the Securities and Exchange Commission (“SEC”) or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. We intend to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). In the future, we may generate revenue from a combination of up-front payments, milestone payments and royalties in connection with our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations ("CROs") and investigative sites that conduct our clinical trials, including the additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our clinical trials, including the additional Phase 3 clinical trial, and other research and development activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG compared to alternative treatments, including any standard of care;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market acceptance of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the implementation of commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG could mean a significant change in the costs and timing associated with the development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently contemplate will be required for the completion of clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, we could be required to expend significant additional financial resources and time on the completion of clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of BCG-unresponsive NMIBC and other expenses by category. We have deferred further development of Vicineum for the treatment of SCCHN and VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of BCG-unresponsive NMIBC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,110&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,234&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,977&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,513&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,172&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,202&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,640&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,663</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, insurance, investment banking fees, patent, consulting and accounting services, pre-commercial United States market research and pre-launch market readiness for the potential commercial launch of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the “Restructuring Plan”). The Restructuring Plan included a reduction in our workforce by 18 positions (or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum. Restructuring costs related to the Restructuring Plan were recorded in operating expenses in our Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed. The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region as well as discount rates applied to the projected cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years ended December&nbsp;31, 2021 and 2020 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,308&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,544&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,236&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,308&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,312&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,191&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,393&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,302&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,091&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,528&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,700&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,093&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,313&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,528&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss Before Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,609)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,343</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,273&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,718&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,397)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(98)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2021 was $26.5 million, primarily due to the $20 million milestone achieved pursuant to the Roche License Agreement upon initiating a Phase II clinical trial, $5.0 million related to the Qilu License Agreement (achievement of the IND milestone, clinical supply revenue, and license revenue for additional purchase price due to the recovery of VAT), and $1.5 million upfront milestone revenue achieved pursuant to the MENA License Agreement. Revenue for the year ended December 31, 2020 was $11.2 million, which was due to the recognition of revenue pursuant to the Qilu License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $25.3 million for the year ended December&nbsp;31, 2021, compared to $29.2 million for the year ended December&nbsp;31, 2020. The decrease of $3.9 million was primarily due to lower costs associated with technology transfer and manufacturing ($7.4 million). This was partially offset by increases in employee-related compensation driven by increased headcount as part of the commercial build and the retention program implemented after receipt of the CRL in August 2021 ($2.1 million), regulatory and clinical consulting fees ($1.0 million)</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other R&amp;D expense, none of which were individually material ($0.5 million). We anticipate that R&amp;D expenses will increase beginning in 2022 due to additional clinical trial activity costs related to our plans to conduct an additional Phase 3 clinical trial for Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $29.4 million for the year ended December&nbsp;31, 2021, compared to $14.3 million for the year ended December&nbsp;31, 2020. The increase of $15.1 million was primarily due to increases in employee-related compensation ($5.0 million), legal costs ($4.8 million), and marketing and commercial expenses ($4.1 million) driven by preparation for the commercial launch of Vicineum prior to the issuance of the CRL in August 2021. Additionally, increases in accounting services ($0.4 million), insurance expenses ($0.4 million), IT expenses ($0.3 million) and others ($0.1 million) contributed to the increase. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the “Restructuring Plan”). The Restructuring Plan included a reduction in our workforce by 18 positions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or approximately 35% of our workforce) as well as additional cost-saving initiatives intended to preserve capital while we continue development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructurin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g expenses were $5.5 million for the year ended December&nbsp;31, 2021, compared to no restructuring expenses for the year ended December&nbsp;31, 2020. The increase was due to one-time costs associated with the Restructuring Plan implemented in response to the CRL for severance and other employee-related costs ($2.8 million) and termination of certain contracts ($2.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles Impairment Charge</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an intangibles impairment charge of $31.7 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&nbsp;31, 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any impairment charges during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the year ended December&nbsp;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The impairment charge of $31.7 million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&nbsp;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relates to the full impairment of our US in-process research and development asset due to expected delays in the start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market at this time.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $56.8 million for the year ended December&nbsp;31, 2021, compared to income of $11.2 million for the year ended December&nbsp;31, 2020. The decrease in the fair value of contingent consideration of $45.7 million from the year ended December&nbsp;31, 2020 to the year ended December&nbsp;31, 2021, was driven by the receipt of a CRL from the FDA, regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. Due to the inherent uncertainty in the path forward for Vicineum at this time, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of the contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success POS; we expect delays in the start of commercialization and estimate lower POS as a direct result of the CRL and our withdrawal of the MAA. We will need to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management’s best estimate. In addition, we now assume a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. We participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped us determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was income of $11.2 million for the year ended December&nbsp;31, 2020. This was primarily attributable to significantly higher discount rates as a result of financial market conditions as of the year ended December&nbsp;31, 2020, offset by changes to the competitive landscape.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (expense) income, net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was $0.1 million for the year ended December&nbsp;31, 2021, compared to other income of $0.1 million for the year ended December&nbsp;31, 2020. The change of $0.2 million was due primarily to lower interest income.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December 31, 2021, we recorded a benefit from income taxes of $8.3 million. In the third quarter of 2021, we determined that the fair value of the Vicineum United States in-process research and development asset was zero, which resulted in an impairment charge of $31.7 million. In connection with this impairment charge, in the third quarter of 2021, we wrote-down the associated deferred tax liability by $8.6 million as a benefit. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the twelve months ended December 31, 2020, we recorded a provision for income taxes of $1.4 million</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision consisted of income taxes paid to non-US jurisdictions pursuant to our commercialization partnership agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years ended December&nbsp;31, 2020 and 2019 </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of our results of operations for the years ended December&nbsp;31, 2020 and 2019, see "Part II - Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2020, filed with the United States Securities and Exchange Commission ("SEC") on March 15, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we had cash and cash equivalents of $162.6 million, net working capital of $194.0 million and an accumulated deficit of $316.3 million. We incurred negative cash flows from operating activities of $68.9 million, $30.8 million and $37.5 million for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively. We believe that our cash and cash equivalents of $162.6 million as of December&nbsp;31, 2021, are sufficient to fund our operating plan into 2024. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we seek to address the issues raised in the CRL we received for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into an Open Market Sale Agreement (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time for an aggregate sales price of up to $35 million through Jefferies (the "ATM Offering"). In October 2020 and February 2021, we entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No.2 modified the Sale Agreement to reflect that we may issue and sell shares of our common stock from time to time for an aggregate sales price of up to an additional $50.0&nbsp;million and $34.5&nbsp;million, respectively. In June 2021, we entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&nbsp;million of our common stock pursuant to the Sale Agreement. Sale of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. As of December&nbsp;31, 2021, we have $97.8&nbsp;million in available ATM capacity.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We raised $175.0 million of net proceeds from the sale of 56.9 million shares of common stock at a weighted-average price of $3.17 per share during the year ended December&nbsp;31, 2021. We raised $38.0 million of net proceeds from the sale of 33.4 million shares of common stock at a weighted-average price of $1.17 per share during the year ended December&nbsp;31, 2020. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $5.4 million and $1.2 million for the year ended December&nbsp;31, 2021 and December&nbsp;31, 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the outbreak of COVID-19. We are proactively executing risk mitigation strategies to attenuate the impact of COVID-19 on us, and at this time, we have not yet experienced any business disruptions as a result of the pandemic. We are continually assessing the effect of the COVID-19 pandemic on our operations, and we are monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to develop and, if approved, commercialize our product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon our ability to attain profitable operations. In order to commercialize our product candidates, including Vicineum, we need to complete clinical development and comply with comprehensive regulatory requirements. We are subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of our product candidates, raising additional capital, development and commercialization by our competitors of new technological innovations, protection of proprietary technology and market acceptance of our products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and we expect to seek additional funds through equity or debt financings or through additional OUS business development partnerships, collaborations, licensing transactions or other sources. We may be unable to obtain equity or debt financings or enter into additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, collaborations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or licensing transactions at favorable terms, or at all, and, if necessary, we may be required to implement cost reduction strategies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">address the issues identified in the CRL we received from the FDA for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, including the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities (including completing the manufacturing process and technology transfer to any third-party manufacturers) to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and our other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of pre-clinical development and laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and our other product candidates, including an additional Phase 3 clinical trial for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on our business</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships, collaborations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA, and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA or comparable non-US regulatory authorities to require that we perform more studies than those that we currently expect to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain future regulatory, development and commercialization milestones under our out-license and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization OUS business development partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues from commercial sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alliances, and licensing arrangements. We do not have any committed external source of funds other than the amounts payable under our out-license and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, strategic </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alliances or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect our ability to raise additional capital in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 “Fair Value Measure and Financial Instruments,” as well as the description of our leases in Note 7 “Property and Equipment”, and the description of our license agreement and collaborations in Note 17, “License Agreements” of Part IV - Item 15. Exhibits and Financial Statements - Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the years ended December&nbsp;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Operating Activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,837)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,129&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,113&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,356&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">107,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,268</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,301)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $68.9 million for the year ended December&nbsp;31, 2021 and consisted primarily of a net loss of $0.3 million, which includes $26.5 million of revenue recognized pursuant to the Roche License Agreement upon Roche initiating a Phase II clinical trial, achievement of the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS partner for Greater China, and license revenue for additional purchase price due to the recovery of VAT by our OUS business development partner for Greater China, adjusted for non-cash items, including share-based compensation of $5.1 million, a decrease in the fair value of contingent consideration of $56.8 million, impairment charge of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a net decrease in operating assets and liabilities of $48.6&nbsp;million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $30.8 million for the year ended December&nbsp;31, 2020 and consisted primarily of a net loss of $22.4 million, adjusted for non-cash items, including depreciation of $0.1 million, share-based compensation of $1.8 million, a change in the fair value of the contingent consideration of $11.2 million and a net increase in operating assets and liabilities of $0.9 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $37.5 million for the year ended December&nbsp;31, 2019 and consisted primarily of a net loss of $107.5 million, adjusted for non-cash items, including depreciation of $0.2 million, share-based compensation of $1.2 million, a change in the fair value of contingent consideration of $71.6 million and a net decrease in operating assets and liabilities of $3.1 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during each of the years ended December&nbsp;31, 2021, and 2020 and $0.1 million for the year ended December&nbsp;31, 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $176.1 million for the year ended December&nbsp;31, 2021 and consisted of $175.0 million in net proceeds from the sale of common stock under the ATM Offering and $1.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $38.1 million for the year ended December&nbsp;31, 2020 and consisted of $38.0 million net proceeds from the sale of common stock under the ATM Offering and $0.1 million in proceeds from the exercise of common stock warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $35.4 million for the year ended December&nbsp;31, 2019 and consisted primarily of $27.8 million in net proceeds from our June 2019 Financing, $5.5 million from the exercise of outstanding warrants to purchase our common stock and $1.9 million in net proceeds from our ATM Offering.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG is not obtained, we will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we received a CRL from the FDA regarding our BLA for Vicineum for the treatment of NMIBC, our lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and our withdrawal of the MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of our intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7 million of impairment charges are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, we have assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that we expect the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on our reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein we determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as our strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bladder in patients previously treated with adequate or less than adequate BCG. We performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of our intangible asset of Vicineum EU rights was not impaired as of December&nbsp;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit’s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and our withdrawal of the MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of our intangible assets, Vicineum US Rights, we concluded that the carrying value of our goodwill of $13.1&nbsp;million was not impaired as of September 30, 2021. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We performed the annual goodwill impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was no goodwill impairment as of December&nbsp;31, 2021. While our stock price has declined since December&nbsp;31, 2021, this is consistent with the general biotech sector overall, as world economic conditions continue to be impacted by the highly contagious Omicron variant. We believe that we have sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. We project future cash flows based on various timeline assumptions and applies a probability to each outcome based on management’s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. We will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales royalties due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. For additional information on how contingent consideration has changed over the relevant period, see "Part IV - Item 15. Financial Statements - Notes to Consolidated Financial Statements - Note 1. Description of Business" of this Annual Report on Form 10-K. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. We reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success (POS); we expect delays in the start of commercialization and estimate lower POS as a direct result of the CRL. We plan to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally and any significant changes or delays could have a significant impact on the fair value of contingent consideration. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management’s best estimate. In addition, we now assume a lower POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company’s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company’s estimated weighted-average cost of capital (“WACC”), which has fluctuated from 8.8% as of December&nbsp;31, 2020, to 7.8% as of March 31, 2021, 6.8% as of June 30, 2021, 8.6% as of September 30, 2021, and 9.3% as of December&nbsp;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.4% as of December&nbsp;31, 2020, to 7.4% as of March 31, 2021, 6.6% as of June 30, 2021, 7.5% as of September 30, 2021, and 8.0% as of December&nbsp;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, we evaluate whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, we will note recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management’s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in "Part IV - Item 15. Exhibits and Financial Statements - Notes to Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements" in our consolidated financial statements, which begin on page F-1 of this Annual Report on Form 10-K.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_34"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements, together with the report of our independent registered public accounting firm, appear in the Index to Financial Statements beginning on page F-1 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices or financial disclosure required to be reported under this Item.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_37"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Annual Report on Form 10-K. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&nbsp;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting ("ICFR"), as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. ICFR includes our policies and procedures, such as our Code of Conduct, which (i) require our employees, officers and directors to adhere to certain ethical standards; (ii) require the maintenance of records, in reasonable detail, to help to ensure that our transactions, assets and liabilities are accurately and fairly recorded; (iii) provide reasonable assurance that transactions are authorized by our management and directors and are recorded as necessary to allow for the accurate preparation of financial statements in accordance with GAAP; and (iv) provide reasonable assurance regarding the safeguarding of our assets and the prevention or timely detection of the unauthorized acquisition, use or disposition of our assets, which could have a material effect on the financial statements. ICFR includes the controls themselves, management's monitoring of those controls, actions taken to correct any deficiencies identified and oversight of our internal control environment by the audit committee of our board of directors. Any system of internal control has inherent limitations and therefore may not prevent or detect misstatements. Projections of any evaluation of the effectiveness of ICFR to future periods are subject to the risk that controls may become inadequate over time because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our ICFR as of the end of our fiscal year 2021 and has reviewed the results of this assessment with the audit committee of our board of directors. Management based its assessment on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that our ICFR was effective as of December&nbsp;31, 2021 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our ICFR as of December 31, 2021 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included immediately below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sesen Bio, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Sesen Bio Inc.’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sesen Bio, Inc. (the “Company”) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ (deficit) equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorName" id="fact-identifier-35" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8zNy9mcmFnOjI2MTg4NGZjNTE3ZDRiMmQ5NDEwOWVkMThkOWFhNTk2L3RleHRyZWdpb246MjYxODg0ZmM1MTdkNGIyZDk0MTA5ZWQxOGQ5YWE1OTZfNDM5ODA0NjU0OTcxMA_2f495277-264d-4d37-988f-cb6f8f3951e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ernst &amp; Young LLP</ix:nonnumeric></span></span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span><br></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2022</span></div><div><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been changes in our internal control over financial reporting during the quarter ended December 31, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br></span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_40"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;9C.&nbsp;&nbsp;&nbsp;&nbsp;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_43"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has adopted a written Code of Business Conduct and Ethics applicable to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Business Conduct and Ethics covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of our property and information and compliance with legal and regulatory requirements. A current copy of the code is posted on the Corporate Governance section of our website, which is located at&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.sesenbio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any substantive amendment to, or waiver from, a provision of this Code and by posting such information on the website address and location specified above.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&nbsp;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;11. &nbsp;&nbsp;&nbsp;&nbsp;Executive Compensation.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&nbsp;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;12. &nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&nbsp;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;13. &nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&nbsp;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;14. &nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be set forth in our 2022 Proxy Statement to be filed with the SEC within 120 days of December&nbsp;31, 2021 and is incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_49"></div><div style="-sec-extract:summary;margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1)&nbsp;Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements listed in the Index to Financial Statements beginning on page F-1 are filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(2) Financial Statement Schedules</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statement schedule listed in the Index to Financial Statements on page F-1 is filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) Exhibits</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form&nbsp;10-K are set forth on the Exhibit&nbsp;Index immediately preceding such exhibits and are incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex21.htm" tabindex="18">Share Purchase Agreement, effective as of September 20, 2016, by and between Eleven Biotherapeutics, Inc., Viventia Bio Inc. and Clairmark Investments Ltd., as representative of the selling shareholders (we hereby agree to furnish supplementally a copy of any omitted schedules to the SEC upon request). Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm" tabindex="18">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm" tabindex="18">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm" tabindex="18">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm" tabindex="18">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit41-fy2021form10xk.htm" tabindex="18">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm" tabindex="18">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm" tabindex="18">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (Reg. No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm" tabindex="18">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm" tabindex="18">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm" tabindex="18">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm" tabindex="18">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex101.htm" tabindex="18">Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 filed on December&nbsp;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex102.htm" tabindex="18">Form of Incentive Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 filed on December&nbsp;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312513487942/d613481dex103.htm" tabindex="18">Form of Non-statutory Stock Option Agreement under the Amended and Restated 2009 Stock Incentive Plan. Incorporated by reference to Exhibit 10.3 to our Registration Statement on Form S-1 filed on December&nbsp;30, 2013 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000045/sesenbio-2014stockincentiv.htm" tabindex="18">2014 Stock Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 25, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex106.htm" tabindex="18">Form of Incentive Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.6 to our Registration Statement on Form S-1/A filed on January&nbsp;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex107.htm" tabindex="18">Form of Non-statutory Stock Option Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&nbsp;10.7 to our Registration Statement on Form S-1/A filed on January&nbsp;23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312515239156/d34817dex101.htm" tabindex="18">Form of Restricted Stock Unit Agreement under 2014 Stock Incentive Plan. Incorporated by reference to Exhibit&nbsp;10.1 to our Current Report on Form 8-K filed on June 29, 2015 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit108_formindemnifica.htm" tabindex="18">Form of Indemnification Agreement by and between Sesen Bio, Inc. and Each of its Directors and Executive Officers. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex1013.htm" tabindex="18">2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.13 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10†<br></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500316000144/ebio-063016x101.htm" tabindex="18">License Agreement, dated as of June 10, 2016, by and among Eleven Biotherapeutics, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on August 12, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11†<br></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex101.htm" tabindex="18">License Agreement, effective January 13, 2003, as amended and restated on October 14, 2015, by and between The University of Zurich and Viventia Bio Inc. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12†</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit101micrometli.htm" tabindex="18">Non-Exclusive Product License Agreement, effective as of October 18, 2005, by and between Micromet AG and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13†</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000120/sesnexhibit102xomanonexc.htm" tabindex="18">Non-Exclusive License Agreement, effective as of November 30, 2001, by and between XOMA Ireland Limited and Viventia Biotech Inc. Incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on November 9, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000105/exhibit101-tcannellemploym.htm" tabindex="18">Employment Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 13, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit101.htm" tabindex="18">Form of Securities Purchase Agreement. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-spaamendment.htm" tabindex="18">Amendment to Securities Purchase Agreement, dated October 28, 2019, by and among Sesen Bio, Inc. and the undersigned parties thereto. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1032sesn-tomcannellstock.htm" tabindex="18">Stock Option Award Agreement, dated August 7, 2018, by and between Sesen Bio, Inc. and Thomas R. Cannell, D.V.M. Incorporated by reference to Exhibit 10.32 to our Annual Report on Form 10-K filed on March 1, 2019 (File. No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18†</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000015/ex1034sesn-fujimbsafullred.htm" tabindex="18">Master Bioprocessing Services Agreement, dated October 4, 2018, between Sesen Bio, Inc. and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Incorporated by reference to Exhibit 10.34 to our Annual Report on Form 10-K filed on March 1, 2019 (File. No. 001-36296). </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">E</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000029/glenmacdonaldebioemploym.htm" tabindex="18">mployment Agreement, dated September 20, 2016, by and between Eleven Biotherapeutics, Inc. and Glen Macdonald, as amended on February 21, 2017. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 10, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000070/sesenbio-monicaforbesemplo.htm" tabindex="18">Employment Agreement, dated August 26, 2019, by and between Monica Forbes and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2019 (File No. 001-36296).</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex101.htm" tabindex="18">Employment Agreement, dated July 26, 2019, by and between Mark R. Sullivan and Sesen Bio, Inc. Incorporated herein by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000090/sesn-09302019x10qex103.htm" tabindex="18">Stock Option Award Agreement, dated August 1, 2019, by and between Sesen Bio, Inc. and Monica Forbes. Incorporated herein by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed on November 12, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm" tabindex="18">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm" tabindex="18">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm" tabindex="18">, dated November 2019, by and between Sesen Bio, Inc. and Jeff</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm" tabindex="18">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500319000096/sesn-atmsalesagencyagreeme.htm" tabindex="18">ries LLC. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on November 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm" tabindex="18">Amendment No. 1 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm" tabindex="18">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000110/exhibit11-amendmentno1to.htm" tabindex="18">, dated October 30, 2020, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on October 30, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25†</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500320000118/sesn-ex101qilulicensea.htm" tabindex="18">Exclusive License Agreement, dated July 30, 2020, by and among Sesen Bio, Inc., Viventia Bio, Inc. and Qilu Pharmaceutical Co., Ltd. Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on November 9, 2020 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm" tabindex="18">Amendment No. 2 to the Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm" tabindex="18">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500321000024/sesenatm-amendmentno2toa.htm" tabindex="18">, dated February 17, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on February 17, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit101-amendmentno2t.htm" tabindex="18">Amendment No. 2 to the Sesen Bio, Inc. 2014 Stock Incentive Plan. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000088/exhibit102-amendmentno1t.htm" tabindex="18">Amendment No. 1 to the Sesen Bio, Inc. 2014 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on May 3, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001485003/000148500321000114/sesn-amendmentno3toatmsa.htm" tabindex="18">Amendment No. 3 to the Open Market Sale AgreementSM, dated June 1, 2021, by and between Sesen Bio, Inc. and Jefferies LLC. Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on June 1, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1030-rsuandcashrete.htm" tabindex="18">Form of RSU Award Agreement for Retention Awards</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31*+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit1031-performancexba.htm" tabindex="18">Form of PSU Award Agreement for Retention Awards </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-12312021x10kex211.htm" tabindex="18">Subsidiaries of Sesen Bio, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/exhibit231eyconsentforfy20.htm" tabindex="18">Consent of Ernst &amp; Young LLP.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-12312021x10kex311.htm" tabindex="18">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-12312021x10kex312.htm" tabindex="18">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-12312021x10kex321.htm" tabindex="18">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000033/sesn-12312021x10kex322.htm" tabindex="18">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)&nbsp;&nbsp;&nbsp;&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></tbody></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit is a compensatory plan or arrangement in which our executive officers or directors participate.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.</span></td></tr></tbody></table></div><div style="margin-bottom:1pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Form 10-K Summary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.&nbsp;</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Capacity</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elly Ryu</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Controller<br>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elly Ryu</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay S. Duker, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carrie L. Bourdow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrie L. Bourdow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;Jason A. Keyes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason A. Keyes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter K Honig, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter K Honig, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael A.S. Jewett, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_58"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tbody><tr><td style="width:1.0%"></td><td style="width:88.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm (PCAOB ID: <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorFirmId" id="fact-identifier-36" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV81OC9mcmFnOjcxYjA3ZmRlZDJlNDRiOTBhZjQwYzg0MWQxNjk1OTI1L3RhYmxlOmY5OGE5ZGRhMGI0NjQ2OTlhZmVmNWQ3MWFiODlkMDNiL3RhYmxlcmFuZ2U6Zjk4YTlkZGEwYjQ2NDY5OWFmZWY1ZDcxYWI4OWQwM2JfMS0wLTEtMS01MDgyMy90ZXh0cmVnaW9uOmNmNjA0ODY1ODcyZDQ2NTdhMWVlMTliYTQyNmQ1ODIzXzE3MDQyNDMwMjMwNjA0_2bcd8e6a-5ae6-410f-9889-4b49b81396dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonnumeric></span>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_61" tabindex="18">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_64" tabindex="18">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_67" tabindex="18">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Changes in Stockholders’ Equity (Deficit)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_70" tabindex="18">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_76" tabindex="18">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5a63ddb584a0db5ee835d7440b255_79" tabindex="18">8</a></span></div></td></tr></tbody></table></div><div style="margin-bottom:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_61"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Sesen Bio, Inc.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Sesen Bio, Inc. (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’ (deficit) equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Contingent Consideration</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3 and 5 to the consolidated financial statements under the caption “Contingent Consideration,” the Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. Fluctuations in the fair value of the liability result in a charge to earnings (or loss) during the period. As of December 31, 2021, the Company estimated the fair value of the contingent consideration liability as $52.0 million and recorded the change in fair value of $56.8 million as operating income for the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt"><span><br></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the fair value of the contingent consideration liability required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value. In particular, the fair value measurement was sensitive to the significant assumptions underlying the projected commercial sales of Vicineum and probabilities of success and timing of certain milestone events and achievements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company’s process to estimate the fair value of the contingent consideration liability. This included testing controls over management’s review of the significant estimation assumptions and methods used to develop the fair value estimate, the accuracy of the calculations included within the fair value model, and the underlying data used in the model.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the contingent consideration liability, our audit procedures included, among others, assessing the terms of the arrangement, evaluating the methodology used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management’s conclusions. In addition, we involved our valuation professionals to assess the methodology used to determine the fair value of the contingent consideration liability, which included performing corroborative fair value calculations.</span></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Impairment Evaluation of Goodwill and Indefinite-Lived Intangible Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3 and 8 to the consolidated financial statements under the captions “Indefinite-Lived Intangible Assets” and “Goodwill,” the Company’s intangible assets consist of indefinite-lived, acquired in-process research and development (IPR&amp;D) worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. Goodwill on the Company's consolidated balance sheets is the result of the Company’s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of IPR&amp;D requires management to estimate the future discounted cash flows of the underlying asset. Impairment testing of goodwill requires management to estimate the future discounted cash flows of the Company’s one reporting unit.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management’s impairment assessments required significant auditor judgment due to the high degree of subjectivity in evaluating certain assumptions used to estimate the fair value of the reporting unit for and the IPR&amp;D. In particular, the fair value estimates of goodwill and of IPR&amp;D were sensitive to the significant assumptions underlying the projected commercial sales of Vicineum.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the development of the significant assumptions over the Company’s goodwill and indefinite-lived intangible asset impairment review processes. This included testing controls over management’s review of the quantitative impairment analyses of goodwill and IPR&amp;D, including the significant estimation assumptions and methods used, the accuracy of the calculations included within the valuation models, and the underlying data used in those models.</span></div><div style="margin-bottom:3pt"><span><br></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the impairment evaluations over goodwill and IPR&amp;D assets, our audit procedures included, among others, evaluating the methodology and valuation models used and testing the key inputs and significant assumptions discussed above. We evaluated the significant assumptions in light of observable industry and economic trends and standards, external data sources, probability of success benchmarks, and regulatory factors. Our procedures included evaluating the data sources used by management in determining its significant assumptions and included an evaluation of available information that either corroborated or contradicted management’s conclusions. In addition, we inspected the Company’s reconciliation of the fair value of the reporting unit to the market capitalization of the Company and assessed the results. We involved our valuation professionals to assess the methodology and valuation of the discounted cash flow models, including evaluating the reasonableness of certain significant assumptions.</span></td></tr></tbody></table></div><div><span><br></span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorName" id="fact-identifier-37" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjI0MQ_2f495277-264d-4d37-988f-cb6f8f3951e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ernst &amp; Young LLP</ix:nonnumeric></span></span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company’s auditor since 2010.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="dei:AuditorLocation" id="fact-identifier-38" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82MS9mcmFnOjMzOWI5ZWEwZjRlYzRjMmRhYTIxMjE2ZTBkMWQwMzllL3RleHRyZWdpb246MzM5YjllYTBmNGVjNGMyZGFhMjEyMTZlMGQxZDAzOWVfNTQ5NzU1ODE4MjIxOA_5c2af772-bd81-4ce8-94a0-10f6f6e071d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Boston, Massachusetts</ix:nonnumeric></span></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 28, 2022</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_64"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-39" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0xLTEtMS0yNzc0Mw_c427a9bc-4398-4ef3-8f58-10f5d3af827b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162,636</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-40" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNC0zLTEtMS0yNzc0Mw_4a4c21e5-2107-47b1-9fcb-f7d1467d39d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,389</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-41" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0zNjQwNw_a7b9d6ad-5951-462d-9a61-1eba04d83d01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,011</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-42" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0zNjQxNA_bcd87d43-6a0c-4c3c-b40b-68f67e95768d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-43" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0zNjM5Mg_d8f40cd3-57ca-4850-826f-21827656413d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,482</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-44" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0zNjQwMA_b97cb8c1-15bc-4c35-8f59-2b19673cb9e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-45" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0xLTEtMS0yNzc0Mw_bab830d3-76c0-4fab-b042-3a16fb3b3769" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-46" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNS0zLTEtMS0yNzc0Mw_81b98b70-5430-41d5-813d-c8a6106f7910" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,478</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-47" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0xLTEtMS0yNzc0Mw_d6b304cc-5443-4437-a395-b5b1ccabccdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-48" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNi0zLTEtMS0yNzc0Mw_77fa4435-9db0-4b39-85f3-97190de5fd80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-49" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0xLTEtMS0yNzc0Mw_8936dd71-817f-41c7-8b54-6960fd135b98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">205,605</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-50" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfNy0zLTEtMS0yNzc0Mw_e4202f41-88e5-4a17-837d-97f9b1f779f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,867</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="fact-identifier-51" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0xLTEtMS0yNzc0Mw_59a08bda-a49e-4583-9695-d226cdda8fae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="fact-identifier-52" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOC0zLTEtMS0yNzc0Mw_554f5813-c2a0-40dd-8a33-6fa4431cf774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-53" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0xLTEtMS0yNzc0Mw_844b6939-b618-4972-9566-acf19ce6db2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-54" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfOS0zLTEtMS0yNzc0Mw_310f0dc9-8e74-46b1-a209-be8249e68b67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-55" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMS0xLTEtMjc3NDM_10f2a147-b8ec-4bf0-8d1e-b19149602e70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-56" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTAtMy0xLTEtMjc3NDM_9901ff4e-a4d6-415b-82d9-633b567f4e8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,400</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-57" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMS0xLTEtMjc3NDM_0cceaafe-4039-457e-9ab7-3e69fecdd7e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,064</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-58" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTEtMy0xLTEtMjc3NDM_6b1a01cd-c124-4a32-847c-e2b7e51e7d1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,064</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-59" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMzY0MzI_95d8eb86-b49a-49ac-939b-97622e614abe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,192</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-60" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMzY0MzI_b70b091a-ab51-45ce-ae83-dda1a33c1bdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="fact-identifier-61" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMS0xLTEtMjc3NDM_3edd6372-023a-4b7b-8904-4f043278c195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="fact-identifier-62" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTItMy0xLTEtMjc3NDM_df61253c-b48b-4dca-a8d8-9f3596f4f44d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">349</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-63" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtNDU5MTY_ea3f63b6-27bc-49e9-ae14-b212795582fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,142</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-64" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtNDU5MTY_1aa3503e-2e1b-436d-8d6b-ac08e9ea4f60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,956</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-65" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMS0xLTEtMjc3NDM_d1a59f29-614b-418d-ae12-32936860f87f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">240,747</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-66" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTMtMy0xLTEtMjc3NDM_0ca21761-d016-46af-a4ff-a668808490ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,823</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders’ Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-67" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMS0xLTEtMjc3NDM_cb4e35d5-87fc-4f06-9eda-8e5f6a45bcd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,853</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-68" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTYtMy0xLTEtMjc3NDM_7b180eb3-4419-4779-833c-c84915adbe0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,102</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-69" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMS0xLTEtMjc3NDM_e5b34edc-f33c-4648-8497-ac38515bf7b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,255</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-70" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTctMy0xLTEtMjc3NDM_5509dae4-daf4-4ca3-9776-2e5ee525fd8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,973</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-71" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMS0xLTEtMjc3NDM_8509c057-18e1-4ea8-9461-9677407a1bb7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-72" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTgtMy0xLTEtMjc3NDM_6a4eb248-2c79-4a54-ac4f-b434bb8a5157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-73" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-74" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMTktMy0xLTEtMjc3NDM_7ed8e5f0-c603-4675-bad9-785c3c747cad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,985</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="fact-identifier-75" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMS0xLTEtMjc3NDM_b25e04c8-fd46-4cd3-9968-3a0969126359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">460</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="fact-identifier-76" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjAtMy0xLTEtMjc3NDM_e9c24e21-395f-4a3e-8027-2ac0d98db33e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">489</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-77" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMS0xLTEtMjc3NDM_b2981b03-40e0-4590-aaed-b37def878f1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,568</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-78" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjEtMy0xLTEtMjc3NDM_aa67bdb0-c6e5-4e8a-8c72-271da2cb6fe2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,049</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-79" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-80" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjItMy0xLTEtMjc3NDM_e7dc99ea-b63d-429f-9d74-b8e81420deec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,855</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-81" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMS0xLTEtMjc3NDM_442efe3d-b5fb-40a3-b753-6400745aaf46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,969</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-82" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjMtMy0xLTEtMjc3NDM_e38547cd-b141-4cce-9ece-89ac51114611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-83" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjg1OTk_b8be25c0-6618-4ba5-bab5-4a4d780c64da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-84" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjg1OTk_e8d5edad-5f91-4ea9-a618-30238607de6f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-85" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMS0xLTEtMjc3NDM_0302ef1f-e7ee-4433-9b30-3fa35dc78464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="fact-identifier-86" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjUtMy0xLTEtMjc3NDM_2793571b-61de-4cb6-9a21-31ea20e3bd36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-87" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMS0xLTEtNDU5MjU_ed727ce2-d46d-464a-a206-d8dd46de763d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,469</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-88" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzUtMy0xLTEtNDU5MjU_d4469eee-cdb0-4ba0-aba1-d43e0238252f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">114,001</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-89" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMS0xLTEtMjc3NDM_748cc669-cff2-44fd-b6a7-4b8d116bd301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,037</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-90" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjYtMy0xLTEtMjc3NDM_12c6c89c-c044-4564-90db-537661134ba0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,050</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders’ Equity (Deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-91" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_1d9b135f-a2f7-402a-9a19-c06b3ac7d9d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-92" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDU3_6c5638a7-e0d4-49d8-9187-9342a31d7ce2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span> par value per share; <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-93" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_269149d2-8053-4019-a81e-dceb9665154e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-94" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDY5_33659c5f-5b3a-4b9a-b171-d8446bebbf32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized at  December&nbsp;31, 2021 and 2020; <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-95" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_08295af6-3c58-4b06-9087-309fbe303a0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-96" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_4c71215a-6af9-49de-9a7f-5d4af64adcd8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-97" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_a5dd636f-cdd3-4297-b4d7-47a6259e9b6c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-98" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjowOGNhMDdkZjBkM2E0YjMyOTc3ZjYwMjE0NmYxYmQ5Zl81NDk3NTU4MTM5MDc0_ce04d179-b392-43ad-bf37-88ceebac556b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding at December&nbsp;31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-99" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMS0xLTEtMjc3NDM_e65004aa-68fc-4735-9cee-e65cbe12a4e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-100" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMjktMy0xLTEtMjc3NDM_0fa3adb4-da87-4cf1-91b7-2dba042dc67a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-101" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_b7333fe5-ebb1-4092-94c3-1732fa3bf01c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-102" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTEw_c87da43c-0c21-481f-aa37-34fc4e5bab2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span> par value per share; <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-103" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTI0_e162648c-5e3b-416c-982f-4a7289978736" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400,000,000</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-104" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTM4_53157d89-23c4-4111-aa61-8e18478057d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span> shares authorized at December&nbsp;31, 2021 and 2020; <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-105" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_3b9be6e7-fe7a-486f-8e8e-db3038c67d8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-106" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTUy_5b7fec1c-08e6-44f5-8777-245e46e8b4fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199,463,645</ix:nonfraction></span></ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-107" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_6220807b-42e8-4ba2-b416-e8db52fdd5ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-108" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjphYTk0OTk3NmU2OWM0NzQxOWY1NjQxNGMyYzJhOWVmYl81NDk3NTU4MTM5MTY2_94a15690-7b20-40d7-9593-a3652f00f6c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,449,647</ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding at December&nbsp;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-109" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMS0xLTEtMjc3NDM_8f1def5d-5d0e-4622-aeac-71e32d7e30aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-110" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzAtMy0xLTEtMjc3NDM_1944510f-9c70-4093-b7a1-f0e3c019ccc3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-111" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMS0xLTEtMjc3NDM_dce7ddbd-ddba-430e-97df-4992a957f8b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">487,768</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-112" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzEtMy0xLTEtMjc3NDM_c8520221-5a8e-40e3-a0de-c062cc686a21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">306,554</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-113" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMS0xLTEtMjc3NDM_4bad118f-4fde-4308-abf8-393008d50f1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,257</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-114" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzItMy0xLTEtMjc3NDM_e193fe34-734c-412d-9837-a2776339e3ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">315,921</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders’ Equity (Deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-115" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMS0xLTEtMjc3NDM_0aebd621-5b03-483e-85d1-571240e4420c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">171,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-116" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzMtMy0xLTEtMjc3NDM_cdebca43-7523-4204-aa7c-18c34d8db849" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,227</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders’ Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-117" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMS0xLTEtMjc3NDM_215ce228-ddec-4b04-86eb-13e10be191d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">240,747</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-118" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82NC9mcmFnOjMxM2YwMmFjYmNmZDRiNGU4OWU1MDM5ZWI5MDJhOTM5L3RhYmxlOjNiYTc3ODM2NTYwODRkNWM4YjhmNTBmM2E5NzQzZDhhL3RhYmxlcmFuZ2U6M2JhNzc4MzY1NjA4NGQ1YzhiOGY1MGYzYTk3NDNkOGFfMzQtMy0xLTEtMjc3NDM_8d46905d-802b-45d0-b9e7-1a77b7f59f0f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,823</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_67"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2c88f9a9af124db29eb627c2bb0fd0e3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0xLTEtMS0yNzc0Mw_955fb855-c58e-4bfa-9ace-a99aa19e0bf2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,544</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i51b5ef8f93c04e62a666090e00118055_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy0zLTEtMS0yNzc0Mw_16df42d7-7146-46e4-97ba-9a05a36458cd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,236</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if30a5968b1a146dbb7ffcec09da88262_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMy01LTEtMS0yNzc0Mw_5002f366-8174-44ce-b294-71e4e562802f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0xLTEtMS00OTU2Ng_23098667-9591-4937-83f1-dacafd809cbd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,544</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS0zLTEtMS00OTU2Ng_6055c3ad-dfc3-46cb-a6c4-9e4acc90370f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,236</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNS01LTEtMS00OTU2Ng_4cb1108d-f125-4155-95f3-e2d304705bc0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0xLTEtMS0yNzc0Mw_42ce0de9-3533-4ea1-9139-6b74e6c1d8c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,312</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi0zLTEtMS0yNzc0Mw_7dc08a3f-7377-40d5-8a19-a05f120f9650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,191</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNi01LTEtMS0yNzc0Mw_963e0199-8cfc-495a-bf9e-ce6a187478b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,663</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yNzc0Mw_51a694aa-6d20-4749-a926-f1e319b15cb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,393</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-129" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yNzc0Mw_00cf2429-5bd3-4839-96cb-cd579a2ef70c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,302</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-130" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yNzc0Mw_7ff00aa0-16f6-4158-aed8-e035cc5152dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,208</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-131" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0xLTEtMS0yODc1NQ_2b61f082-346c-4222-8618-f70f5e35bf5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,528</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="fact-identifier-132" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy0zLTEtMS0yODc2NA_8b21c6cf-0a07-4a7c-ae38-b24204c51d3a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="fact-identifier-133" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfNy01LTEtMS0yODc3NQ_6fa850d5-494f-4988-9660-730f38dc1ce9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-134" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yODc1NQ_32f72440-6dd6-409a-82ba-ac13c02fdaa8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="fact-identifier-135" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yODc2NA_416cdf83-25f6-42c0-89c7-1557dc00280c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="fact-identifier-136" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yODc3NQ_02d2f742-73a5-41a6-b029-e1adcf936907" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-137" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,840</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-138" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,180</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-139" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOC01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,620</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-140" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0xLTEtMS0yNzc0Mw_ee232fc0-ca17-43e6-bd27-214e3d65dcb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,093</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-141" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS0zLTEtMS0yNzc0Mw_a08fbb26-310d-4620-8aed-c3a9f300ea64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,313</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-142" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfOS01LTEtMS0yNzc0Mw_e1a1a786-4bd4-4e36-bf82-caa16699eae5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,491</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-143" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjg4Mzg_2a57fedd-7b70-48d4-95c8-18156f874987" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,549</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-144" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjg4Mzg_dc25e598-9f3c-4e37-965d-58d5080796fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,077</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-145" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjg4Mzg_62d0caf4-f1a6-443f-8b5f-e023e1102da2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,491</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="fact-identifier-146" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMS0xLTEtMjc3NDM_d5b0b77a-67d7-4795-a490-81757f154f4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="fact-identifier-147" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItMy0xLTEtMjc3NDM_5843c52a-969f-44df-b9a1-c3aa3bef953f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="fact-identifier-148" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTItNS0xLTEtMjc3NDM_78d61d9e-3813-4f34-ad93-66e143c60428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">991</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-149" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMS0xLTEtMjc3NDM_317e8a05-f1db-409f-b803-08067796d34f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,609</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-150" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtMy0xLTEtMjc3NDM_97bd15c2-b4d2-4803-bcd7-1459d5cd6d43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,952</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-151" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTMtNS0xLTEtMjc3NDM_bd40abd1-a5a9-4f7c-83f9-2a0a1c5b4325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-152" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMS0xLTEtMjc3NDM_31d95823-0302-4b16-a6d6-6067ff7e0b42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,273</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-153" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtMy0xLTEtMjc3NDM_0c026e21-1b23-40ef-bc8c-8c77f4b10966" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,445</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-154" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTQtNS0xLTEtMjc3NDM_ffb1cdd7-8f42-434e-9d29-f0c5673f8b07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-155" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_2bccea8f-4ed7-49ee-8933-ecc3d24d2c4f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-156" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMS0xLTEtMjc3NDM_56134193-a39d-41e8-8ff0-ae0549d50a63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-157" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_04753fc1-0ac6-42f6-92f5-fad075f64c9d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-158" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtMy0xLTEtMjc3NDM_8912388c-6614-49a0-b6dd-a1ca15a101b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,397</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-159" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_87ae26ff-1706-4b89-b019-5642bf12a078" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-160" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTUtNS0xLTEtMjc3NDM_deeb1d50-7a0b-4d9f-b50d-a61f59e0471f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on adjustment of exercise price of certain warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="fact-identifier-161" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjkwMTY_e723fb68-6ad4-4f06-add1-7481211c3a48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="fact-identifier-162" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjkwMTY_41e471dd-fe89-401b-8aef-f8424acb3f1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="0" id="fact-identifier-163" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjkwMTY_6a1d3f93-5f57-424a-9d07-72a84f7d6bb0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="fact-identifier-164" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_c31311e3-afb6-46ab-8f98-ff2e5f631ce3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="fact-identifier-165" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMS0xLTEtMjg5NTk_d68d798a-ac66-41c1-b88c-01af6aa6e050" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-166" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1273d8ad-2140-4818-9fc3-9d93b11e7538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-167" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtMy0xLTEtMjg5NTk_1f1094e7-68f8-4613-829d-201f8de3ba76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,544</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-168" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_2b71b8f9-23f3-40c5-b330-bd8d69923958" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-169" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTgtNS0xLTEtMjg5NTk_ff4267d8-8cda-4854-b2b6-ab069eab48c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" id="fact-identifier-170" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_3dcf45b4-e36a-449a-932f-9b63593d2eca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" id="fact-identifier-171" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMS0xLTEtNDU5MzI_53ac7a66-f9e5-4afb-9bf1-38ccab2df4ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="fact-identifier-172" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_3c4f7391-f1d5-4da7-b520-56ef98bef3a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="fact-identifier-173" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtMy0xLTEtNDU5MzI_d983829a-90ea-4972-944c-431a1a41098e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.19</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="fact-identifier-174" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_658eef7f-2a55-44a0-97a0-09863d992453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="fact-identifier-175" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMjEtNS0xLTEtNDU5MzI_f1f23e88-9297-4dc3-bd9b-6ae0912d5102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.18</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-176" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_00f6e191-d783-4e19-a795-d0600cac7ce6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-177" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMS0xLTEtMjc3NDM_e23418f5-5b57-418a-ace3-372e3dcf1383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">182,323</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-178" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_407116ad-e5f4-447d-b5e1-be5a416f8acc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-179" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtMy0xLTEtMjc3NDM_980ba4b3-48c5-45e5-b7f4-89b8496cd6f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118,221</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-180" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_0d5ab724-813f-4c2f-a2b4-b7bf4a214c01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-181" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV82Ny9mcmFnOmVkNmVjMDU0ZWI0YzQyMmZhYWZjY2MzYjA3MTJiMDAyL3RhYmxlOmJjYmM1ZDQ1MTU5MDQxOWVhZTc4ZGJhMmExMTU4ODI4L3RhYmxlcmFuZ2U6YmNiYzVkNDUxNTkwNDE5ZWFlNzhkYmEyYTExNTg4MjhfMTYtNS0xLTEtMjc3NDM_e59ad112-ea24-4477-a261-d79c6a223c2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,929</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_70"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tbody><tr><td style="width:1.0%"></td><td style="width:26.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.962%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br>Paid-in<br>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders’<br>Equity (Deficit)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0bf44be67ed84033b15e86e3de2e9088_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-182" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0xLTEtMS0yNzc0Mw_d8de166f-d74f-40d7-beaa-231d93ce2dfd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,456,180</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0bf44be67ed84033b15e86e3de2e9088_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-183" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi0zLTEtMS0yNzc0Mw_d6df409d-5a6a-4920-b7f6-69374d78c30d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4c1773348a6144f8927754151f83c6b2_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-184" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi01LTEtMS0yNzc0Mw_ce36fcae-ec5c-4a27-aac1-f7bf3478a8ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230,154</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic78f2f0a6b1d4a20ad7e12e40d1cacd4_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-185" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi03LTEtMS0yNzc0Mw_bf9a07ab-5f3f-4a38-8bb6-1bf5e8cc92ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">186,024</ix:nonfraction></span>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-186" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMi05LTEtMS0yNzc0Mw_72b5258f-8f1b-4293-937c-3a492010c054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,207</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i21d87267df014bc9b3e806eba7f1b0f5_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-187" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy03LTEtMS0yNzc0Mw_1f9ed555-7dd4-4e70-ab39-7c68abb6fe62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-188" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMy05LTEtMS0yNzc0Mw_a603efe2-732f-4aad-bea5-f8087731ffd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-189" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC01LTEtMS0yNzc0Mw_12660377-b858-4bd2-be4e-bd92916fd95e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-190" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNC05LTEtMS0yNzc0Mw_1eb2604e-106e-4043-84e3-59de920ae204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options and vesting of RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-191" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS0xLTEtMS0yNzc0Mw_1a93878f-a49b-4015-8fde-b9e66f953768" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,812</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-192" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS01LTEtMS0yNzc0Mw_1c894e25-0507-4318-82d6-c588aeea5774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-193" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNS05LTEtMS0yNzc0Mw_427ec341-3f9f-49d6-b111-5a0429b86e46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-194" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi0xLTEtMS0yNzc0Mw_90564f58-e4b2-483f-aff9-1c6f44a97385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,283</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-195" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi01LTEtMS0yNzc0Mw_369444d3-db77-4313-8f21-3cf80028417f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-196" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNi05LTEtMS0yNzc0Mw_b17e1780-368b-4447-96f8-6d6907ef24be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="fact-identifier-197" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0wLTEtMS0yNzc0My90ZXh0cmVnaW9uOjk3MjRkYTM0MWE2NzQ3ZjU4ZmE2ZmEzMTI3ZWIyZDRlXzU0OTc1NTgxMzg5Nzc_bca1c4c5-3009-4445-a3ba-cdb96b0e4b6f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.2</ix:nonfraction></span> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-198" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0xLTEtMS0yNzc0Mw_ba4eb62f-c69f-40d9-a98a-a0e3856629dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,410,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-199" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy0zLTEtMS0yNzc0Mw_17b2ac41-f411-49c1-ad97-68938a4ae7f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-200" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy01LTEtMS0yNzc0Mw_be098684-13ae-416e-8ade-7e8e116107e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,812</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-201" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfNy05LTEtMS0yNzc0Mw_52773094-3822-469b-a122-e95ebca7d79c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,833</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-202" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0xLTEtMS0yOTA5MQ_a7843989-92a6-4ffe-b266-8b4535e5e841" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,772,928</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i56d90314fd70472fa324352884486d5d_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="fact-identifier-203" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC0zLTEtMS0yOTA5MQ_253644d0-9e5a-4bee-b711-54bf4e431c72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i24d912e249d446ec8ebceff6c436ebba_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-204" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC01LTEtMS0yOTA5MQ_d622f749-1bf2-4ee9-be5c-c43acd825d37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,474</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-205" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOC05LTEtMS00NjI5Ng_0460dbf6-f1d7-4a3f-9299-b82c37e0b3c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,481</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="fact-identifier-206" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0wLTEtMS00MDA5MC90ZXh0cmVnaW9uOjE3NzdjOWZiZTc4ZDRiNWY5YTkzYzdiNWRiOTBlMjZkXzU0OTc1NTgxMzg5NzA_f4ccd4c5-09a3-4375-b3d6-850eed18226c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-207" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS00MDEwMw_cd42b65f-9887-4fcc-9158-f209317d54f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,062,206</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9196b3b160ff4b34a4c29c91d25a3a74_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-208" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS00MDEwMw_eed521c3-1624-4950-853e-0dafd4c016ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3412d8401e304f0aae1eecacbcdbab85_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-209" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS00MDEwMw_7aecef4a-82b7-4a13-b6b6-69b5afc951d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,934</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9304759dd01344a5a9f94f3cad016e8a_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-210" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS00MDEwMw_a4f9db66-3149-4558-af30-4e602c28a880" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,936</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-211" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0xLTEtMS0yNzc0Mw_f66eb284-a3c0-49e8-8a1c-17097970459d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,801,409</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5f6b2a50799e4d0b96fe33c9e0849def_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-212" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS0zLTEtMS0yNzc0Mw_1d029cd5-6867-4940-b6cc-b2683b6a94bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibf8c7f863b2f43bb922132621a9e5cda_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-213" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS01LTEtMS0yNzc0Mw_9f6a90f8-6d08-4bd5-a267-bdc7a2cd4606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">266,717</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ifc289b8985ac49eb80e78ca2748e4a96_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-214" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS03LTEtMS0yNzc0Mw_7e791209-b185-411d-aa27-f422a4a4d640" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">293,524</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-215" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfOS05LTEtMS0yNzc0Mw_51ea597f-6777-4161-a3f8-1fcdea91a821" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,700</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i06678b0cf6c04477b759eb44801366df_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-216" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtNy0xLTEtMjc3NDM_9be35b65-90dc-4ab6-8b27-24f5d4c3031a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,397</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-217" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTAtOS0xLTEtMjc3NDM_9b936e69-5c10-416d-aa8a-8a0c1fa3655c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,397</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-218" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtNS0xLTEtMjc3NDM_f54e199f-81f4-476b-97a9-adf5523061c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,757</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-219" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTEtOS0xLTEtMjc3NDM_e4394c68-598b-4aa8-a2b9-628040a7433a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,757</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-220" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItMS0xLTEtMjc3NDM_8316c5ad-c741-4ac4-b579-a2c193aa60c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-221" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItNS0xLTEtMjc3NDM_8d4022d9-2425-45d5-a0f9-704643f9e8c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-222" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTItOS0xLTEtMjc3NDM_71a89f3d-8225-4bf7-8eee-928483c99d56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of common stock under 2014 ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-223" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtMS0xLTEtMjc3NDM_a2dc0553-3da5-471b-8094-60ad8c892ea5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,186</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-224" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtNS0xLTEtMjc3NDM_0f49d931-1667-4f3c-a423-d7510c4e690d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="fact-identifier-225" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTMtOS0xLTEtMjc3NDM_472263cf-8a80-46ee-b6d3-df70c6ce5294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ea16c2dffdd41e98b80a0361f17c02b_D20200101-20201231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-226" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtMS0xLTEtMjc3NDM_c7c23d14-0649-4b66-a65a-e69ae40d100c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">238,110</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieda202dba19040eaa95b34c4ad43fc99_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="fact-identifier-227" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtNS0xLTEtMjc3NDM_982d13f9-c08b-42d3-9cfe-18a6ff18aa34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">131</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="fact-identifier-228" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTUtOS0xLTEtMjc3NDM_58497511-c2d4-4a37-af8e-7b449681343a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">131</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="fact-identifier-229" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjo5MGI5OTljN2E5YmI0MGFkYmJmNDE0OWQxM2FiZTg3N181NDk3NTU4MTM4OTcw_2fe6374a-3877-44fe-8e57-b85b10de254b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-230" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMS0xLTEtMjc3NDM_3053161d-fcce-47c7-a668-fe03c3bd7c88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,369,942</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i31dbe97dacd24eec8dd2d72c2149de53_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-231" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtMy0xLTEtMjc3NDM_a34928b1-b773-4ca5-aab0-b527b7ee4357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id593ab74c6634403b9f73b261b779b5a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-232" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtNS0xLTEtMjc3NDM_e9adfaaf-5135-4176-a5d9-7fe9c5200622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,925</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib1cd661b638041f898d4ddc61a940fa7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-233" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTYtOS0xLTEtMjc3NDM_a692a336-248b-4794-bf07-58bfcdd16666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,958</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iededb75b8b3d41909c578b96949d296b_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-234" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMS0xLTEtMjc3NDM_e61031a6-0c23-464b-98a7-c3d680d4f222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,449,647</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iededb75b8b3d41909c578b96949d296b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-235" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctMy0xLTEtMjc3NDM_416b73ae-2865-472e-9c0c-1b066ce07d4f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id0b663c4ccd24528baa91746670f2709_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-236" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNS0xLTEtMjc3NDM_7246dd05-ac7a-4709-8ef4-5baf31e6d2af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">306,554</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i92612297cd0642f585229a45cac68bd8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-237" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctNy0xLTEtMjc3NDM_8cd11026-c01d-42d7-9d7c-982bf3c328c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">315,921</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-238" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTctOS0xLTEtMjc3NDM_e32d68c3-9324-4966-a8fd-08ae0d465efc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,227</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i548b9f86fcd54ebe9243040061933762_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-239" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtNy0xLTEtMjc3NDM_413445d8-ae7c-4195-8ee3-fdbc722d2979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-240" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTgtOS0xLTEtMjc3NDM_9e48b881-7af3-4170-94a7-80d91309bbd5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-241" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktNS0xLTEtMjc3NDM_5f3e7a6f-9101-4b75-9cf6-92895e40db8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,143</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-242" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMTktOS0xLTEtMjc3NDM_67d1491e-1f16-4b31-8592-30bf402af3d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,143</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-243" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtMS0xLTEtMjc3NDM_30e7adb0-5730-443e-a3fb-107974f6713a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,610</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-244" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtNS0xLTEtMjc3NDM_5760d775-5236-4dc5-94ee-ff5284307bb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-245" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjAtOS0xLTEtMjc3NDM_978870f2-0b0e-4c6a-b9c7-74a30271ec30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-246" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMS0xLTEtMjc3NDM_70634e9b-dc1a-4252-8c46-09104de4b620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,048,059</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="fact-identifier-247" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItMy0xLTEtMjc3NDM_6eb55470-c445-46bc-b0c6-e7e7ba3831fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i16ee67ef6bd649078581dadd0ed62d0b_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-248" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItNS0xLTEtMjc3NDM_821c27fe-e77b-4b57-b61d-ab4758801d0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,124</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-249" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjItOS0xLTEtMjc3NDM_98bdaf4c-8725-471f-82c0-e298da2a55ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,126</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="fact-identifier-250" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMC0xLTEtMjc3NDMvdGV4dHJlZ2lvbjpmOGE0ODQyNGRlMTc0OWRhYTRjZmQ0ZTlmMzI0MmRiYl81NDk3NTU4MTM4OTcw_0f8c243f-4365-409b-9730-4495e08a44a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.4</ix:nonfraction></span> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-251" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMS0xLTEtMjc3NDM_2bfa1b11-a74a-4a37-9f8a-8235625ba313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,932,329</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i15ad345699544975afdfa5647ec5ebb1_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-252" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtMy0xLTEtMjc3NDM_56f1d63b-26fe-4e42-87cd-d91a2a35c81b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i449b028e12ab447dbe3d1ff217dca3f7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-253" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtNS0xLTEtMjc3NDM_248893e3-3ac4-417c-a76e-dbcc2b9e7cf7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,905</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie6cc5cde3c2444458bf73121a4a8d8f5_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-254" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjMtOS0xLTEtMjc3NDM_3ca3ae41-9308-4d3e-b627-d28a001e83da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,962</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8c9ad583a050492ebb28f616a7b10aaf_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-255" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMS0xLTEtMjc3NDM_3f2cc55c-f99b-47a8-b60f-55e6f92e1a1e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199,463,645</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8c9ad583a050492ebb28f616a7b10aaf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-256" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtMy0xLTEtMjc3NDM_9e743bab-60bd-4b9e-9097-d67fafda6000" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6bdadfe711654c368dce057e84bccbf9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-257" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNS0xLTEtMjc3NDM_1a2bb20f-a76e-4e4d-a414-cf0247dd97e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">487,768</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3d93ef4c012e45c7b10ee227a4cdf96d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-258" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtNy0xLTEtMjc3NDM_8c4c463c-3ac7-4e13-8b03-ad8290be25c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,257</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-259" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83MC9mcmFnOmJlNzVjMDU3Y2U5ZTQ3MjNiYTdmOTk5YTEzNDU1ZDE4L3RhYmxlOmZmNjNlODcxYTBmODRkZDc5NTFjNmIyZjU2MjNhOGVhL3RhYmxlcmFuZ2U6ZmY2M2U4NzFhMGY4NGRkNzk1MWM2YjJmNTYyM2E4ZWFfMjQtOS0xLTEtMjc3NDM_e53fad47-f051-4162-8219-cc92542fc001" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">171,710</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_76"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-260" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0xLTEtMS0yNzc0Mw_f2026e3a-01f0-4c12-8d50-6b5d724f02f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-261" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy0zLTEtMS0yNzc0Mw_b1a1b020-a960-42c8-9466-fe83d0f3c939" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,397</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-262" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMy01LTEtMS0yNzc0Mw_3a75e822-882d-43c1-9954-cf92a0f73969" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="fact-identifier-263" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0xLTEtMS0yNzc0Mw_12a2d367-6a47-435b-9453-8f32fc679950" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="fact-identifier-264" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS0zLTEtMS0yNzc0Mw_1c60d6fa-02ed-493c-bbe6-67e51acbe170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="fact-identifier-265" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNS01LTEtMS0yNzc0Mw_5c3b0749-d686-4766-a077-5b167faead5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">219</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-266" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0xLTEtMS0yNzc0Mw_5860771b-d0f6-47b3-b3cf-0aa68cd86686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,143</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-267" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi0zLTEtMS0yNzc0Mw_426d5422-5114-4ff7-876c-051d288731cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,757</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-268" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNi01LTEtMS0yNzc0Mw_dffced38-f9ca-4e4f-9683-864022efa08e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-269" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0xLTEtMS0yNzc0Mw_4d7b5ef8-8022-4e30-9680-ae521d60b66a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,840</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-270" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy0zLTEtMS0yNzc0Mw_6a424469-d5f6-418c-ad15-9ff42c6f356c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,180</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-271" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNy01LTEtMS0yNzc0Mw_1abdfbb5-4d5c-4c5c-b6d0-7b68769e255f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,620</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-272" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0xLTEtMS0yOTUyMg_b29b8dd9-602b-4add-907a-c4d61f9bb04f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="fact-identifier-273" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS0zLTEtMS0yOTUyMg_1e993444-5cd6-4412-95ad-db2a346ef5c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" id="fact-identifier-274" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfOS01LTEtMS0yOTUyMg_bb57271f-fa75-413b-a99c-06f2cba56eeb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-275" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjk1NDY_e1e4b669-0055-4b1d-9530-644253d17ea2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,493</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="fact-identifier-276" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjk1NDY_0ed09fc7-a32d-4d19-815c-d1a80e6a1dd2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="fact-identifier-277" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjk1NDY_a5f849b5-5e1f-4aeb-87f2-0428320a4920" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-278" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMS0xLTEtMjc3NDM_e02ebc7a-4030-4011-93ef-b6e68a960c95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,964</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-279" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtMy0xLTEtMjc3NDM_dba15542-e519-4f19-be1a-48ce4bc867da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,304</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-280" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTAtNS0xLTEtMjc3NDM_b1a6ecc7-78b5-4455-b406-1c00f301116a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,188</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="fact-identifier-281" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMS0xLTEtMjc3NDM_d61428c7-520f-49f2-a3d4-565e37959c0f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">249</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-282" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtMy0xLTEtMjc3NDM_7fda028b-4e8f-4ebf-9777-ba02918f59a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="fact-identifier-283" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTEtNS0xLTEtMjc3NDM_997c8d4c-746a-4520-b946-3b99346ef320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">535</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-284" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMS0xLTEtMjc3NDM_eb281b58-4173-4f3e-9dfe-691580192494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,424</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-285" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItMy0xLTEtMjc3NDM_4d42d619-addb-4549-93e5-d67ce3d8ba1b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,035</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-286" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTItNS0xLTEtMjc3NDM_e97ce54e-6a23-4e82-a0d9-2fcee3b7a2a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,556</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-287" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMS0xLTEtMjc3NDM_52d8c648-ddf2-45d1-94d2-720da1dc4633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-288" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtMy0xLTEtMjc3NDM_c5c1f332-826c-44f8-a8f8-c53924e462a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="fact-identifier-289" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTMtNS0xLTEtMjc3NDM_adef1942-0119-4afd-9896-0a3a9ebe1147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-290" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMS0xLTEtMjc3NDM_9e265158-dfb7-4222-8f5d-ed02dd0f4921" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,878</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-291" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtMy0xLTEtMjc3NDM_dcb6b7f9-9e39-4c88-8d31-0474cfb52b22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,837</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-292" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTQtNS0xLTEtMjc3NDM_e9c7f656-1770-4b2b-b02d-a019e1a6c5be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,521</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-293" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMS0xLTEtMjc3NDM_7e8e3e06-e091-4b4b-8001-11dee1416ec4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-294" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtMy0xLTEtMjc3NDM_d09a2056-67f0-4a5a-96cb-49bac7d0d4b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-295" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTYtNS0xLTEtMjc3NDM_af112bb2-6b7d-4e73-a2da-becdd511e586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-296" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMS0xLTEtMjc3NDM_c2706baf-26dd-43b1-b3f0-0dc4cdbb6eae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-297" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctMy0xLTEtMjc3NDM_76ddfa3c-c1e4-47ea-bb4f-60b0056d9c46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-298" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTctNS0xLTEtMjc3NDM_79155849-bbc7-43f8-9169-dd633e1643ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-299" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMS0xLTEtMjc3NDM_d246a34c-da2b-4cfc-90cb-96a25189f8fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-300" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktMy0xLTEtMjc3NDM_12b15fbb-54ea-40b1-8b31-4fa603bde56e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:ProceedsFromIssuanceofCommonStockandWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-301" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMTktNS0xLTEtMjc3NDM_0ddc56c4-cdd0-4415-bd85-0c6642ce863b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">27,833</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-302" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMS0xLTEtMjc3NDM_825e08f4-3cdd-46e8-bd79-c9afc20b9fe9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,126</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="fact-identifier-303" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtMy0xLTEtMjc3NDM_3c6bfcc1-b971-43ca-998d-fc1fcd7a3f4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">131</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-304" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjAtNS0xLTEtMjc3NDM_bfcdb125-d590-46c4-b066-cf3b5aaddabc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,481</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-305" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMS0xLTEtMjc3NDM_e840e667-6ac3-42ce-bc58-c0df9061495a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">174,962</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-306" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtMy0xLTEtMjc3NDM_91f0b7ac-d1c7-4842-bdea-5bd0cf47a69f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,958</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-307" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjEtNS0xLTEtMjc3NDM_d97f695a-806e-48c1-bbef-5fd1d8371437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,936</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-308" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMS0xLTEtMjc3NDM_44e32ed6-d257-404f-bab1-f238fe09987b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-309" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItMy0xLTEtMjc3NDM_0b13d8c9-7dd5-4539-99e8-aeaa918cf89b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-310" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjItNS0xLTEtMjc3NDM_2f7e9b1a-854d-4dab-99f0-001f7c4eb6cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of common stock pursuant to ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="3" id="fact-identifier-311" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMS0xLTEtMjc3NDM_8b61d594-028a-4b7a-bcf2-c5cf1e30e692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="fact-identifier-312" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtMy0xLTEtMjc3NDM_936e34bc-ef1f-469c-af68-e70012322998" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="fact-identifier-313" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjMtNS0xLTEtMjc3NDM_f9a2f7e7-ca66-45e7-93fe-c41845925f5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-314" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMS0xLTEtMjc3NDM_48a70d8e-fa59-4862-8f3b-8cb8b3f154a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">176,129</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-315" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtMy0xLTEtMjc3NDM_b1a06b34-fb74-4ed4-abd3-73834ae98c94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,113</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-316" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjQtNS0xLTEtMjc3NDM_dc746aa0-987f-46c3-af18-9328ea38cf5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,356</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-317" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMS0xLTEtMjc3NDM_2f74ba01-d8b0-4a13-8a33-19880ed971c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,247</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-318" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtMy0xLTEtMjc3NDM_fd3f894e-5e61-4288-973a-b45746dafe34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,268</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-319" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjUtNS0xLTEtMjc3NDM_8178d96c-c622-44f2-a2e2-0b2348d83cb5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,301</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-320" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMS0xLTEtMjc3NDM_930b9a7b-f53d-44cc-a095-595eb9adc2d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,409</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-321" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtMy0xLTEtMjc3NDM_28208a53-9917-4f6f-9b0a-9e1e4dca619b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,141</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-322" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjYtNS0xLTEtMjc3NDM_6f33d0cf-a984-468e-93ea-ce1f618acbb1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,442</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-323" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMS0xLTEtMjc3NDM_dce16000-a845-4b75-8f84-65f81e9db6c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162,656</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-324" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctMy0xLTEtMjc3NDM_1a05970e-c902-4ad3-899d-758b4937df3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,409</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-325" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMjctNS0xLTEtMjc3NDM_1b67f8d3-c9c3-40e3-94d5-0a0336f2f362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,141</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-326" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMS0xLTEtNDgyNTU_05994ce0-d047-48cf-b74e-f500e49c6b0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162,636</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-327" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtMy0xLTEtNDgyNTU_60ecc157-9105-4809-9734-6751d9425a04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,389</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-328" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzMtNS0xLTEtNDgyNTU_09739e2d-5e6d-439c-bffc-1ede682db75d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,121</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-329" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtNDk1NzU_2bcc88b4-aeb4-4d1e-8c4e-29ed567422c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-330" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtNDgyNTU_fd716fb0-dd6f-458f-af0f-9c4c00d9e17a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-331" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtNDgyNTU_88b7a9b2-0b46-4482-9119-66c5f90cc940" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term restricted cash </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="fact-identifier-332" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMS0xLTEtNDgyNTU_8fd097ca-f9ee-4d29-a600-04aaaf53333d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="fact-identifier-333" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtMy0xLTEtNDgyNTU_ad304fb8-34a7-4edd-b0a9-3ab9c4597d2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="fact-identifier-334" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzUtNS0xLTEtNDgyNTU_28b55b85-e0f1-4a55-bfbb-9ec87d7ed5b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-335" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtNDgyNTU_7f55a34b-6574-49a1-86f8-922d9951743a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162,656</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-336" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtNDgyNTU_192bdcee-e361-4d64-9370-a13563759cdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,409</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-337" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtNDgyNTU_e96756bc-71ec-4fc3-aca8-7888bb62ebfa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,141</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="fact-identifier-338" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMS0xLTEtNDgzNDQ_626ee158-ddde-432d-8c7e-e7af4691280a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">174</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="fact-identifier-339" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktMy0xLTEtNDgzNDQ_7acd5551-a350-4013-84f1-53e374cfef93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">154</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="fact-identifier-340" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzktNS0xLTEtNDgzNDQ_04298934-8aaf-4790-b9bb-619a6b950741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">153</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets related to the adoption of ASC 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:fixed-zero" scale="3" id="fact-identifier-341" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMS0xLTEtMjc3NDM_e66c45fc-ae85-4ccb-9265-2626bb962469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:fixed-zero" scale="3" id="fact-identifier-342" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtMy0xLTEtMjc3NDM_f19fb015-ec24-4185-8802-c9451009a82f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-343" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzYtNS0xLTEtMjc3NDM_46aecb11-5c2d-41a1-8580-da834233ff74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">236</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="fact-identifier-344" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMS0xLTEtMjk2NDA_c70d1f4c-f018-4509-b8af-ec8bad994859" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="fact-identifier-345" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtMy0xLTEtMjk2NDA_931706f8-7230-4e9a-8040-020a07b4944b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">290</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="fact-identifier-346" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfMzQtNS0xLTEtMjk2NDA_1341fa1b-0dd4-4cab-9898-006b8b6d6157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deemed Dividend on adjustment of exercise price on certain warrants</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="fact-identifier-347" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMS0xLTEtMjc3NDM_05e13490-8ff4-4d1e-878d-7a89bfdcc203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" scale="3" id="fact-identifier-348" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtMy0xLTEtMjc3NDM_064b3121-9836-44ff-97b9-21f5cd82cb7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">147</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="sesn:IssuanceOfWarrantForCommonStock" format="ixt:fixed-zero" scale="3" id="fact-identifier-349" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV83Ni9mcmFnOjUwM2EwYTE5ZTg5NDRmZTBiNTg4NTk3NjllNGIzZDA1L3RhYmxlOmI0YjVkZjU3NDg5MjQ0ZTdiOTE5MGIxMmFlMjkzYjM5L3RhYmxlcmFuZ2U6YjRiNWRmNTc0ODkyNDRlN2I5MTkwYjEyYWUyOTNiMzlfNDEtNS0xLTEtMjc3NDM_86d431f4-3a2b-4a71-a5be-99635c6134f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:center"><span><br></span></div><div style="margin-top:7pt;text-align:center"><span><br></span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NatureOfOperations" id="fact-identifier-350" continuedat="ibba5d0f8a1fe4a39813a038a48f32801" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMTA5MzY_e6604ff1-8ac8-46a5-9392-f4bb6974e690" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">DESCRIPTION OF BUSINESS</ix:nonnumeric></span></span></div><span><ix:continuation id="ibba5d0f8a1fe4a39813a038a48f32801" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the “Company”), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company’s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with bacillus Calmette-Guérin ("BCG"). The Company has an ongoing single-arm, multi-center, open-label Phase 3 VISTA clinical trial of Vicineum as a monotherapy in patients with BCG-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of <span><ix:nonfraction unitref="patient" contextref="idbcc2cd80c644c9bba710067ba49b410_I20180430" decimals="INF" name="sesn:NumberOfPatients" scale="0" id="fact-identifier-352" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNTQ5NzU1ODI4NzQ5NA_af879fd8-4d8c-4a2e-95ec-e27c4132c9c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">133</ix:nonfraction></span> patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it has accepted for filing the BLA. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On July 13, 2021, the Company participated in a productive Late-Cycle Meeting with the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. In the meeting, the FDA confirmed that there was no Advisory Committee meeting planned at that time, and that no post-marketing requirements, including a confirmatory trial, had been identified at that time. Also in the meeting, the Company and the FDA discussed remaining questions related to manufacturing facilities inspection, product quality information requests and additional information related to chemistry, manufacturing and controls (“CMC”), and a timeline to submit additional supporting information was agreed upon. On August 13, 2021, the Company received a complete response letter (“CRL”) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Any changes in these assumptions and estimates or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The Company believes it has a clear understanding of what additional information regarding CMC is required for resubmission of a BLA. Additionally, although not an issue raised in the CRL, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that the Company can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the “Selling Shareholders”) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (“Clairmark”) (the “Share Purchase Agreement”), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the “Viventia Acquisition”). In connection with the closing of the Viventia Acquisition, the Company issued <span><ix:nonfraction unitref="shares" contextref="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-353" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjMxNA_6894dc74-7007-42f6-83bd-6e438155e9d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.0</ix:nonfraction></span> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <span><ix:nonfraction unitref="number" contextref="i5fb4126fec9d47d299096c36c0f06713_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="fact-identifier-354" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjQxOA_b0dca6c2-67a1-454c-bf36-889061f744c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.9</ix:nonfraction></span>% of the voting power of the Company as of immediately prior to the issuance of such shares. Clairmark is an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<span><ix:nonfraction unitref="usd" contextref="i36e9d8387a934ec497a4731a279af3dc_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-355" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMjk4Mg_42ee455f-d2d9-4a6d-b363-7d7ec4dd630e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12.5</ix:nonfraction></span> million payable upon the first sale of Vicineum (the “Purchased Product”), in the United States; (ii) a one-time milestone payment of $<span><ix:nonfraction unitref="usd" contextref="i533b84da1d2441468aadec080d52600b_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-356" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzExMQ_0a033b47-8eb2-454b-a808-f2e08e564190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.0</ix:nonfraction></span> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<span><ix:nonfraction unitref="usd" contextref="if2334efa0613474c99d0b53f5f47619c_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-357" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzI1Nw_9fa571a7-9e60-4f13-9395-711d69599fc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <span><ix:nonfraction unitref="number" contextref="i7059bd4c3d114e288eb8029d693c5dd6_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="fact-identifier-358" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzM2OQ_e086b366-a2ca-4482-8cc3-9230d5c29547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <span><ix:nonnumeric contextref="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="fact-identifier-359" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzYzNQ_d995a7c1-c9e4-4c5a-a4e9-b1d581f65f19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">fifteen years</ix:nonnumeric></span> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i12c907d5d02240ea9db06eca33edac7a_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="fact-identifier-360" continuedat="iff44311d7016422b8d292d6e3cf83d1e" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfMzk5Nw_132de40a-e094-45d2-be74-1b7a7eb1b546" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">seven </ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="iff44311d7016422b8d292d6e3cf83d1e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">years</ix:continuation></span> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of December&nbsp;31, 2021, none of these individuals are active employees or members of the Company's board of directors. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, the Company had cash and cash equivalents of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-362" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY0OQ_8d120f8d-ae45-4efb-981b-2dc23b20b96a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162.6</ix:nonfraction></span> million and an accumulated deficit of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-363" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDY4Mg_eff316ed-7c10-4609-9cee-3918a34125e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316.3</ix:nonfraction></span> million. The Company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">curred negative cash flows from operating acti</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vities of $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-364" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc1Ng_a2784e9e-5c4f-49a5-8807-efd244278c91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68.9</ix:nonfraction></span> million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-365" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2MA_7d6e60cf-d629-44dc-b9d7-563ce0cc5f1e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30.8</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-366" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84Mi9mcmFnOjc2ZWRmMzBiMmIxODQzMzc4ODVlNmQ0ZjhjYzU5NzlkL3RleHRyZWdpb246NzZlZGYzMGIyYjE4NDMzNzg4NWU2ZDRmOGNjNTk3OWRfNDc2Nw_2531fa83-d891-46fa-957d-4383eba0f5b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37.5</ix:nonfraction></span> million for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively. Since the Company’s inception, it has received no revenue from sales of its products, and the Company anticipates that operating losses will continue for the foreseeable future as it seeks to address the issues raised in the CRL it received for a BLA for Vicineum for the treatment of BCG unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete the follow-up stage of the ongoing Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, complete any additional clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financed its operations to date primarily through private placements of its common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, its initial public offering ("IPO"), follow-on public offerings, sales effected in "at-the-market" ("ATM") offerings, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out-license agreements. See “Note 12. Stockholders’ Equity” below for information regarding the Company’s recently completed equity financings. Management believes that the Company’s cash and cash equivalents as of December&nbsp;31, 2021 will be sufficient to fund the Company's current operating plan for at least the next twelve months from the date these consolidated financial statements were issued.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future success is dependent on its ability to develop, and if approved, commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and ultimately upon its ability to attain profitable operations. In order to commercialize its product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, the Company needs to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of its product candidates, raising additional capital, development and commercialization by its competitors of new technological innovations, protection of proprietary technology and market acceptance of its products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, requires substantial working capital, and the Company expects to seek additional funds through equity or debt financings or through additional outside of United States (“OUS”) business development partnerships, collaborations, licensing transactions or other sources. The Company may be unable to obtain equity or debt financings or enter into additional OUS business development partnerships, collaborations or licensing transactions at favorable terms, or at all, and, if necessary, may be required to implement cost reduction strategies. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will incur substantial expenses if and as it:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addresses the issues identified in the CRL it received from the FDA for its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the European Medicines Agency’s (“EMA”) Withdrawal Assessment Report, which the Company expects will include the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks marketing approvals for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities to commercialize Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintains, expands and protects its intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hires additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expands its operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducts research and pre-clinical and clinical development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeks to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-licenses or acquires the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, initiation, progress, timing, costs and results of laboratory testing and clinical trials for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG and its other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on the Company’s business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company’s ability to establish additional OUS business development partnerships, collaborations or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for its product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities, including those associated with the manufacturing process and technology transfer to third-party manufacturers to facilitate such commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company’s obligation to make milestone, royalty and other payments to third-party licensors under its licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the Company in-licenses or acquires rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA and comparable non-US regulatory authorities for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, including the potential for the FDA, EMA or comparable non-US regulatory authorities to require that the Company perform more studies or clinical trials than those that it currently expects to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company’s ability to achieve certain future regulatory, development and commercialization milestones under its out-license and OUS business development partnership agreements </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as the Company can generate substantial product revenues from commercial sales, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic collaborations, OUS business development partnership agreements, partnerships, alliances, and licensing arrangements. The Company does not have any committed external source of funds other than the amounts payable under the license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”) and the license agreement with Qilu Pharmaceutical, Co., Ltd. (“Qilu”). To the extent the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Company raises additional funds through government or other third-party funding, strategic OUS business development partnerships, collaborations, alliances or licensing arrangements, the Company may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company. If the Company is unable to raise additional funds when needed, the Company may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on the Company’s operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect the Company’s ability to raise additional capital in the future.</span></div></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_85"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:BasisOfAccounting" id="fact-identifier-367" continuedat="ia4999b482cec4d51af7fb31604f9e2e5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOQ_685e53f4-d18b-481d-9bc3-5d10787d13e6" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">BASIS OF PRESENTATION</ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ia4999b482cec4d51af7fb31604f9e2e5" continuedat="i195efad864d9459e927233899a3c2691" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</ix:continuation></span></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i195efad864d9459e927233899a3c2691" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:UseOfEstimates" id="fact-identifier-370" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNg_4e5588d3-cc94-4113-80d6-746889d436ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets, goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); research and development expenses; and going concern considerations.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="fact-identifier-371" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxNw_cfe9bd45-c01d-4370-a0fc-ab6139497ab3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&nbsp;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="fact-identifier-372" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84NS9mcmFnOjc0MjVmMTc5OGRkZDRmYjNiNjUzMzgwMjc2MGQ0YTUzL3RleHRyZWdpb246NzQyNWYxNzk4ZGRkNGZiM2I2NTMzODAyNzYwZDRhNTNfMjQxOA_8aa20fb3-ce39-4b28-92e7-5ee07f6c6ff0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div></ix:nonnumeric></span></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="fact-identifier-373" continuedat="ifbe4e2477f79461ebf644aeaf4a3caab" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzk_5d14b5b9-c387-485d-8ee0-2402c0b10a3a" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonnumeric></span></span></div><span><ix:continuation id="ifbe4e2477f79461ebf644aeaf4a3caab" continuedat="i0d13368947874d10b490a65b30d41614" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="fact-identifier-375" continuedat="i287f28ff538c4909a35720a57daf3d15" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjI_6773808a-55e5-48d2-a0d9-88e693199802" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Cash, Cash Equivalents, Restricted Cash and Concentration of Credit Risk</ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i287f28ff538c4909a35720a57daf3d15" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company's cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation ("FDIC") insurance coverage limit of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-377" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzE3_7a6c87fe-383d-4fd6-88c0-40cb19c78f58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span> per depositor, per FDIC-insured bank, per ownership category. Restricted cash represents cash held by the Company's primary commercial bank to collateralize a letter of credit issued related to a license agreement and the credit limit on the Company's corporate credit card, and are classified as short term and long term, respectively. The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject the Company to credit risk principally consists of cash equivalents and accounts receivable. As of December&nbsp;31, 2021 and 2020, the Company limited its credit risk associated with cash equivalents by placing investments in highly-rated money market funds.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="fact-identifier-378" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDk_ea794164-6971-43cf-8f3e-4875b9f309ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and costs of improvements and renewals are capitalized. Depreciation is recognized using the straight-line method over the estimated useful lives of the relative assets. The Company uses an estimated useful life of <span><ix:nonnumeric contextref="id0d7d3d671d44f1fb8dc94865706738c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="fact-identifier-379" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTM4OA_305cde46-1b1b-4f36-b4ee-e1cf56460954" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five years</ix:nonnumeric></span> for lab equipment, <span><ix:nonnumeric contextref="i0f42726b9d2d45519a3279adbdeaf414_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="fact-identifier-380" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMA_c4c2f676-74a3-44b5-9426-7fa9046f0efc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four years</ix:nonnumeric></span> for furniture and fixtures, <span><ix:nonnumeric contextref="ib16d8fcfc6064d57a72284ee2689a0c5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="fact-identifier-381" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ0MQ_cee98dac-07d2-4338-9ae7-0db94adcf06d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three years</ix:nonnumeric></span> for computer equipment and software and the lesser of <span><ix:nonnumeric contextref="i649bc58c14754d8497732ebb7fb60f40_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="fact-identifier-382" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ5OA_4ddf5223-522c-4ba6-a21c-01a87c3ea95a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five years</ix:nonnumeric></span> or the remaining lease term for leasehold improvements.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" id="fact-identifier-383" continuedat="i0b429936ae5d4b8aa8e6b4daf01020ac" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzU_7443fc48-60af-4f5f-bbac-8c2d65d18806" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of BCG-unresponsive NMIBC is not obtained, the Company will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. The Company recognizes an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of its intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i0d13368947874d10b490a65b30d41614" continuedat="i03d93ed113ea48d2a857778460b73815" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i0b429936ae5d4b8aa8e6b4daf01020ac" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of NMIBC, its lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum (and Vysyneum in the EMA) as a result of the CRL and the withdrawal of the Company's marketing authorization application (“MAA”), an interim impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company’s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $<span><ix:nonfraction unitref="usd" contextref="i5a2a6758069a4a888d0e5d69c12d58ab_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-386" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNDM5ODA0NjUzOTM3NA_c02efd29-01bb-4ba2-b5db-6bc5e7f85ba3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.7</ix:nonfraction></span> million of impairment charges were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. However, while similar delays in timelines and reduced probabilities of success also affected the estimated fair value of the Company's intangible asset of Vicineum EU rights, this asset was not impaired as of September 30, 2021. At that time, management assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and probability of clinical and regulatory success (“POS”) assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management’s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company’s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. The Company participated in Type A Meetings with the FDA on October 29, 2021 and December 8, 2021 to discuss questions related to CMC and clinical issues raised in the CRL. Both meetings helped the Company determine the appropriate path forward for Vicineum. Based upon the outcome of these meetings, the Company plans to conduct an additional Phase 3 clinical trial. Also, during the Clinical Type A Meeting, the Company aligned with FDA to include patients with less than adequate BCG into its new clinical trial. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&nbsp;31, 2021.</ix:continuation></span> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="fact-identifier-387" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTcwNDI0MzAzMzYwNzE_4c16c954-3f23-4f74-9d3c-67ca22e61849" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t recognize any impairment charges during the year ended December&nbsp;31, 2020. </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="fact-identifier-388" continuedat="ie778b4f275ab42d788125de08eff5351" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzE_a5c6aab4-51b2-4d7c-8a9f-15ccc078a7a8" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheets is the result of the Company’s acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit’s carrying value, including goodwill, then goodwill is considered not to be impaired. The Company recognizes a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. The Company has only <span><ix:nonfraction unitref="unit" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-389" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NjI_85cd7542-13ad-4d77-a33d-3cc6ea654fb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span> reporting unit. In addition, on a quarterly basis, the Company performs a qualitative review of its business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company’s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021. While an impairment was recognized in one of the Company’s intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-390" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5NDg_2c08ed4f-7114-4293-bc18-3431a4d4af0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.1</ix:nonfraction></span>&nbsp;million was not impaired as of September 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was <span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-391" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NTM_0fbd0bee-2456-4a4c-9790-af997d841998" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> goodwill impairment as of December&nbsp;31, 2021. Management believes the Company has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i03d93ed113ea48d2a857778460b73815" continuedat="ic57c448309894de6b6a320984b9a8a1c" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="ie778b4f275ab42d788125de08eff5351" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management’s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. The Company will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-394" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTc1Mg_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> goodwill impairment during the year ended December&nbsp;31, 2020.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="sesn:ContingentConsiderationPolicyTextBlock" id="fact-identifier-395" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjU_c404c114-e2c1-4455-85e0-79bfdad93375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a discounted cash flow model to estimate the fair value of the contingent consideration liability each reporting period, which represents the present value of projected future cash flows associated with regulatory approval milestones and royalties on net sales due to the selling shareholders of Viventia Bio Inc. as a result of the Viventia Acquisition in September 2016. See "Note 1. Description of Business" for additional information. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company's revenue projection models are timing of product launch and probabilities of clinical and regulatory success ("POS"); the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL. The Company plans to conduct an additional clinical trial, which will lead to delays in the start of commercialization globally. The Company has assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management’s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately <span><ix:nonfraction unitref="number" contextref="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="fact-identifier-396" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NjM_28dc195a-1041-4f72-be4e-d4696f71814c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">45</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="fact-identifier-397" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Njg_aac8409a-90e6-4f12-b167-bb277fd7512e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">55</ix:nonfraction></span>% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of the Company’s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-398" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1NzM_6980510a-676e-4371-8807-38aaac3ceb96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-399" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1Nzc_5e96845d-0dad-48e5-9066-28aa466f0dc6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% earnout is derived from the Company’s estimated weighted-average cost of capital (“WACC”), which has fluctuated from <span><ix:nonfraction unitref="number" contextref="i028ccf70c10c4129a5d10bd536d297b3_I20201231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-400" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODE_1ba7af8a-e782-4c0b-a7ae-d59bb4a47392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.8</ix:nonfraction></span>% as of December&nbsp;31, 2020, to <span><ix:nonfraction unitref="number" contextref="i2de469ec0aa540adac05ef95232f5a15_I20210331" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-401" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1ODc_034f23e7-f618-45b4-8323-03d6d708360e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.8</ix:nonfraction></span>% as of March 31, 2021, <span><ix:nonfraction unitref="number" contextref="ib6a34442b9744cb6ae08c574b84b89b9_I20210630" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-402" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MzU_e78facfe-2a39-439b-85d2-5ee6ad94eee9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.8</ix:nonfraction></span>% as of June 30, 2021, <span><ix:nonfraction unitref="number" contextref="i4609a0afbc594078808154f146946ab1_I20210930" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-403" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTk_ceb76db2-7c90-46e7-be7f-f88ed773c9bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.6</ix:nonfraction></span>% as of September 30, 2021, and <span><ix:nonfraction unitref="number" contextref="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-404" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ1OTM_eef6d3c8-4728-4515-910b-0e17462e8300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9.3</ix:nonfraction></span>% as of December&nbsp;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <span><ix:nonfraction unitref="number" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="fact-identifier-405" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MDU_7ab5424e-5f5b-4f82-aecc-0a467a98cc19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.4</ix:nonfraction></span>% as of December&nbsp;31, 2020, to <span><ix:nonfraction unitref="number" contextref="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="fact-identifier-406" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTE_8c5487ad-b537-47a0-bfde-12dbb6625b3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.4</ix:nonfraction></span>% as of March 31, 2021, <span><ix:nonfraction unitref="number" contextref="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="fact-identifier-407" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MTc_ff2b4afe-2186-4d11-a46f-12a9ce58fd8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.6</ix:nonfraction></span>% as of June 30, 2021, <span><ix:nonfraction unitref="number" contextref="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="fact-identifier-408" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2MjM_d95d7b5e-e1f5-4f32-aaf9-92becf224eeb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.5</ix:nonfraction></span>% as of September 30, 2021, and <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="3" name="sesn:DebtInstrumentIndexRateHighYield" scale="-2" id="fact-identifier-409" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIyMjQ2Mjk_16b69e59-ed1a-4544-ba11-cc8d13dedb6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.0</ix:nonfraction></span>% as of December&nbsp;31, 2021.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="fact-identifier-410" continuedat="i5f96ae4ec1e34f768f7cb267b50aead0" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDU_da5565b4-e26b-4d69-a4a4-1cecb027fc07" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2019, the Company adopted ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 842”) using the optional transition method outlined in ASU No. 2018-11,&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842), Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The adoption of ASC 842 represents a change in accounting principle that aims to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet for both operating and finance leases. In addition, the standard requires enhanced disclosures that meet the objective of enabling financial statement users to assess the amount, timing and uncertainty of cash flows arising from leases. The reported results for the year ended December&nbsp;31, 2021, 2020 and 2019 reflect the application of ASC 842 guidance, while the reported results for priors were prepared in accordance with the previous ASC Topic 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 840") guidance. The adoption of ASC 842 resulted in the recognition of operating lease right-of-use assets and corresponding lease liabilities of $<span><ix:nonfraction unitref="usd" contextref="i4b6d609604934e33aa33ca5fc59ce894_I20190101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-411" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_08682c8c-532a-4ff3-abb1-fa2bbebf917c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i4b6d609604934e33aa33ca5fc59ce894_I20190101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-412" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfODQ3MA_b44d4d02-80fd-40f3-8916-eef1ca4c1b06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span></ix:nonfraction></span> million on the Company’s consolidated balance sheet as of January 1, 2019. </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ic57c448309894de6b6a320984b9a8a1c" continuedat="i69578fc097d34816a88c634f445c6a2c" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i5f96ae4ec1e34f768f7cb267b50aead0" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on the Company’s financial condition, results of operations or cash flows; however, the adoption did result in significant changes to the Company’s financial statement disclosures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the adoption of ASC 842, the Company utilized certain practical expedients outlined in the guidance. These practical expedients include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accounting policy election to use the short-term lease exception by asset class;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Election of the practical expedient package during transition, which includes:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&nbsp;&nbsp;&nbsp;&nbsp;An entity need not reassess whether any expired or existing contracts are or contain leases;</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&nbsp;&nbsp;&nbsp;&nbsp;An entity need not reassess the classification for any expired or existing leases. As a result, all leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases under ASC 842, and all leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases under ASC 842; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&nbsp;&nbsp;&nbsp;&nbsp;An entity need not reassess initial direct costs for any existing leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s lease portfolio as of the adoption date and as of December 31, 2021 includes: a property lease for manufacturing, laboratory, warehouse and office space in Winnipeg, Manitoba, a property lease for its headquarters in Cambridge, MA, and a property lease for office space in Philadelphia, PA. The Company determines if an arrangement is a lease at the inception of the contract and has made a policy election to not separate out non-lease components from lease components, for all classes of underlying assets. The asset components of the Company’s operating leases are recorded as operating lease right-of-use assets and reported within other assets on the Company's consolidated balance sheet. The short-term and long-term liability components are recorded in other current liabilities and other liabilities, respectively, on the Company’s consolidated balance sheet. As of December&nbsp;31, 2021, the Company did not have any finance leases.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and operating lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. Existing leases in the Company’s lease portfolio as of the adoption date were valued as of January 1, 2019. The Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, if an implicit rate of return is not provided with the lease contract. Operating lease right-of-use assets are adjusted for incentives received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are recognized on a straight-line basis over the lease term, in accordance with ASC 842, and also include variable operating costs incurred during the period. Lease costs also include amounts related to short-term leases.</span></div></ix:continuation></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="fact-identifier-415" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4Mzg_68c1d800-fb03-4527-9adf-c961e3aa90cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="fact-identifier-416" continuedat="if30ae5a8df09419d97cea21db765793d" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MjM_1ef8bcfb-73b7-43fd-b7dc-a644b9fb0322" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the grant-date fair value of share-based awards granted as compensation as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to market conditions. From time to time, the Company has granted to its executives' stock option awards which contain both performance-based and service-based vesting criteria. Performance milestone events are specific to the Company’s corporate goals, including certain clinical development objectives related to the new clinical trial, regulatory and financial objectives. Share-based compensation expense associated with performance-based vesting criteria is recognized using the accelerated attribution method if the performance condition is considered probable of achievement in management’s judgment. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the fair value of the underlying stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each grant of options during the years ended December&nbsp;31, 2021, 2020 and 2019 was determined using the following methods and assumptions:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lack of historical exercise data and given the plain vanilla nature of the options granted by the Company, the expected term is determined using the “simplified" method, as prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 ("SAB 107"), whereby the expected life equals the arithmetic average of the vesting term </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i69578fc097d34816a88c634f445c6a2c" continuedat="ie4191a8e53c243bb9d2f3ebdc64c8931" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="if30ae5a8df09419d97cea21db765793d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(generally <span><ix:nonnumeric contextref="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="fact-identifier-419" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQwODc_92084f93-1651-4897-8f2d-0144000000bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four years</ix:nonnumeric></span>) and the original contractual term (<span><ix:nonnumeric contextref="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="fact-identifier-420" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQxMjY_c90bb293-9d9e-425a-bf8b-5b98fbc57fec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span>) of the option, taking into consideration multiple vesting tranches. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the interest rate payable on United States Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility is based on historical volatilities of a representative group of publicly traded biopharmaceutical companies, including the Company's own volatility, which were commensurate with the assumed expected term, as prescribed in SAB 107.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend Yield. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dividend yield is <span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="fact-identifier-421" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTQ3MzA_65ed8b91-5813-4420-a1b9-c43d0574ccd8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>% because the Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, a dividend on its common stock.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="fact-identifier-422" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4MzY_125fe576-e0c1-4395-a24a-4e3211d5f18b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss ("NOL") and research and development credit ("R&amp;D credit") carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes accrued interest and penalties related to uncertain tax positions as income tax expense in its consolidated statements of operations. As of December&nbsp;31, 2021 and 2020, the Company did not have any uncertain tax positions.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="fact-identifier-423" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTg4NDE_c4e97964-d7d3-4411-b6f6-6b8c1d933140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenue from out-license agreements and OUS business development partnership agreements, including the License Agreement with Roche and its OUS partnerships. Under each of these agreements, the Company granted the counterparty an exclusive license to develop and commercialize the underlying licensed product. These agreements contain up-front license fees, development and regulatory milestone payments, sales-based milestone payments, and sales-based royalty payments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether the out-license agreements and OUS business development partnership agreements are in scope of ASC 606, which it adopted as of January 1, 2018. Under ASC 606, in determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under these agreements, management performs the following steps:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)   Identification of the contract;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)  Determination of whether the promised goods or services are performance obligations including whether they are                          distinct in the context of the contract;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)  Measurement of the transaction price, including the constraint on variable consideration;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)  Allocation of the transaction price to the performance obligations; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)  Recognition of revenue when or as the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development and Regulatory Milestones and Other Payments</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of an arrangement that includes development milestone payments, management evaluates whether the development milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated development milestone value is included in the transaction price. Development milestone payments that are not within the Company's control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For payments pursuant to sales milestones and royalty payments, the Company will not recognize revenue until the subsequent sale of a licensed product occurs. For arrangements with one than one performance obligations, the milestones are generally allocated entirely to the license performance obligation, as (1) the terms of milestone and royalty payments relate specifically to the license and (2) allocating milestones and royalties to the license performance obligation is consistent with the overall allocation objective, because management’s estimate of milestones and royalties approximates the standalone selling price of the license.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ie4191a8e53c243bb9d2f3ebdc64c8931" continuedat="i01fbe849109a4f97906fb5e357fe6a07" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In December 2021, a $<span><ix:nonfraction unitref="usd" contextref="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-425" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5OTk_a5b21596-6c35-4076-981c-c807eaafbac3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million milestone was achieved due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<span><ix:nonfraction unitref="usd" contextref="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" decimals="-6" name="sesn:LicenseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-426" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTY5ODY_b1063518-33dd-44b7-9602-1a7dfeacae92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million with payment terms of <span><ix:nonnumeric contextref="i537b107b17f34737a20ec184a594ae82_D20211201-20211231" name="sesn:LicenseAgreementMilestonePaymentTerm" format="ixt-sec:durday" id="fact-identifier-427" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMTE1NDQ4NzIxOTcwMTE_70646b17-d4ff-4dd0-93e1-8cef01cf0991" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. Management evaluated the transaction under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i695006bd273747aeb95e43b893e8b867_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-428" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjY3OQ_c5caa3f9-de7f-45c5-9f78-553872bb3834" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;million as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<span><ix:nonfraction unitref="usd" contextref="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-429" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfMzI5ODUzNTAxNjgwMg_2d6ef542-d325-488f-a8df-f4573102205b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million was received. </ix:continuation></span></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i01fbe849109a4f97906fb5e357fe6a07" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company recognized $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-431" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDM4Ng_33f6a9e1-7734-430e-8088-02830519ab81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.5</ix:nonfraction></span>&nbsp;million of license revenue related to the Roche, Qilu and MENA License Agreements during the year ended December 31, 2021 and $<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-432" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV84OC9mcmFnOjFmYzE4ZDBkZDRmNDRhNjFiZGVkZWQzMjhkMGRmNzU2L3RleHRyZWdpb246MWZjMThkMGRkNGY0NGE2MWJkZWRlZDMyOGQwZGY3NTZfNTQ5NzU1ODI0NDQwMg_2384a6cb-9234-453e-92f1-8b31ea1771d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;million of license revenue related to the Qilu License Agreement during the year ended December 31, 2020.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="fact-identifier-433" continuedat="i1983cbbac1ed46ffb0b2f760a46c78af" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OQ_6c9c2e44-7608-454d-a239-3d824236c00c" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonnumeric></span></span></div><span><ix:continuation id="i1983cbbac1ed46ffb0b2f760a46c78af" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="fact-identifier-435" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85NC9mcmFnOjEwNTQyZThiNGRmNTQwMTA5N2ZiN2VmMGUwMzMzNzdiL3RleHRyZWdpb246MTA1NDJlOGI0ZGY1NDAxMDk3ZmI3ZWYwZTAzMzM3N2JfMzM0OA_8e420737-a050-44d0-8ea2-b48d956480fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2021</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2019-12"). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments in ASU 2019-12 also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted. The method with which the amendments in this ASU are to be applied varies depending on the nature of the tax item impacted by amendment. The Company adopted this guidance effective January 1, 2021, and it did not have a material impact on its financial position, results of operations or cash flows.</span></div></ix:nonnumeric></span></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="fact-identifier-436" continuedat="ib8df77c39d3240a1b755ba6b55afafb9" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDAzOQ_768dfd06-eb00-4a85-8d77-c2d349b415e0" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonnumeric></span></span></div><span><ix:continuation id="ib8df77c39d3240a1b755ba6b55afafb9" continuedat="i435d468fd3b04536926c8c04f574da12" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="fact-identifier-438" continuedat="i8fd0e2394fa0458a98bbee093bcf1ad2" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NDA_7423ef5b-5642-4d7d-93a4-dde85bcf2cc9" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company’s consolidated balance sheets approximated their fair values as of December&nbsp;31, 2021 and 2020 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&nbsp;&nbsp;&nbsp;&nbsp;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&nbsp;&nbsp;&nbsp;&nbsp;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonnumeric></span><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><span><ix:continuation id="i8fd0e2394fa0458a98bbee093bcf1ad2" continuedat="ibdba3b03dc6d4e76ab919d17aab4abbb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Level 3</ix:continuation></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ibdba3b03dc6d4e76ab919d17aab4abbb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">:&nbsp;&nbsp;&nbsp;&nbsp;Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data.</ix:continuation></span> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="fact-identifier-441" continuedat="iaa5c401233cf4a84ac7ddc2094cab294" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MA_afd775d5-dfd3-4cd1-a719-1aa45172a908" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of December&nbsp;31, 2021 and 2020 (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i435d468fd3b04536926c8c04f574da12" continuedat="i8906baf0e60b4719b742c2fbbc357b60" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="iaa5c401233cf4a84ac7ddc2094cab294" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:13pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br>Markets<br>(Level&nbsp;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br>Inputs<br>(Level&nbsp;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br>Inputs<br>(Level&nbsp;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-444" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0xLTEtMS0yNzc0Mw_2f6104cc-996a-4686-985b-6a99ed01b75f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,382</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-445" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC0zLTEtMS0yNzc0Mw_9f8fbac0-4fea-4d26-a811-c75c9dceb116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,382</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-446" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC01LTEtMS0yNzc0Mw_deee05f7-c22a-42f7-9292-d0211cfae383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,382</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-447" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC03LTEtMS0yNzc0Mw_e75d8d9c-c133-471b-9f99-418e4fda1970" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-448" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNC05LTEtMS0yNzc0Mw_052eb447-85fb-4135-9a96-1701af5f8cc8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-449" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0xLTEtMS0yNzc0Mw_b561be6d-bb69-41a1-9109-2c37fb7aa2bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-450" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi0zLTEtMS0yNzc0Mw_ed2f70f5-e4b1-4309-9a30-c1d894b41de6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-451" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi01LTEtMS0yNzc0Mw_c70996eb-fdb3-49c8-aa7c-df47bae062e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-452" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi03LTEtMS0yNzc0Mw_6e17a0db-b65b-4179-a3f0-6e209a2d7abf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-453" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNi05LTEtMS0yNzc0Mw_bf8d7a63-6604-49ce-a6c0-0538d40c2b2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration - long term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib942d47e8aca410e959ff68b5d97942f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-454" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0xLTEtMS0yNzc0Mw_3e92c08a-89d0-4a0c-83c9-70361eedb084" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3f3d4b0f71404387b7089a237b8a5500_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-455" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy0zLTEtMS0yNzc0Mw_9a703a3d-17f0-45fa-9147-832b5427c89d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9280baa377514c5b8f3b86112af15bc1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-456" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy01LTEtMS0yNzc0Mw_cce00826-d798-4122-8a8b-7839a2ac28e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3a8e07a02a314fe58d21f5e73b65454b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-457" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy03LTEtMS0yNzc0Mw_be18999c-d583-4d8e-8055-278bfef1bea3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2904e8fab3f54e409e119eb43ab1f654_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-458" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjc3NTIyYWVmMDQ4MjQzODc4OTM5YzNkOGJmYzAwNTY0L3RhYmxlcmFuZ2U6Nzc1MjJhZWYwNDgyNDM4Nzg5MzljM2Q4YmZjMDA1NjRfNy05LTEtMS0yNzc0Mw_ef37d1a3-3440-41c9-861f-6bfa06983605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br>Markets<br>(Level&nbsp;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br>Inputs<br>(Level&nbsp;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br>Inputs<br>(Level&nbsp;3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-459" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0xLTEtMS0yNzc0Mw_31a004b6-d28e-4d18-b217-0bcde89984b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,374</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-460" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC0zLTEtMS0yNzc0Mw_ae51873c-01e4-4b48-b874-497ed5f92e34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,374</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-461" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC01LTEtMS0yNzc0Mw_6f4c2e60-7529-4867-8baa-e1eddd261659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,374</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-462" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC03LTEtMS0yNzc0Mw_447d6aef-1429-401d-aaf4-c5fc76e8a933" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="fact-identifier-463" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNC05LTEtMS0yNzc0Mw_dc2a1d1f-0344-4f27-9fcb-3676f2832aae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-464" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0xLTEtMS0yNzc0Mw_540804c0-cea1-400b-b540-03a59d9a6ebf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,985</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-465" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi0zLTEtMS0yNzc0Mw_0431842b-d616-42ba-a199-7b7222769570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,985</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-466" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi01LTEtMS0yNzc0Mw_5f9352af-a776-4420-a867-03108529dd9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-467" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi03LTEtMS0yNzc0Mw_d2505ecb-eeb2-4c6a-b945-2b5e72ac1517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-468" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNi05LTEtMS0yNzc0Mw_011d8e67-00d1-458f-adbc-fb071f990e1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,985</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, net of current portion</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9bdc10f8bd0b4b62b55799b14aaa895d_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-469" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0xLTEtMS0yNzc0Mw_9a518215-c89d-4ea1-ba52-526d27770ffb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,855</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib5309a9a57784300b6ab55b4dbfaa087_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-470" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy0zLTEtMS0yNzc0Mw_cf8b2d48-2714-4bc9-befa-5106eb49f841" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,855</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic6f21fbe1815427897b0c6ef0565f88f_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-471" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy01LTEtMS0yNzc0Mw_b8a4f32f-ea42-4bd9-bde8-2a6b5c4e266f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i33449a16f50d42fda82fa03444b362a5_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-472" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy03LTEtMS0yNzc0Mw_bebc9c23-8df7-4dbc-943b-3abaf4da05b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4c7c5bb2754d4323bf79ba191bc841ba_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-473" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjFhMDRhZTRlNDdhOTQ0YzFiNzBhNjQyODUxOWY3NWYwL3RhYmxlcmFuZ2U6MWEwNGFlNGU0N2E5NDRjMWI3MGE2NDI4NTE5Zjc1ZjBfNy05LTEtMS0yNzc0Mw_140baebe-ca1c-4136-b974-459644f8181a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,855</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company’s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved ranging from 2025 to 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from <span><ix:nonfraction unitref="number" contextref="ib03bde29f9a84402bee0c3bc6cf735f5_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-474" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMDAxMA_96e4f383-ebfc-4ea2-95f2-eb2068d180c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.0</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="i58772c205c8a4b93bd99d62ff3f8e8af_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-475" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NTY_0593a624-4442-4a62-a30b-bceb768a6bca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.3</ix:nonfraction></span>% as of December&nbsp;31, 2021 and <span><ix:nonfraction unitref="number" contextref="i294acb7d2420400b8155b9d8ca59ecac_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-476" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyMg_4dcd7c38-e00d-411f-ad48-716cc41112fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.4</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="i80a8c65717624d59b77914baa103c3bf_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-477" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjAyOA_2bca2bad-007f-4416-9609-2c1581063298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.8</ix:nonfraction></span>% as of December&nbsp;31, 2020. There have been no changes to the valuation methods utilized during the year ended December&nbsp;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="fact-identifier-478" continuedat="icb2456fcd5844c048201bda7a606daca" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfNDA0MQ_609233e2-f0e6-44e5-8c82-6aa959eeac10" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth a summary by quarter of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&nbsp;31, 2021 (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i8906baf0e60b4719b742c2fbbc357b60" continuedat="i183d6a8fb6784a0dba44f424ba67ead8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="icb2456fcd5844c048201bda7a606daca" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&nbsp;31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-481" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMC0xLTEtMS0yNzc0Mw_4608251b-7b7b-40f9-a8fb-e8da3b1b5004" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,840</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9873482dcdab4f8e99687d14de08bf30_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-482" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMS0xLTEtMS0yNzc0Mw_061fab41-b98b-4a58-a6b0-15b2d03cad2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,160</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-483" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMi0xLTEtMS0yNzc0Mw_3b022d13-2ede-4ceb-a3e9-13ffb4675c94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia0ab9cefc27e4b67b11ffb55b439770b_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-484" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMy0xLTEtMS0yNzc0Mw_c27af503-1354-4d3e-9eac-659c1875838c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,600</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-485" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNC0xLTEtMS0yNzc0Mw_0137421a-b009-41f4-9f04-161a39d83308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">170,600</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic90b2409cd1e47e9a97d51b1bda3f754_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-486" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNS0xLTEtMS0yNzc0Mw_b28a0236-140a-4605-8f37-b13c8ab59b28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">114,000</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-487" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNi0xLTEtMS0yNzc0Mw_7b8bd602-aeef-48f3-bdf9-7c81c43737e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,600</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-488" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfNy0xLTEtMS0yNzc0Mw_7162395d-9a14-44ee-998d-632c5e9077c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,600</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&nbsp;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-489" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfOC0xLTEtMS0yNzc0Mw_e7e6953b-de7b-407f-8bec-53c2ace4e031" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&nbsp;31, 2021, current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-490" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTAtMS0xLTEtMjc3NDM_82599e7d-c96e-40fd-8542-d66a83aff52f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&nbsp;31, 2021, net of current portion</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-491" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOmE5ZDMzNjM1ZDFhZDQ3Mzk5MTRlNTYyZWYyZmQzYzRhL3RhYmxlcmFuZ2U6YTlkMzM2MzVkMWFkNDczOTkxNGU1NjJlZjJmZDNjNGFfMTEtMS0xLTEtMjc3NDM_65e6ac33-1175-4c42-aa1c-1a431df66de7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's total contingent consideration liability, measured on a recurring basis at each reporting period, for the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&nbsp;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usd" contextref="i461f7c863e8845a1bf3aecbdde6819d0_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-492" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMC0xLTEtMS0zMDI3Ng_89337f78-097e-4c35-a783-4f88457bf005" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,840</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - short term </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iccafbadd781745f8a66ce65217af032c_D20210101-20211231" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-493" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMS0xLTEtMS0zMDI4NA_86832af2-5324-41dc-a4be-1707b5f89b2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,985</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration - long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iccafbadd781745f8a66ce65217af032c_D20210101-20211231" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-494" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMi0xLTEtMS0zMDI5Mg_ad6469f9-4219-4413-9bac-cea1a8aa19d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">47,855</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&nbsp;31, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i208c2cdd76674e1490701e0cd5f02c0f_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-495" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RhYmxlOjNkNGU4YjU2Zjc2ZDQ3MzA4NWU0NDJmMDVkZTBmOGFhL3RhYmxlcmFuZ2U6M2Q0ZThiNTZmNzZkNDczMDg1ZTQ0MmYwNWRlMGY4YWFfMy0xLTEtMS0zMDMxMA_4093d389-3124-4c5f-bb2e-7668c8073c5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i183d6a8fb6784a0dba44f424ba67ead8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The fair value of the Company’s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-497" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTA5OTUxMTYzNDE3Ng_0a9c0fb3-bd28-48d0-9c60-92ae775ff46f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-498" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMjk4MA_c6912ff7-f528-4d70-9683-cc0c9654886a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% earnout is derived from the Company’s WACC, which has fluctuated from <span><ix:nonfraction unitref="number" contextref="i028ccf70c10c4129a5d10bd536d297b3_I20201231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-499" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEwMA_7ae83321-ac68-4486-9508-6f2e2cb6cf88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.8</ix:nonfraction></span>% as of December&nbsp;31, 2020, to <span><ix:nonfraction unitref="number" contextref="i2de469ec0aa540adac05ef95232f5a15_I20210331" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-500" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzEzMA_8121cf6c-6333-47ab-b549-a8ce6b90c583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.8</ix:nonfraction></span>% as of March 31, 2021, <span><ix:nonfraction unitref="number" contextref="ib6a34442b9744cb6ae08c574b84b89b9_I20210630" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-501" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE1NQ_e78a1cf8-bea4-4c56-8356-fb0c5b782922" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6.8</ix:nonfraction></span>% as of June 30, 2021, <span><ix:nonfraction unitref="number" contextref="i4609a0afbc594078808154f146946ab1_I20210930" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-502" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzE3OQ_909cf822-16e8-494c-82d8-fb0ccab765d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.6</ix:nonfraction></span>% as of September 30, 2021, and <span><ix:nonfraction unitref="number" contextref="i6ca95efd59f64d3e87b9f4bb772103cc_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="fact-identifier-503" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzg0ODI5MDczMTU5NQ_564da084-42ab-4d1d-bfb2-eb4bd8366f4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9.3</ix:nonfraction></span>% as of December&nbsp;31, 2021. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <span><ix:nonfraction unitref="number" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-504" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ0MQ_abd5161f-48b9-4573-91ba-05b44fa22a01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.4</ix:nonfraction></span>% as of December&nbsp;31, 2020, to <span><ix:nonfraction unitref="number" contextref="ia2453680b1ee48d49d18b917c46773a0_I20210331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-505" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ3MQ_b3dd341c-5899-41d5-b39c-defb295313c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.4</ix:nonfraction></span>% as of March 31, 2021, <span><ix:nonfraction unitref="number" contextref="i07b9561ea6f64a83a3ebb4afb35cfcf4_I20210630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-506" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzQ5Ng_6528f9b2-59d9-4e23-83d5-1b6b892ebd28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.6</ix:nonfraction></span>% as of June 30, 2021, <span><ix:nonfraction unitref="number" contextref="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-507" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMzUyMA_6a13d7fd-fde7-41e6-94a7-a7e768945725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.5</ix:nonfraction></span>% as of September 30, 2021, and <span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="fact-identifier-508" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5NjM_f61c647f-318c-440e-be5f-1b5d07460998" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.0</ix:nonfraction></span>% as of December&nbsp;31, 2021. The decrease in the fair value of contingent consideration of $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-509" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTcwNDI0MzAyNzQ5NzY_3dbc9b6f-21d3-4118-a572-b7866858adc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56.8</ix:nonfraction></span> million for the year ended December&nbsp;31, 2021 was driven by the receipt of the CRL from the FDA, in which the FDA determined that it could not approve the BLA for Vicineum in its present form, and the Company’s withdrawal of its MAA with EMA. In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. Incorporating the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company’s revenue projection models are timing of commercial product launch and probabilities of clinical and regulatory success; the Company expects delays in the start of commercialization and estimates lower POS as a direct result of the CRL and the Company’s withdrawal of its MAA. The Company plans to conduct an additional Phase 3 clinical trial in order to resubmit a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG, which will lead to delays in the start of commercialization globally. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management’s best estimate. In addition, the Company now assumes a lower POS in achieving certain clinical and regulatory milestones in the range of approximately <span><ix:nonfraction unitref="number" contextref="if746ed8ff7f24e03a3e8aa08c41614f2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="fact-identifier-510" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODQ_e8f080e9-4caa-41f8-999b-2396e8948d5f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">45</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="fact-identifier-511" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV85Ny9mcmFnOmJmNzgzYzUyMWM1ZjQxMWRiYTJiY2IyNDExZDljYWYxL3RleHRyZWdpb246YmY3ODNjNTIxYzVmNDExZGJhMmJjYjI0MTFkOWNhZjFfMTE1NDQ4NzIxMzU5ODk_94b0c53b-ee74-4909-8519-3ad243c3e295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">55</ix:nonfraction></span>% globally.</ix:continuation></span> Any changes in these assumptions and estimates as a result of these meetings, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1294"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="fact-identifier-512" continuedat="i4063b9e6833049349cce4488af91d3b1" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMTU0NDg3MjA5Njk1NA_3f893826-ea4b-4f5a-aec4-33f318ecfcb1" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">RECEIVABLES </ix:nonnumeric></span></span></div><span><ix:continuation id="i4063b9e6833049349cce4488af91d3b1" continuedat="i7f3a4e3d5bd647d98a031256aa4919bf" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of December 31, 2021 is $<span><ix:nonfraction unitref="usd" contextref="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-514" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEwOA_09a50a2e-ea8b-45c2-b032-4890e61a345d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;million, comprised primarily of a $<span><ix:nonfraction unitref="usd" contextref="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-515" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEzNA_3e38b8bb-fcde-48b9-82a7-c97dcf7fcba6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million milestone achieved in December 2021 due to Roche initiating a Phase II clinical trial. The Company invoiced Roche $<span><ix:nonfraction unitref="usd" contextref="ie4d28c1f27f14fd5aeefc11c4ce245d0_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-516" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE0Nw_b2f62b13-8133-4bef-a106-830ff3e58fcc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million with payment terms of <span><ix:nonnumeric contextref="i15fd8a9c40534aeaaf4598e6db3abbf6_D20211201-20211231" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="fact-identifier-517" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2Mg_5206b3da-fb31-4b10-8a5e-8d0dc52db337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement. In January 2022 the payment of $<span><ix:nonfraction unitref="usd" contextref="i69a83c24db234a7e8561b517d543d5e4_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-518" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE2OA_fc225545-834f-4a3a-8019-3ac6acf44f39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million was received. Additionally, i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". As such, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="ia21f2148bbe744ea9737cdc30b3b639e_I20210630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-519" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xNzA0MjQzMDIzNTk5MQ_8b0a6c6e-0b27-4a2b-815b-fb7db0bb2e5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.9</ix:nonfraction></span>&nbsp;million of revenue and accounts receivable for the additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of December 31, 2021 is $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-520" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzEyNw_547e89e7-9ae7-49d3-bf3d-d6c180bab0ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.5</ix:nonfraction></span>&nbsp;million. The Company recorded $<span><ix:nonfraction unitref="usd" contextref="i29d7312d27104fbb9ae3fe30ac6400a3_D20211001-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-521" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE4MQ_1d186cb8-2b4e-4aea-a3df-d400b5950ed5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.4</ix:nonfraction></span>&nbsp;million to other receivables in the fourth quarter of 2021 for German VAT recovery related to drug substance sent to Baxter. The Company received a payment for $<span><ix:nonfraction unitref="usd" contextref="i34539641171840f78745ef893c090fa7_D20220101-20220131" decimals="-5" name="sesn:ProceedsFromValueAddedTaxRecovery" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-522" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjk0L2ZyYWc6MTcxYmFhZjBiNWM0NDYyY2FiOWRiM2M0OGU5OWI4ZjgvdGV4dHJlZ2lvbjoxNzFiYWFmMGI1YzQ0NjJjYWI5ZGIzYzQ4ZTk5YjhmOF8xMDk5NTExNjI4MzE5NQ_3e9e4d0f-c6fa-4f2a-8ff7-5cd3763b0f44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.8</ix:nonfraction></span>&nbsp;million in January 2022 and expects to collect the remaining balance.</span></div></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i7f3a4e3d5bd647d98a031256aa4919bf" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The accounts receivable and other receivable balances as of December 31, 2020 were de minims.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="fact-identifier-524" continuedat="ib6f7c0a9013b4b80bed6ea8816a60fbb" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzNA_619a8025-11e3-4a7e-89b0-1da7551cbcd4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">PROPERTY AND EQUIPMENT</ix:nonnumeric></span></span></div><span><ix:continuation id="ib6f7c0a9013b4b80bed6ea8816a60fbb" continuedat="idf21fe5aa1d7413ca48b5e26c45f6df3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="fact-identifier-526" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzIzOQ_b7839ba6-6c80-42e0-9267-a05863c7580b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of property and equipment, net as of December&nbsp;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3ea343b4020f4cf29f1266e2dc6a6b09_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-527" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMS0xLTEtMjc3NDM_d38c3547-0fd2-460c-ad9c-bb5bc8e39491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">569</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib230fbf43aab492384091cb48ddd7af2_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-528" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzItMy0xLTEtMjc3NDM_6d0190e1-cb51-482a-8b86-e843f9a92638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">570</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iea35f777e5264bc1a11c1a5275407d2e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-529" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMS0xLTEtMjc3NDM_4e1e9ed3-2fc3-49db-ab5e-f0cb94a4e15b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5a9439e6445a46079edce40b074a4cb1_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-530" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzMtMy0xLTEtMjc3NDM_9f784e7c-7d02-476e-8827-c4b3ff47c3eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idf1ae7c86aed4911bffc0db6ed1d7ca4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-531" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMS0xLTEtMjc3NDM_45edb1a2-af3d-466a-ad3b-acf40931bcdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1c4126ae783347adb9e0ab895ddfa18d_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-532" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzQtMy0xLTEtMjc3NDM_0e5cd4ee-ceb2-457c-841e-ae1cf1e9f04a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">97</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic1e085c71b3d4eb89b00ee3fce28ada1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-533" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMS0xLTEtMjc3NDM_152a371b-8542-4709-bb3d-4d83840aaf68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2c1639a88a7f44d28ddedc2f01af5b1b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-534" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzUtMy0xLTEtMjc3NDM_dcdf47bc-bc7d-4dca-83bd-3b0ce1cf1f4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if671dcdd4df94af4a5b9fb93620a325b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-535" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMS0xLTEtMjc3NDM_7bce8263-5e17-47b4-856e-773d7a015a20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">293</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i76e5f96e4bd74651b225f0392286c025_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-536" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzYtMy0xLTEtMjc3NDM_85d444d3-bffb-4b2a-ad5a-2d14f2461d91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">293</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-537" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMS0xLTEtMjc3NDM_7096aa13-b14b-40a0-9a9c-0ec9f1cdd715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,009</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-538" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzctMy0xLTEtMjc3NDM_2d675c0c-e7c7-450e-98b9-11f1b82d3c13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,004</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="fact-identifier-539" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMS0xLTEtMjc3NDM_327c2412-3695-4076-a16d-114d6f4d0577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">966</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="fact-identifier-540" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzgtMy0xLTEtMjc3NDM_8aea25c9-573e-4b47-95d9-a2a767f14654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">881</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Property and Equipment, Net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-541" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMS0xLTEtMjc3NDM_b373cdf7-172f-4567-bb55-9193226973f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-542" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90YWJsZTo4NGM1NDllNGI1Mzk0NTJiOWY1NDg3MDllMzdkMzkzOS90YWJsZXJhbmdlOjg0YzU0OWU0YjUzOTQ1MmI5ZjU0ODcwOWUzN2QzOTM5XzktMy0xLTEtMjc3NDM_58929297-3264-4666-8bb3-320365a66ea8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="idf21fe5aa1d7413ca48b5e26c45f6df3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Depreciation expense was $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-544" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE2OA_fd25404f-9821-4e53-9fa0-e1156e8989a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-545" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3Mg_e3eeefc9-53b6-4f98-8ef6-01053cb26b32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-546" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDAvZnJhZzoxMzJjOTNkNDMxNTg0OGE4YmQ4NDkyYWE2OGQ2ODQ1OC90ZXh0cmVnaW9uOjEzMmM5M2Q0MzE1ODQ4YThiZDg0OTJhYTY4ZDY4NDU4XzE3OQ_8d9f53af-68c4-48f5-8f84-4f665fef2e1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="fact-identifier-547" continuedat="ibb9a0940960f44e39a70d06783fc393a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0Nw_331f5533-0791-4771-8328-730505aa14f2" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">INTANGIBLES AND GOODWILL</ix:nonnumeric></span></span></div><span><ix:continuation id="ibb9a0940960f44e39a70d06783fc393a" continuedat="id04c4c6753494a6bb7b8bf769d47fa54" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's consolidated balance sheet are the result of the Viventia Acquisition in September 2016. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="fact-identifier-549" continuedat="idaa75f9575d340f2ac5725373da7746e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzQ0OA_2d59a69d-481b-4611-8a8b-4ebd0ebdde01" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth the composition of intangible assets as of December&nbsp;31, 2021 and 2020 (in thousands):</ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><span><ix:continuation id="idaa75f9575d340f2ac5725373da7746e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum United States rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if52b03759bf044b3b5e17cf2a7c4a0b9_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-551" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMS0xLTEtMjc3NDM_ff93b3fa-ed06-4c3b-9893-ca4c85f3ab5f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic12322603449433985e3779be27b8eab_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-552" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzMtMy0xLTEtMjc3NDM_97b1ce3c-d910-411f-8408-05278e393029" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7d622315903d4829a4f582cfffed067f_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-553" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMS0xLTEtMjc3NDM_a76c8970-a2d2-49bf-8f29-672a073d2774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i425fb86623034e39aa2df73efd925f25_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-554" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzQtMy0xLTEtMjc3NDM_4cdd5a8a-5bf4-4b42-9056-16aa121823d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6fe412d00cd048258c144cd9ed556654_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-555" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMS0xLTEtMjc3NDM_541b5eba-3656-4a13-a394-ef4a7bacf19c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,700</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9f1e110f756945ed9233483c148b8a4a_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-556" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90YWJsZTo2Y2ViNDc2NWNiMTQ0YzM5OGNmMjQxYzI3YmM2YmFhMy90YWJsZXJhbmdlOjZjZWI0NzY1Y2IxNDRjMzk4Y2YyNDFjMjdiYzZiYWEzXzUtMy0xLTEtMjc3NDM_0fabd042-1889-4a1f-b6ec-32acac6642a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,400</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the US and EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="id04c4c6753494a6bb7b8bf769d47fa54" continuedat="i4e7ac8915f4d4555957ed35b5c1a717e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of NMIBC, the Company’s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company’s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company’s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $<span><ix:nonfraction unitref="usd" contextref="i65d83f49999a40659f8cb5c98716447b_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-558" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjA1NzQ_5f4fdc49-8a86-4d49-92e5-f3bb96e8f571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.7</ix:nonfraction></span>&nbsp;million of impairment charges as of September 30, 2021 are due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At this time, management has assessed that the carrying value of the Vicineum EU rights is not at significant risk of impairment in the future within the current range of commercialization timelines and POS assumptions. This is primarily due to the fact that the Company expects the Vicineum sales outside of the US to be two to three times the expected sales volume in the US, based on management’s reassessment of the total addressable global market for high-risk NMIBC during the quarter ended June 30, 2019, wherein management determined that both the global market size and the estimated potential Vicineum commercial sales within the global market were likely higher than the Company's previous estimate. In addition, the EU asset is burdened with significantly less expense than the US asset, as the Company’s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of December&nbsp;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="fact-identifier-559" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjMyOTc_4c16c954-3f23-4f74-9d3c-67ca22e61849" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t recognize any impairment charges during the year ended December&nbsp;31, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-560" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_05812bca-c78b-4387-adf4-82f58d499d88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-561" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzU0OTc1NTgxNzM0NDc_381b5dd2-ad7e-4641-8e1f-666ffad548de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.1</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million as of December&nbsp;31, 2021 and 2020. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company's withdrawal of its MAA, a quantitative impairment analysis was conducted during the third quarter of 2021, in advance of the Company's typical annual assessment date of October 1. While an impairment was recognized in one of its intangible assets, Vicineum US Rights, the Company concluded that the carrying value of its goodwill of $<span><ix:nonfraction unitref="usd" contextref="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-562" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU4OTc_ed5ddec5-e381-4248-acda-9db0502458b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.1</ix:nonfraction></span>&nbsp;million was not impaired as of September 30, 2021, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately <span><ix:nonfraction unitref="number" contextref="i02b5f8ea9c52413084c453c81936288b_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="fact-identifier-563" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MTY_c5b58db6-7d25-466d-b62a-6d606c3baa1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45</ix:nonfraction></span>%. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October and December 2021, we participated in a CMC Type A Meeting and a Clinical Type A Meeting, respectively, with the FDA to discuss issues raised in the CRL and to discuss design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. Following these Type A Meetings, we believe we have greater clarity of the requirements for potential resubmission of a BLA. We have a Type C Meeting scheduled with the FDA for March 28, 2022, in which we expect to discuss the study protocol for the additional Phase 3 clinical trial that we plan to conduct for potential resubmission of our a BLA for Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. The Company performed the annual impairment test, which incorporated the impact of the CRL and the subsequent Type A Meetings in the fourth quarter of 2021 and concluded that there was <span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-564" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEyMDk0NjI3OTQ3NjAw_46390fca-693f-4d5d-9a2a-3eca1f36867f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> goodwill impairment as of December&nbsp;31, 2021. The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management’s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from <span><ix:nonfraction unitref="number" contextref="ia43faec616e1467283e341842cd9d4ab_I20210930" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="fact-identifier-565" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MjU_28270a63-9b48-4906-80b8-ea028337fd73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="ibecee94376694fc393e30898f2ff86a2_I20211231" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="fact-identifier-566" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzEwOTk1MTE2NDU5MzQ_9939a189-5e56-43eb-b28c-517e1b71d7e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55</ix:nonfraction></span>% globally) also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG. </span></div></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i4e7ac8915f4d4555957ed35b5c1a717e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Based on the annual testing and quarterly reviews performed, the Company concluded that there was <span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-568" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDMvZnJhZzplYjZhZThmOGQ1ZmI0YTU1OTU0ODFiMGU0N2E5NWY1ZS90ZXh0cmVnaW9uOmViNmFlOGY4ZDVmYjRhNTU5NTQ4MWIwZTQ3YTk1ZjVlXzMyOTg1MzQ5MjUzMzk_1fa5dabd-517d-40c7-bd11-b8c8aa25b0af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> goodwill impairment during the year ended</ix:continuation></span> December&nbsp;31, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="if1c5a63ddb584a0db5ee835d7440b255_106"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="fact-identifier-569" continuedat="i89d6ae9216b84bd493fec8602df777a3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4NzU_4c3721cd-2cfc-47f8-af42-070f0de68cdb" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ACCRUED EXPENSES</ix:nonnumeric></span></span></div><span><ix:continuation id="i89d6ae9216b84bd493fec8602df777a3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="fact-identifier-571" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90ZXh0cmVnaW9uOjllOWQwY2ZkMDA0NTQ5Nzc5YzRhMmU0YzZjMjUyYTVkXzE4Nzk_b74a5883-6db9-4dba-a086-10343357f204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of December&nbsp;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-572" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMS0xLTEtMjc3NDM_d45200ca-7885-47cd-b382-a7f966f60619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,841</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-573" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzItMy0xLTEtMjc3NDM_35f8c81a-35c0-4141-afc5-fca174e67f5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,372</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-574" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMS0xLTEtMjc3NDM_0cfbbcec-0563-480a-99e3-94e6b96bb09c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,967</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-575" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzMtMy0xLTEtMjc3NDM_ef40fd3d-1a61-4342-a92c-2808829bf2b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,892</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-576" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMS0xLTEtMjc3NDM_72116434-bf65-4e4e-b910-a4ee29309b76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,497</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-577" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzQtMy0xLTEtMjc3NDM_282a8404-3832-4cff-b613-2239630476bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-578" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMS0xLTEtMjc3NDM_bfa3018a-124c-4e11-8cae-005e6da9e6a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,941</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-579" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzUtMy0xLTEtMjc3NDM_97de0620-58a1-456a-9baa-42e25063a572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">684</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-580" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMS0xLTEtMjc3NDM_cd0d71dc-5969-49da-bb1c-582f8b807c37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-581" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzYtMy0xLTEtMjc3NDM_bbcbaa63-f88e-45f7-a3f9-222f84a64979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-582" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMS0xLTEtMjc3NDM_5eb5bb18-dd0f-4c89-bbcb-45b455a756cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,255</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-583" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDYvZnJhZzo5ZTlkMGNmZDAwNDU0OTc3OWM0YTJlNGM2YzI1MmE1ZC90YWJsZTpiMmFhZjVkZjY1ODA0NWEwOTNlOWJiZDdjNTM1OTI4NS90YWJsZXJhbmdlOmIyYWFmNWRmNjU4MDQ1YTA5M2U5YmJkN2M1MzU5Mjg1XzctMy0xLTEtMjc3NDM_13c611f4-4ce3-4ac8-9ba3-7c941988ef31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,973</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="fact-identifier-584" continuedat="if654d9468c214f5597c04394e0f68927" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzI4ODE_93963bda-ea0b-4424-9f90-aa9058e78405" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">COMMITMENTS AND CONTINGENCIES</ix:nonnumeric></span></span></div><span><ix:continuation id="if654d9468c214f5597c04394e0f68927" continuedat="iab24b3a355f94386b82971e65c6a7852" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company’s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-586" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMwOTU_c9f406a9-d055-4d0c-993b-b8236785b4b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-587" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMDU_5423c41e-43ba-467c-a834-ed54ece6c1fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> complaints allege violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-588" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMTU_d62740a2-625a-4d0c-8e11-4a1febf90081" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> complaints seek compensatory damages and costs and expenses, including attorneys’ fees. On October 29, 2021, the court consolidated the <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-589" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMjU_aedc41f6-d2c9-4140-98fd-2404ca1c9715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the “Securities Litigation”), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (“Lead Plaintiffs”) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the “Amended Complaint”). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. Defendants’ response to the Amended Complaint is due to be filed on March 7, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D’Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company’s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company’s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant, but no defendant has yet been served. The <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-590" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxMzU_600a355b-9668-4de0-83f8-5b8dcf67dee9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D’Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The <span><ix:nonfraction unitref="lawsuit" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-591" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMDkvZnJhZzpiMmNmNzE3NmYyN2M0ZGI2ODZkZWNhNmNlNmU4ODdjMy90ZXh0cmVnaW9uOmIyY2Y3MTc2ZjI3YzRkYjY4NmRlY2E2Y2U2ZTg4N2MzXzU0OTc1NTgxODMxNDU_f51f3929-deb3-42a0-8ffc-b07e4088c3ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys’ fees. On October 18, 2021, the court consolidated the two federal cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the “Federal Derivative Litigation”). On December 22, 2021, the court entered a joint stipulation among the parties </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="iab24b3a355f94386b82971e65c6a7852" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. Defendants intend to seek a similar stay of the state court derivative litigation in the event any defendant is served.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements and offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_1172"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="fact-identifier-593" continuedat="i39521ac584644431883e162113c537f6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5Nw_739ee0de-025c-4509-8863-f8dcbf43ee4d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">LEASES</ix:nonnumeric></span></span></div><span><ix:continuation id="i39521ac584644431883e162113c537f6" continuedat="i387da479d1d140c28b40eee483f42dc1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <span><ix:nonfraction unitref="sqft" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-595" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMg_3d0c34f2-8718-424f-a29a-aeb6fee4d29e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">31,100</ix:nonfraction></span> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <span><ix:nonnumeric contextref="i81e534a3b6984e9ca7a46fb4761feeec_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="fact-identifier-596" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEyOQ_cb823a0e-f701-4256-83e5-0897114fb834" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span>, through September 2022, with a right to extend the lease for <span><ix:nonfraction unitref="term" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="INF" name="sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-597" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzExNw_899d3252-1e39-48b3-8ddb-a4602c2b622b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> subsequent <span><ix:nonnumeric contextref="i81e534a3b6984e9ca7a46fb4761feeec_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="fact-identifier-598" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzE1OA_09622a00-c0c3-412a-bac3-e9de27b48058" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three-year</ix:nonnumeric></span> term. The minimum monthly rent under this lease is CAD $<span><ix:nonfraction unitref="cad" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-599" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njc4_c6f560ef-c85e-4904-9f3b-e11779fbd40b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18,100</ix:nonfraction></span> (approximately $<span><ix:nonfraction unitref="usd" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-600" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4Njg4_aa46e359-c968-499e-81eb-3b711b3abe54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14,300</ix:nonfraction></span> at exchange rates in effect on December&nbsp;31, 2021). In addition to rent expense, the Company expects to incur CAD $<span><ix:nonfraction unitref="cad" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-601" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzQ1_e575234f-9c43-4b38-b42d-3288b583ee5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18,200</ix:nonfraction></span> per month related to operating expenses (approximately $<span><ix:nonfraction unitref="usd" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-602" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjM4NzU1_28d4dbf5-6e86-4632-9135-843647f906e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14,300</ix:nonfraction></span> at exchange rates in effect on December&nbsp;31, 2021). Operating lease cost under this lease, including the related operating costs, were $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-603" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTA4_9db33a23-ae24-4e2d-bee8-76a98f5d683a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-604" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTQw_43cffc2c-b41f-4758-91bf-0656fc66709a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span>&nbsp;million for the year ended December&nbsp;31, 2021 and $<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-605" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NTcw_26ba0f83-b0a7-4b6c-b97e-a26ead905a3c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-606" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NjAx_eecbb385-2fe8-4a56-9b8d-6e23f72087f6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span>&nbsp;million for the year ended December&nbsp;31, 2020, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company’s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27"><span><ix:nonnumeric contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="fact-identifier-607" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_24cd649b-2112-449b-ab1a-3a647520cb27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUx_eb85556e-c4f8-44b4-b3cc-92e356c13f8a">other assets</span></ix:nonnumeric></span></span> on the Company's consolidated balance sheets. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951"><span><ix:nonnumeric contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="fact-identifier-608" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_022d7593-eb4f-42ef-b175-aeb57fb94951" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUy_6f552a84-71dc-4d6e-a045-5249ed246d77">other current liabilities</span></ix:nonnumeric></span></span> and the long-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469"><span><ix:nonnumeric contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="fact-identifier-609" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_d63a6871-1e6b-4e7b-8089-9d4335f88469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDUz_fca36aa3-a34e-4dea-8f95-2d56ff9daba1">other liabilities</span></ix:nonnumeric></span></span> on the Company’s consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every <span><ix:nonnumeric contextref="ie35eeadb1df94fb4940973f807cc6e7d_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="fact-identifier-610" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDI3_b34c1b8f-e463-41bb-acc7-cc69d065f1b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three months</ix:nonnumeric></span> to <span><ix:nonnumeric contextref="i2d207bdc8bb44456958770de74b1eabe_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="fact-identifier-611" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF81NDk3NTU4MTY0NDQ2_78e53d5f-8b75-4260-a03e-6e8aff1a9df6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">six months</ix:nonnumeric></span> and currently extend through June 2022 and May 2022, respectively. The minimum monthly rent for these office spaces is $<span><ix:nonfraction unitref="usd" contextref="i68866b76b55f41f7a5558f5272486883_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-612" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDM1_598bd5ee-84ff-4caf-9302-45b7cd7dd6bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,100</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i4b8cf18e833d4913a7dc5dbc354f10c4_D20210101-20211231" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-613" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMDk5NTExNjQwNDQ1_3f982f27-33f3-4538-abc4-60ed4e1be2d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18,400</ix:nonfraction></span>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="fact-identifier-614" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzA5OA_ce2ea70f-aa89-4114-903f-eeab7a46f202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December&nbsp;31, 2021 and 2020 is as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lease Cost:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease (including related operating costs)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-615" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTEtMS0xLTM5NjIy_8824d3d7-fa7f-4d83-a647-dd1b0a431a99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">327</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-616" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8yLTMtMS0xLTQxMTc2_2cf518c9-969d-4f6d-a8e0-10cdcd34172d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term property leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-617" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTEtMS0xLTM5NjI1_bc303976-ba11-4fbb-9ad7-b252dad70350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">262</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-618" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF8zLTMtMS0xLTQxMTc5_2d132eaf-013d-470f-b5c1-d5177eec60f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">261</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="fact-identifier-619" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTEtMS0xLTQ5NDI3_0d9e6910-e320-43cb-a4cb-1c3c9afbc963" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">589</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="fact-identifier-620" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6N2MzZDI0MWQ1MmQ4NDM2NDliZWE0YjYxZGQzZGM2NTAvdGFibGVyYW5nZTo3YzNkMjQxZDUyZDg0MzY0OWJlYTRiNjFkZDNkYzY1MF80LTMtMS0xLTQ5NDI3_ccb1d5e5-6278-44d3-836c-baf2fa92c7cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">562</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Supplemental Information:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-621" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTEtMS0xLTQ5NDMx_bc7e97f8-46dc-419d-93a2-8cc4ab35d7d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-622" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8xLTMtMS0xLTQ5NDMx_9c601c97-0d68-4107-a688-d2530dfdee08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.75</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-623" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTEtMS0xLTQ5NDMx_2e06c13a-7a45-4e26-9ece-30126280c8cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-624" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6OTZlM2Y4N2ZkMjI0NDkyMWJiNjI0YTQxY2I0MTJmNzgvdGFibGVyYW5nZTo5NmUzZjg3ZmQyMjQ0OTIxYmI2MjRhNDFjYjQxMmY3OF8yLTMtMS0xLTQ5NDMx_8784130f-3af4-4a7b-831d-bcf7eaabfcc6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="fact-identifier-625" continuedat="ib5d243719d74443d874bb2e304e871ce" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGV4dHJlZ2lvbjpjNzljM2Y0NmY4OWE0ZWRiYjIxZGQyYTBkODRiMjIwZF8xMTU0NDg3MjExNzEwMA_2450b5dd-6506-4634-a7ee-729d50b3647f" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth the Company's future minimum lease payments under non-cancelable leases as of December&nbsp;31, 2021 (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><span><ix:continuation id="i387da479d1d140c28b40eee483f42dc1" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="ib5d243719d74443d874bb2e304e871ce" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Minimum Lease Payments:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments (2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="fact-identifier-628" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8xLTEtMS0xLTQxMTg1_788b2a2b-e87e-44ee-993a-dd88f54dea5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="fact-identifier-629" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8yLTEtMS0xLTQxMTg1_beb9503d-02b4-4807-b2ae-15da2a7babb1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="fact-identifier-630" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTcyL2ZyYWc6Yzc5YzNmNDZmODlhNGVkYmIyMWRkMmEwZDg0YjIyMGQvdGFibGU6ZDUzNDYxNTQwNDMwNDNlZWIxOTExYTY0MWYxNjMwZDEvdGFibGVyYW5nZTpkNTM0NjE1NDA0MzA0M2VlYjE5MTFhNjQxZjE2MzBkMV8zLTEtMS0xLTQ5NDQ5_b62254f8-67af-4c3d-9bbb-305464b98609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">124</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></ix:continuation></span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_112"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="fact-identifier-631" continuedat="i64847604ff5346e1b47b3fe12be3e462" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM2_7e44bc56-57b4-42d2-86f1-a337909e9aac" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">STOCKHOLDERS' EQUITY DEFICIT</ix:nonnumeric></span></span></div><span><ix:continuation id="i64847604ff5346e1b47b3fe12be3e462" continuedat="i02fee32c97b046bf934f367942177039" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the "Sale Agreement") with Jefferies LLC ("Jefferies"), under which the Company may issue and sell shares of its common stock, par value $<span><ix:nonfraction unitref="usdPerShare" contextref="i16b4c01413da485fa2ac23775d55bed5_I20191130" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-633" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQyOTI_57301754-2b30-4d01-b6ed-62dd5a406a73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share, from time to time (the “ATM Offering”) for an aggregate sales price of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<span><ix:nonfraction unitref="usd" contextref="i65be1969c492411ba4743fe748508e67_D20191101-20191130" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-634" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzMTI_e9cb6198-f620-45ab-9d93-917297cfdc51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">35</ix:nonfraction></span>&nbsp;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through Jefferies. In October 2020 and February 2021, the Company entered into Amendments No. 1 and No. 2 to the Sale Agreement, respectively. Amendments No. 1 and No. 2 modified the Sale Agreement to reflect that the Company may issue and sell shares of its common stock from time to time for an aggregate sales price of up to an additional $<span><ix:nonfraction unitref="usd" contextref="id6ed6ecc802f45c586c3b6cfff6e28d2_D20201001-20201031" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-635" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNjY_273b1909-596b-48d8-9a9d-c882db3ef274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="ibfb861283e22418081b9e629463e783d_D20210201-20210228" decimals="-5" name="sesn:SaleOfStockAdditionalSharesAuthorizedForSale" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-636" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzNTE_f5aeefa2-82d4-474b-9a7d-c30a2653276b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">34.5</ix:nonfraction></span>&nbsp;million, respectively. In June 2021, the Company entered into Amendment No. 3 to the Sale Agreement, which modified the Sale Agreement to remove the maximum dollar amount of shares of common stock that may be sold pursuant to the Sale Agreement. In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<span><ix:nonfraction unitref="usd" contextref="i072f60a137e94674991638220c6ed9ec_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-637" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQzOTI_75402b7e-436c-4934-9eed-ffd609b7b236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200</ix:nonfraction></span>&nbsp;million of common stock pursuant to the Sale Agreement. Sales are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company’s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <span><ix:nonfraction unitref="number" contextref="i65be1969c492411ba4743fe748508e67_D20191101-20191130" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="fact-identifier-638" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NDQ0MTE_66932d0b-718e-4ec3-b309-11e928859972" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company raised $<span><ix:nonfraction unitref="usd" contextref="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-639" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNDc_8137ddee-77f1-42ac-996d-f00b12343ee7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">175.0</ix:nonfraction></span> million of net proceeds from the sale of <span><ix:nonfraction unitref="shares" contextref="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-640" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNTQ_46f34930-4686-4dee-9b79-f3148bf217ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56.9</ix:nonfraction></span> million shares of common stock at a weighted-average price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="fact-identifier-641" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjA_758e79af-be69-4ab8-aef3-d137b82ac7a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.17</ix:nonfraction></span> per share during the year ended December&nbsp;31, 2021, compared to</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-642" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNjU_44ca959c-0202-4115-98e3-0a5ab800f8ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38.0</ix:nonfraction></span> million of net proceeds from the sale of <span><ix:nonfraction unitref="shares" contextref="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-643" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzA_9d3a0855-a37c-4515-9db3-9708acf1df9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33.4</ix:nonfraction></span> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock at a weighted-average price of</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="fact-identifier-644" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzNzU_7c46c6b3-c8f2-4049-9d0f-ea79253773f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.17</ix:nonfraction></span></span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share during the year ended December&nbsp;31, 2020. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled $<span><ix:nonfraction unitref="usd" contextref="i8da3dc1428c245a8bbee31a81e0e0f63_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-645" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTAzODQ_e4a6a0fa-d67c-4fb1-ba49-20196ba8fe5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.4</ix:nonfraction></span> million and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="ia477efe150e845c9a6ac4fa801048491_D20200101-20201231" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-646" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NjI3OTA_9e68453e-1c08-4d70-85b0-1f80db0d52b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.2</ix:nonfraction></span> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the year ended December&nbsp;31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2019 Financing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company raised $<span><ix:nonfraction unitref="usd" contextref="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-647" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyNTE_73e0daed-83fa-4f34-a7b5-f8527330ea41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.8</ix:nonfraction></span> million of net proceeds from the sale of <span><ix:nonfraction unitref="shares" contextref="ic5968409f67d42aaab4bd37d24b402cf_D20190601-20190630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-648" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIyODc_383644e1-4dde-40e1-a2e0-a9cd2399dc77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.4</ix:nonfraction></span> million shares of common stock and accompanying warrants to purchase an additional <span><ix:nonfraction unitref="shares" contextref="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="-5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-649" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzIzNjU_e1b356d5-2ce9-4d27-984f-cb39cc10b653" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.4</ix:nonfraction></span> million shares of common stock in an underwritten public offering (the "June 2019 Financing"). The combined purchase price for each share of common stock and accompanying warrant was $<span><ix:nonfraction unitref="usdPerShare" contextref="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="2" name="sesn:CommonStockAndWarrantOrRightsPricePerShare" scale="0" id="fact-identifier-650" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI1NDM_072bed4a-7755-4739-a7ae-71b8bb87cb61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.47</ix:nonfraction></span>. Subject to certain ownership limitations, the warrants issued in the June 2019 Financing were exercisable immediately upon issuance at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-651" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzI3MDM_64052909-36f1-4f63-87de-7552b8da026f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.47</ix:nonfraction></span> per share, subject to adjustments as provided under the terms of such warrants, and had a <span><ix:nonnumeric contextref="ifd395e5e95f84b618c6884bc4356ae1a_I20190630" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="fact-identifier-652" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTM3_94791cac-cb12-4618-a9f3-14ff128dfbdb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one-year</ix:nonnumeric></span> term that expired on June 21, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-653" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5MjA_bb83ea6d-02b2-4b9e-af48-f50576274e8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million shares of "blank check" preferred stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-654" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzM5NjQ_81cfc0f3-616e-4f9c-ad11-95239a1aa7ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-655" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_3ca3ebd3-ceb3-4889-9eaf-9abc99c50214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-656" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_a6fac8ff-e9aa-4eb3-9005-f84aa39202c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-657" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_d2dedf03-e918-4c25-883e-d5fc0ebacf4e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-658" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQ0MDg_ea01a3c4-a76d-4098-a784-c8b743d25bfe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> preferred stock issued and outstanding as of December&nbsp;31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company’s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-659" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NDU_1e7dd183-5f40-4b42-9bef-bb5f5e95df67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200</ix:nonfraction></span>&nbsp;million to <span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-660" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTk1MTE2NTA0NTg_c348de83-c14b-49bd-9c2d-cf888e978f23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400</ix:nonfraction></span>&nbsp;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-661" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_6ebfddf1-ebe8-4834-a0d7-2f87dc8dafbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-662" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxMzg_db6a0c66-ced2-4ce5-bc01-7eeb19fd5fa6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-663" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_4ee5e4f9-967d-4976-9eb1-20191f57d79c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-664" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQxNTk_e39cf994-80dc-4e30-b9eb-865d78a3fb90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of December&nbsp;31, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="fact-identifier-665" continuedat="ia4722139eff04e0e9245e60e56e4d057" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQx_e2d3a93c-58e5-45b5-9c7a-15385f9d3f74" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of December&nbsp;31, 2021 and 2020 (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i02fee32c97b046bf934f367942177039" continuedat="i1d313d2300ce41b6a98f9d81b1bff38f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><span><ix:continuation id="ia4722139eff04e0e9245e60e56e4d057" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tbody><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-668" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMS0xLTEtMjc3NDM_910551ff-0edd-4ace-b6e8-8ce8933428fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199,464</ix:nonfraction></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-669" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzItMy0xLTEtMjc3NDM_a27d7ee9-291a-4add-9b4a-3af4f3b3d8b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,450</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="icf0d8f6abc7e49829c395d208a3436f2_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="fact-identifier-670" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMS0xLTEtMjc3NDM_6c3143f6-0678-466e-8f1f-018d1cbdb64a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id916d4f7441d4a088be2fca47e276005_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-671" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzQtMy0xLTEtMjc3NDM_374d992d-1ae3-4701-a457-1fc525ae1f9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,247</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-672" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-673" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,703</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-674" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzUtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,147</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-675" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_56772896-3e55-466f-b924-dedd6bd06979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-676" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtNTM0MzA_d80264ab-c6f1-432d-8ba1-4fc5db1e7474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i75020eb264af4e39a21665962a79801e_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="fact-identifier-677" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtNTM0MzA_4b97d569-fe12-470c-9bc5-50f38d8dcaed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4f92707265b84c70ae5a42f1daae1378_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-678" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMS0xLTEtMjc3NDM_30dfc1b1-9752-400b-ba96-9417a25ea788" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,933</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i40e1aa3b61664f47b00658c43dfd99fb_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-679" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzYtMy0xLTEtMjc3NDM_63bf073f-26a3-4fb6-b85e-2f8b79cf9394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,863</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7858b2eb979a432a96faff9ead49ee39_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-680" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMS0xLTEtMjc3NDM_fe758fc7-3233-4288-b148-df3ce01d4ba6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i44d44dfab69545dabde220a346b37456_I20201231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="3" id="fact-identifier-681" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzctMy0xLTEtMjc3NDM_d41b0414-1081-4ec8-9edd-143eca070f7c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-682" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMS0xLTEtMjc3NDM_927d8cf2-97b0-4647-8862-d301aa2224f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">229,640</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-683" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTpkMzc3NWFjNjYwNTQ0ZDJmYjlhYTA5ZjU1YmIyNzU2Yi90YWJsZXJhbmdlOmQzNzc1YWM2NjA1NDRkMmZiOWFhMDlmNTViYjI3NTZiXzgtMy0xLTEtMjc3NDM_71869167-bb97-4d4c-948c-bcbbe5af8626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">157,707</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <span><ix:nonfraction unitref="vote" contextref="i7d680ddb634f4fa1a161f8bb6be7754d_D20210101-20211231" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-684" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzUxMDY_53e774c3-db66-417c-8e3c-847bd3c59c7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company’s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging - Contracts in Entity’s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASC 815-40")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="fact-identifier-685" continuedat="ib1b366df086a4b2794c0b74538a33289" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExNTQy_5bd98541-2eb0-486b-9ba3-3f44582bc53c" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth the Company's warrant activity for the year ended December&nbsp;31, 2021 (in thousands):</ix:nonnumeric></span></span></div><span><ix:continuation id="ib1b366df086a4b2794c0b74538a33289" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i877528c6538245119864f9c0c2e52211_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-687" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMi0xLTEtMjc3NDM_aefb2aaa-9afa-42eb-b301-dc5786cdc184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.47</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i466f369ef0774c33bd619700d8de5551_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="3" id="fact-identifier-688" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtNi0xLTEtMjc3NDM_c2999a41-537e-4805-81fc-374ed4f6e7f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-689" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtOC0xLTEtMjc3NDM_317e127c-1712-4008-874b-5ad1a479fc8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-690" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTAtMS0xLTI3NzQz_359b4cf0-c66f-405e-909e-8e9036ae6c11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iedd6b32bc59a43fca0efd324d52bc24f_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-691" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTItMS0xLTI3NzQz_0e037dab-8c41-419e-a33a-cfe8ecf604bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i877528c6538245119864f9c0c2e52211_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="3" id="fact-identifier-692" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzEtMTQtMS0xLTI3NzQz_5fdbf0cd-5273-4243-8008-03069bb9d96a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="fact-identifier-693" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMi0xLTEtMjc3NDM_d53a4938-9c9e-403f-a842-84e559cfc33e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.55</ix:nonfraction></span>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i31cacad06c024286911346564a7662f0_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-694" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItNi0xLTEtMjc3NDM_1a79f56f-c083-43f2-972e-934ced65baca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,705</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-695" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItOC0xLTEtMjc3NDM_fba4d9fa-40de-4e61-a017-9c18cdf1089a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-696" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTAtMS0xLTI3NzQz_078aeb3f-caf2-4bbc-82bc-128015051945" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,573</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-697" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTItMS0xLTI3NzQz_949ebfa7-ed1d-4574-a367-31a573148621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3f1ca4ba5f564a0e98ed8b849570c5b6_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-698" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzItMTQtMS0xLTI3NzQz_9483ef98-0beb-4fb0-ba39-ff73c27316f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="fact-identifier-699" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMi0xLTEtMjc3NDM_43411bfd-62c6-47b1-a430-0ce1cc7da529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.55</ix:nonfraction></span>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i6ae2e392a7c740b1988ab6b7b8b786d1_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-700" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtNi0xLTEtMjc3NDM_e4aab035-3916-446f-aa83-5ab38e2c4ee9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">487</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-701" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtOC0xLTEtMjc3NDM_bc321b98-1943-4767-b1df-1c6b2c1b0af4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="3" id="fact-identifier-702" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTAtMS0xLTI3NzQz_9139048e-0de8-49a5-bc08-442ffff09749" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">475</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-703" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTItMS0xLTI3NzQz_ec630fe7-d845-4311-a56b-a7be93357b82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia04bc4d9fb344cbdbb56eb72c1cfa632_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-704" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzMtMTQtMS0xLTI3NzQz_4c5f1b17-e021-43ae-a126-6b6c14faab54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ie688301f8b994be195f31b42f85842e5_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-705" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMi0xLTEtMjc3NDM_faed7136-7dd6-438a-b55d-f4871ced7bba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.83</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9d5371af6c3e495888104af773d10b15_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-706" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtNi0xLTEtMjc3NDM_aebae70f-e477-4dc5-9a36-c208f713fa28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-707" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtOC0xLTEtMjc3NDM_2f4b494e-7430-4bc5-a592-685b5ab9f4e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-708" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTAtMS0xLTI3NzQz_077aed76-0531-4c0b-b787-7e2372788cc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i71b1a8e363e244b6a73e67406e097122_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-709" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTItMS0xLTI3NzQz_7d1b3434-84ff-4c81-8d81-a833b92ab512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ie688301f8b994be195f31b42f85842e5_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-710" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzQtMTQtMS0xLTI3NzQz_3b65d639-74dc-4aef-ad3d-8177afff248b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i174b4bb16b14432aaeeb74b47fc49556_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-711" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMi0xLTEtMjc3NDM_021065e4-676a-4d69-8777-d926571b80dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.04</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7e67736b7d564e33bad48ed099f8786c_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-712" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtNi0xLTEtMjc3NDM_72775c32-c429-4fe7-bfd5-a37b423c2ebe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-713" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtOC0xLTEtMjc3NDM_bbd7cdb4-e8e3-43b3-8033-63bb38cdbffd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-714" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTAtMS0xLTI3NzQz_0aa9c38f-ae9a-4985-9733-20740c83598c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic128bae021684a57b2549146b666bae9_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-715" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTItMS0xLTI3NzQz_b6b0caa1-8e61-4c95-9554-d8e1661a199c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i174b4bb16b14432aaeeb74b47fc49556_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-716" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzUtMTQtMS0xLTI3NzQz_6dcede5a-f057-4588-9206-644832f44964" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-717" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtNi0xLTEtMjc3NDM_86590912-d088-4a89-b44c-8a7ce404965c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,247</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-718" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtOC0xLTEtMjc3NDM_afca3ae4-daa8-48ef-92fa-a7f5f459edcd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-719" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTAtMS0xLTI3NzQz_acc08e48-28a1-4719-a791-adfe42b15595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,048</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="fact-identifier-720" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTItMS0xLTI3NzQz_e64bb57d-0d63-4331-a57b-411f1e5aa5a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="fact-identifier-721" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90YWJsZTo0OTY3ZmY0NjI4YjE0Y2IwOTJlNzIzZmI1MTUxYTBmMy90YWJsZXJhbmdlOjQ5NjdmZjQ2MjhiMTRjYjA5MmU3MjNmYjUxNTFhMGYzXzYtMTQtMS0xLTI3NzQz_f0653ebc-5258-46c7-bd0c-b41ce413b32f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:6pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification described below and (ii) subject to further adjustment based on down round provision added by amendment described below.</span></div></ix:continuation></span><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&nbsp;31, 2021, the Company received proceeds of $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-722" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzY4ODI_b2538625-e132-41df-b3ff-6e0696e87191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span> million from the exercises of <span><ix:nonfraction unitref="shares" contextref="id8512f475d73400cabc282795a6d7b65_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-723" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODQ4_5c41e71d-53c9-4a9e-9cb4-ba4980643690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.6</ix:nonfraction></span> million 2018 Warrants and <span><ix:nonfraction unitref="shares" contextref="i9d6f7dc3e40241ae80526287991a41e8_D20210101-20211231" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-724" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzE3MDQyNDMwMjg1ODY2_32a13328-c767-440f-8b94-7d7a6f124ba6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span> million 2017 Warrants.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Modifications</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with holders of its outstanding 2018 Warrants and 2017 Warrants to purchase the Company's common stock. At such time, the 2018 Warrants and 2017 Warrants utilized the same form of warrant, which contained a prohibition on variable rate transactions (as defined therein). Warrant holders agreed to waive such </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i1d313d2300ce41b6a98f9d81b1bff38f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prohibition in exchange for certain concessions from the Company. Management evaluated the warrants after modifications and determined that they continued to be equity-classified under the derivative scope exception of ASC 815-40. The warrants were revalued immediately before and immediately after the modifications to calculate the $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-726" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzc2ODI_a0c53eb4-adfe-4204-a6ca-b08e86aa9328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span> million incremental value of the modified warrants. The Company considers this incremental value to be akin to an offering cost since the modifications were directly related to enabling the ATM Offering and would not have otherwise been incurred. Therefore, in the fourth quarter of 2019, management initially capitalized the $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-727" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzgwMDM_1d5c3655-8171-4437-8dda-543569741cf1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span> million to deferred financing cost asset, with an offsetting credit to additional paid-in capital, and then reclassified the deferred financing cost asset to reduce the ATM Offering proceeds within equity as proceeds were received from sales of common stock under the ATM Offering. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Warrants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2018 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2018 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2018 Warrant Amendment Agreements"). As consideration for those holders executing the 2018 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<span><ix:nonfraction unitref="usdPerShare" contextref="id470afa5cc9848b2a4b4f535d4b6c1f0_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-728" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4MTI_1cc293e3-8973-4028-abc7-de95552be397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.20</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i4ec6e4d46e284f0594c5222b5698833c_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-729" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODA_ffa3ef42-1aa7-4fa3-a8c4-da265355ee9f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.60</ix:nonfraction></span> per share of the Company's common stock, resulting in proceeds of $<span><ix:nonfraction unitref="usd" contextref="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-730" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg4ODc_72ddfcca-3acf-4e2a-8bfc-2b08fe51aac4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.0</ix:nonfraction></span> million from the exercise of <span><ix:nonfraction unitref="shares" contextref="i1ee5396d2d524f2d86a5b3a2cfac0875_D20191001-20191031" decimals="-5" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-731" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5Xzg5MTE_2d2b27ac-860a-4ff6-b756-555d199675da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.4</ix:nonfraction></span> million warrants. Pursuant to the 2018 Warrant Amendment Agreements, the prohibition on certain variable rate transactions included in the 2018 Warrants was amended to exclude ATM offerings and the exercise price of the warrants was reduced from $<span><ix:nonfraction unitref="usdPerShare" contextref="i1f9a990e22cc41d8af941ad8a743ae8d_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-732" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNTI_1291e85c-1290-4c08-9f0f-80e65f007714" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.20</ix:nonfraction></span> to the lesser of (a) $<span><ix:nonfraction unitref="usdPerShare" contextref="icc016955920f4e64b8ed1852c953e88a_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-733" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzkxNzY_0f0aa094-14f6-4dd7-8759-3a82218dbc7e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.95</ix:nonfraction></span> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2018 Warrant Amendment Agreements. During the second quarter of 2020, the anti-dilution provision was triggered to lower the exercise price of the warrants to $<span><ix:nonfraction unitref="usdPerShare" contextref="iae3ad21e639847039d2f1b31b55bc122_I20200630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-734" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzQzOTgwNDY1NjY1ODg_31e1df23-6a93-4a34-b93a-f7b1748dd031" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.55</ix:nonfraction></span>; as such, the Company recognized a deemed dividend of approximately $<span><ix:nonfraction unitref="usd" contextref="i0db3ec5f4dbd471f8ba45bdc77ad6b70_D20200101-20200630" decimals="-5" name="sesn:OtherDividendAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-735" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzU0OTc1NTgxOTQyNTg_9a954fc7-9d2f-401c-94ff-40b2929f859f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>&nbsp;million which reduced the income available to common stockholders. As the Company has an accumulated deficit balance, there is no overall impact to additional paid-in capital, as the deemed dividend is recorded as offsetting debit and credit entries to additional paid-in capital. Therefore, the amounts were not presented on the Statement of Stockholders' (Deficit) Equity. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2018 Warrant Exercise Agreements and 2018 Warrant Amendment Agreements, the Company entered into an amendment to the Securities Purchase Agreement dated March 21, 2018 related to the March 2018 Financing, by and among the Company and each purchaser identified on the signature pages thereto, with certain holders representing greater than <span><ix:nonfraction unitref="number" contextref="i1dda2c9095f1418e975214cb9c010492_D20191001-20191031" decimals="3" name="sesn:ClassofWarrantorRightMinimumPercentageofSecuritiesIssued" scale="-2" id="fact-identifier-736" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwMjM1_b799e79d-f1b9-4df3-b4c4-87f31d62e20f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.1</ix:nonfraction></span>% of the securities issued based on initial subscription amounts, pursuant to which the prohibition on variable rate transactions, including ATM offerings, was deleted in its entirety.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into transactions with the holders of its outstanding 2017 Warrants pursuant to which such holders either (i) exercised their warrants pursuant to a Warrant Exercise Agreement (the "2017 Warrant Exercise Agreements") or (ii) amended their warrants pursuant to a Warrant Amendment Agreement (the "2017 Warrant Amendment Agreements"). As consideration for those holders executing the 2017 Warrant Exercise Agreements, the Company reduced the exercise price of the warrants from $<span><ix:nonfraction unitref="usdPerShare" contextref="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-737" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTUy_ad7ff1da-ba2d-46c5-8ee6-4bf9607c3cf0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.80</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-738" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzEwOTU4_2793cb63-ab65-4ca2-b28f-b778369ea774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.55</ix:nonfraction></span> per share of the Company's common stock. Pursuant to the 2017 Warrant Amendment Agreements, the prohibition on certain variable rate transactions, including ATM offerings, included in the 2017 Warrants was deleted in its entirety and the exercise price of the warrants was reduced from $<span><ix:nonfraction unitref="usdPerShare" contextref="idbac2d7aba3c4de4b6d4a6dc65959c22_I20190930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-739" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjQ3_9073db12-96ee-4d9e-a540-ac65ed7cb195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.80</ix:nonfraction></span> to the lesser of (a) $<span><ix:nonfraction unitref="usdPerShare" contextref="i0f7f6ecb0494491d88fad487ab7a97f5_I20191031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-740" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTIvZnJhZzo3NDBlNWY4NTQ3NWY0MGY0YjBmZjhiYmY0Yzg2ZjI2OS90ZXh0cmVnaW9uOjc0MGU1Zjg1NDc1ZjQwZjRiMGZmOGJiZjRjODZmMjY5XzExMjcx_6f8cc366-09b6-4939-8583-570c45bef617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.55</ix:nonfraction></span> per share of common stock and (b) the exercise price as determined from time to time pursuant to the anti-dilution provisions in the 2017 Warrant Amendment Agreements. As of December 31, 2021, there has been no adjustment to the exercise price of these warrants.</span></div></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_115"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="fact-identifier-741" continuedat="i7b551d63c02d438fabcadf0aad1ace39" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTI_0de47367-445f-4cf0-b1cc-3fd8c4b9543b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">EARNINGS (LOSS) PER SHARE</ix:nonnumeric></span></span></div><span><ix:continuation id="i7b551d63c02d438fabcadf0aad1ace39" continuedat="ic65ea764bd7b4097b98b96e9e43d299d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company’s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, an entity that presents earnings per share shall recognize the value of the effect of an anti-dilution provision in an equity-classified freestanding financial instrument in the period the anti-dilution provision is triggered. That effect shall be treated as a deemed dividend and as a reduction of income available to common stockholders in basic earnings per share. The </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ic65ea764bd7b4097b98b96e9e43d299d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deemed dividend is added back to income available to common stockholders when applying the treasury stock method for diluted earnings per share.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods with net income, diluted net earnings per share is calculated by either (i) adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period as determined using the treasury stock method or (ii) the two-class method considering common stock equivalents, whichever is more dilutive. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two-class method was not applied for the twelve months ended December&nbsp;31, 2021, 2020 and 2019 as the Company’s participating securities do not have any obligation to absorb net losses. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation if their effect would be anti-dilutive.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="fact-identifier-744" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90ZXh0cmVnaW9uOjg5NjhlNzM5ZjM2MjQzMWViNjE0ODY2ODg0MDZhMGI3XzI2NTM_17f75c07-f177-4cae-8a58-5d989d57f860" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of December&nbsp;31, 2021, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tbody><tr><td style="width:1.0%"></td><td style="width:53.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i150fe7eff7ea4fdb9a21acd3372500e8_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="fact-identifier-745" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMS0xLTEtMjc3NDM_39a0808f-c9d2-42f1-991b-cbc252ad0fb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if5156f45bd4749bab08cc813bedda252_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-746" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItMy0xLTEtMjc3NDM_e76a5d14-38e6-44ad-8d7a-457737977b18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,247</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if90f693a8f7e416ba3582374b0255711_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-747" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzItNS0xLTEtMjc3NDM_2909ea05-d786-4317-b624-39325a9fa0fe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,895</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i869669607507416cbf1ba3f4f38801c2_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-748" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_08d38973-b036-4532-8535-f59d6eed6280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-749" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMS0xLTEtMjc3NDM_2cb9d910-4172-4a92-9f7e-16207187cdaa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,703</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iacaf22a440424d6bb0a69785b86d6575_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-750" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtMy0xLTEtMjc3NDM_dafa9df4-9ca2-435c-91ec-c63628a4731b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,147</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ica1ef2678e204ea598c3a695c7bf3daa_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-751" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzMtNS0xLTEtMjc3NDM_af73c356-a304-4f6e-8966-302801591b55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,236</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-752" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMS0xLTEtMjc3NDM_ffa71af8-7574-4c20-a6f8-b6c8ffb594b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,902</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-753" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtMy0xLTEtMjc3NDM_e4d017ca-379f-48ca-8788-261f3bb5852c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,394</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-754" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTUvZnJhZzo4OTY4ZTczOWYzNjI0MzFlYjYxNDg2Njg4NDA2YTBiNy90YWJsZTo1MWVhOTU0MTQwZDA0M2IzODc1MGExNzQ2YjBlNzJkZS90YWJsZXJhbmdlOjUxZWE5NTQxNDBkMDQzYjM4NzUwYTE3NDZiMGU3MmRlXzQtNS0xLTEtMjc3NDM_b16b51bc-d679-47ec-bdfd-2e0addd079a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,131</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_118"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="fact-identifier-755" continuedat="id1dda67426ed4fd1b6959c2404bbe51b" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTU_b27d7d5c-6561-442c-b226-22dd2b03cc22" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SHARE-BASED COMPENSATION</ix:nonnumeric></span></span></div><span><ix:continuation id="id1dda67426ed4fd1b6959c2404bbe51b" continuedat="i776285e607dc44d9b8d67e368ce989ca" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="fact-identifier-757" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTE_357bbcb8-85d6-41a2-a41d-b4d589ef2c05" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Consolidated Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2a2bec33068b42c392f0adee71a7e697_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-758" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMS0xLTEtMjc3NDM_337bb4a4-5e78-4570-900d-22177a44ccb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">973</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i46b84bfa887d467f8571564e41e8618e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-759" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItMy0xLTEtMjc3NDM_40131021-58fb-46ff-a77f-93bb3dc55a75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">350</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idd3279ce60c04cfdb6610631e4f95328_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-760" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzItNS0xLTEtMjc3NDM_78d72139-f29c-44b9-91d3-1908cb1ff2de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">188</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6966455303f44235a15aa41b9bdb897d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-761" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMS0xLTEtMjc3NDM_233ec184-4205-404e-b0e0-c8602953579e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,170</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie8dfe926ee5f4392a3f17922b1910370_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-762" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtMy0xLTEtMjc3NDM_bda2f461-dd85-4b3b-9e50-b93abbbd4ed9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,407</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i33db38ac6691417da69866ecf8c6be7e_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-763" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzMtNS0xLTEtMjc3NDM_cf34d716-cfe8-4db9-b7fb-075db583b612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,049</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-764" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMS0xLTEtMjc3NDM_633b37c4-85dd-4e12-9513-3bb766bdce0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,143</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-765" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtMy0xLTEtMjc3NDM_7d1a2ff3-adaa-4eae-a67d-d3e15f55c371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,757</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-766" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTo4MWMzMmNlNWMwMGI0YTJiOTE0Yjc0YTRmM2YyZDkxMS90YWJsZXJhbmdlOjgxYzMyY2U1YzAwYjRhMmI5MTRiNzRhNGYzZjJkOTExXzQtNS0xLTEtMjc3NDM_3e7ce7b9-480e-40ae-aaa3-11e79164b199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,237</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <span><ix:nonfraction unitref="shares" contextref="i3155b0a68be6497d8886c0858eccfe59_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-767" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5NTM_7f397d5d-fd56-4455-a781-aa5cf2216c07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.9</ix:nonfraction></span>&nbsp;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the “evergreen” or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company’s stockholders in May 2021, the Company’s stockholders approved an amendment to the 2014 Plan that increased by <span><ix:nonfraction unitref="shares" contextref="i9b59ed3d58ff421abae5edfb38249ce6_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-768" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5Nzc_1faa14ff-51ff-4546-a461-cb0bc6c9f11f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12</ix:nonfraction></span>&nbsp;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <span><ix:nonfraction unitref="shares" contextref="ie05ac20284034cf78dcee6454eac36b6_I20211231" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-769" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjY5OTM_36c99eb0-2bee-44a3-a63a-08abd1b2e085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.9</ix:nonfraction></span>&nbsp;million shares of common stock available for issuance under the 2014 Plan as of December&nbsp;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <span><ix:nonnumeric contextref="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="fact-identifier-770" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE2_dda0d53f-8e02-418c-9648-50b542563c11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four-year</ix:nonnumeric></span> period at the rate of <span><ix:nonfraction unitref="number" contextref="i9542ee3724344137b968a7e2f78a7249_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="fact-identifier-771" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkxMDY_e3a34e56-839b-4dd2-a02f-2cffbe2d36bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25</ix:nonfraction></span>% of the grant vesting on the first anniversary of the date of grant and <span><ix:nonfraction unitref="number" contextref="i6565370c486e4b11b00a6d3e11fa682f_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="fact-identifier-772" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjkwODk_ea415101-6e77-440a-bfbe-2274bac09b3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.25</ix:nonfraction></span>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <span><ix:nonnumeric contextref="id1cf5c75e0b64dffb52642a1682648a8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-773" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNjg5NzM_a844a8a3-b635-44d9-95e9-f0c7ef043ab1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> from the date of grant. There were approximately <span><ix:nonfraction unitref="shares" contextref="ie05ac20284034cf78dcee6454eac36b6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-774" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTYz_f608c282-7fb8-4e98-b36b-48376fbc2691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.8</ix:nonfraction></span>&nbsp;million stock options outstanding under the 2014 Plan as of December&nbsp;31, 2021.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i776285e607dc44d9b8d67e368ce989ca" continuedat="ib4c0d1a54ea24444977605acddaa9fa5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the “Retention Program”). Pursuant to the Retention Program and effective as of October 1, 2021, the Company’s non-executive employees received a combination of a cash bonus award and a one-time restricted stock unit (“RSU”) award which vests in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <span><ix:nonfraction unitref="shares" contextref="id3fee83c1a8e4b838f1b1364ca7244be_I20211231" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-776" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0ODY_5697cc46-5dcb-4e6a-95c7-7bcb2fe6d7b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of the Company’s common stock. The Company recorded an expense of $<span><ix:nonfraction unitref="usd" contextref="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-777" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1MzA3Njk_54200e50-1ab3-468c-943c-4a011f117b7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million for retention-related RSUs for the year ended December&nbsp;31, 2021. Additionally, the Company expensed $<span><ix:nonfraction unitref="usd" contextref="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="sesn:ShareBasedPaymentArrangementExpenseOnCashBonus" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-778" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTE4_f8a0cdbb-4a94-4798-bfea-e6434cfcf962" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.6</ix:nonfraction></span>&nbsp;million in relation to the cash bonus portion of the retention program.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company’s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (“PSU”) award equal to the value of approximately <span><ix:nonfraction unitref="number" contextref="i5019c429efc54a3d939b95facb6113a9_I20211231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="fact-identifier-779" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk1MTQ_84d6940c-d869-4b0f-9fd3-b45c6a765963" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">fifty</ix:nonfraction></span> percent of current base salary. Each PSU represents a contingent right to receive <span><ix:nonfraction unitref="shares" contextref="i5019c429efc54a3d939b95facb6113a9_I20211231" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-780" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzU0OTc1NTgxNzk0OTQ_d1812718-027e-4b3c-9601-09947a368e6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of the Company’s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As none of the retention milestones were met in the year ended December&nbsp;31, 2021 and achievement was deemed not probable, the Company did not record expenses for retention-related PSUs. As of December&nbsp;31, 2021, the unrecognized compensation expense for the retention-related PSUs, granted on October 1, 2021, was $<span><ix:nonfraction unitref="usd" contextref="i7f275e89a3774f7cbca3fb8965e7a354_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-781" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzNDE0_0e54b0c3-fd3f-43ee-bbe8-b8adb21be1d4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>&nbsp;million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="fact-identifier-782" continuedat="i3f3f7245d55f4e5c997ff592b6019f64" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTA1_7f0bb4b7-f92b-4b90-bb0a-134cdf78c1a2" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">A summary of the status of restricted stock units is presented below: </ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;text-align:center"><span><ix:continuation id="i3f3f7245d55f4e5c997ff592b6019f64" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.304%"><tbody><tr><td style="width:1.0%"></td><td style="width:75.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&nbsp;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i75020eb264af4e39a21665962a79801e_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="fact-identifier-784" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzEtMS0xLTEtNDk4ODc_0af45ba9-406e-4a90-85da-ed259cb407a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-785" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzItMS0xLTEtNDEyNTE_ad38eb0f-e78b-4d24-ad20-91465f17c271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,482</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="fact-identifier-786" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzMtMS0xLTEtNDEyNTE_92847b98-fede-4836-991b-512ca3b9f43e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">559</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-787" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_56772896-3e55-466f-b924-dedd6bd06979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i3950633399b7426dbfabb5690ebcde85_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-788" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTozNzM2NTM5MTY3M2Y0ZTRmYjQ4YmIwNTIzMjFhODNhOC90YWJsZXJhbmdlOjM3MzY1MzkxNjczZjRlNGZiNDhiYjA1MjMyMWE4M2E4XzQtMS0xLTEtNDEyNTE_d80264ab-c6f1-432d-8ba1-4fc5db1e7474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span></ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining contractual life of unvested RSUs and PSUs as of December 31, 2021 is <span><ix:nonnumeric contextref="i236e48ddc6a94a599dcf3205c23f5cc6_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="fact-identifier-789" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_1c50baf7-8259-4358-97fc-383961d622dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="i7817f8de6df64ad18500b0cd69c002c3_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="fact-identifier-790" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQzOTgwNDY1NTA3Njc_3d5b5c3f-0d63-4510-a5d1-3a733e187fbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.75</ix:nonnumeric></span></ix:nonnumeric></span> years. The Company did <span><ix:nonfraction unitref="shares" contextref="i30373a67e51d44d48f81e5dc9200383a_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="fact-identifier-791" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_41193f40-646d-48d3-82c4-a484608e1b8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="if99964945ffc46049f3cdcd6ac3fa481_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="fact-identifier-792" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMxNTMx_89bd10bc-200f-49ca-a17a-c27214aa05a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span>t grant restricted stock units during the years ended December 31, 2020 and 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <span><ix:nonnumeric contextref="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-793" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTY_4d6a45b1-b542-4bf2-892d-bb500b4edec8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> from the date of grant. There were approximately <span><ix:nonfraction unitref="shares" contextref="i490d1d5e48ec48a5a059c01fa7a92934_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-794" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzExNTk_6dd553a0-c5ee-402b-a919-c45d33571c02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million fully vested stock options outstanding under the 2009 Plan as of December&nbsp;31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <span><ix:nonfraction unitref="shares" contextref="if520d25ca9304b37b3cf574ce10e6659_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-795" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzIxNjU_57055c67-cc86-4818-af1c-6d59c8b43fb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.8</ix:nonfraction></span> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of December&nbsp;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="fact-identifier-796" continuedat="i6fc290ed65e546fca5fbd0f61fa139aa" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NTI_19016efd-c1b8-4ac8-8179-78e19a38ed25" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth a summary of the Company’s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the years ended December&nbsp;31, 2021, 2020 and 2019:</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ib4c0d1a54ea24444977605acddaa9fa5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><span><ix:continuation id="i6fc290ed65e546fca5fbd0f61fa139aa" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br>Contractual&nbsp;<br>Life<br>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br>Intrinsic<br>Value<br>(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-799" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMS0xLTEtMjc3NDM_4fb695d8-f96d-432b-bdb4-8116f61acbdd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,942</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-800" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtMy0xLTEtMjc3NDM_af5a338a-5672-46b1-b946-f9bc81ba9069" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.12</ix:nonfraction></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i04ad27b86d2646489f5ab053b12babde_D20180101-20181231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-801" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNS0xLTEtMjc3NDM_c1af431e-c713-46cb-b3f4-03de97517791" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.14</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707ab57c26dd479d83f5e95b7b236b54_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-802" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEtNy0xLTEtMjc3NDM_946d63df-3b2f-4a9b-8a09-1abb6ab3a5e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-803" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMS0xLTEtMjc3NDM_72c04cd1-c468-436c-934a-700911e575d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,986</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-804" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzItMy0xLTEtMjc3NDM_d3b3cf70-d72c-413e-b1c2-b5ca851d10f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="fact-identifier-805" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMS0xLTEtMjc3NDM_584c1449-a173-4e86-965c-5eb271ff6357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-806" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzMtMy0xLTEtMjc3NDM_7e0d9c39-c378-4032-af62-6152d71b3730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.10</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-807" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMS0xLTEtMjc3NDM_bb8d0f39-4f50-45f0-b2ca-e7535b38223f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,602</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-808" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzQtMy0xLTEtMjc3NDM_afa21597-1064-43d5-a903-66e7a8ed164f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.78</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-809" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMS0xLTEtMjc3NDM_66cbf305-e0ef-427c-8021-e5ec776b7e3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,236</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-810" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtMy0xLTEtMjc3NDM_b9c521cd-7545-45da-91c0-62797951edf3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.52</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-811" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNS0xLTEtMjc3NDM_b48fde18-61db-4058-8b6f-9333c5a4800b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.83</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-812" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzUtNy0xLTEtMjc3NDM_4cc96530-aa66-4f10-b59a-daf0fda028db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">358</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-813" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMS0xLTEtMjc3NDM_4b3841e4-d52f-4008-83a9-832fd0195c77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,044</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-814" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzYtMy0xLTEtMjc3NDM_16d92292-6fe3-4122-af15-7130fb390083" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.87</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="fact-identifier-815" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMS0xLTEtMjc3NDM_f2a9282c-51e0-4d92-ad77-f5ea652a117c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-816" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzctMy0xLTEtMjc3NDM_4e6c5364-1148-45b1-b441-6a965e9dd9bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.13</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="fact-identifier-817" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMS0xLTEtMjc3NDM_bc2d3678-803a-4dfb-ad69-561685710fa7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">121</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-818" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzgtMy0xLTEtMjc3NDM_c31b0853-16a8-4b93-8ee0-14860c31b5d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.04</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-819" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMS0xLTEtMjc3NDM_11066062-e3db-45ef-95bd-de78ce7a14ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,147</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-820" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktMy0xLTEtMjc3NDM_12e67679-3e50-4533-a5a8-53d867e6854d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.26</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-821" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNS0xLTEtMjc3NDM_2176f3a1-16e3-4663-8089-777ad18ae62d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.50</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-822" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzktNy0xLTEtMjc3NDM_2a51f7c8-8320-44ba-a7ef-2351ea17524e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,160</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-823" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTEtMS0xLTI3NzQz_5fbfe593-ba80-446d-898e-667aab23d766" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,273</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-824" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEwLTMtMS0xLTI3NzQz_050d040f-73e9-4af7-9aa9-65dd15e4cc3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.32</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="fact-identifier-825" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTEtMS0xLTI3NzQz_5981ec71-4c8f-43d5-9e55-50dea1c0e5f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-826" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzExLTMtMS0xLTI3NzQz_0d078480-c179-45c8-b0d7-cde184a61258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.23</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-827" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTEtMS0xLTI3NzQz_61343905-a4eb-48a5-ad99-cf11f75d7a0f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,683</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-828" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEyLTMtMS0xLTI3NzQz_22ea50e1-5302-4425-b3ab-e6fe21e5d1b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.70</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-829" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTEtMS0xLTI3NzQz_8ea95c32-8a3d-4175-810e-2295d18d848e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,703</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-830" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTMtMS0xLTI3NzQz_4a09f860-8337-45b6-9981-483726e727b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.93</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-831" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTUtMS0xLTI3NzQz_9ff0ac61-c10b-49e2-81d4-3d9062f49e70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.03</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-832" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzEzLTctMS0xLTI3NzQz_d7b14e7d-0431-4818-a98e-0fc70df2494d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-833" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTEtMS0xLTI3NzQz_48d8c939-c9cc-4f20-9a62-36b8327d683b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,562</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-834" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTMtMS0xLTI3NzQz_2aff1d20-bdb3-45da-8e13-380f8baf8d12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.65</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-835" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTUtMS0xLTI3NzQz_e89ec540-10a7-4681-bed9-7e598477d0a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.41</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="fact-identifier-836" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTphNzIyYzEyOGRiYTQ0NzZjOWU1YzE2N2M2ZTBiODU2Yi90YWJsZXJhbmdlOmE3MjJjMTI4ZGJhNDQ3NmM5ZTVjMTY3YzZlMGI4NTZiXzE0LTctMS0xLTI3NzQz_621d72b9-fdb2-4448-9ab2-22349e84cb52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-837" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzMTc3_54ef698f-abba-4e89-bb7d-fb71f8ea83ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.1</ix:nonfraction></span>&nbsp;million for the year ended 2021. The stock option related expenses were</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-838" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NDU_02263348-6907-486d-b8de-b16e19ec44fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.6</ix:nonfraction></span> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-839" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NTI_8557f087-3ae3-4b3e-a899-55b265425390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-840" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NjA_da286c26-cc58-4032-854d-74a7795db2c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively.  The RSU related expense was</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usd" contextref="i4783731a8dd54e899dde7fba10e5ff70_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-841" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc4MDIzNjY0OTQ_54200e50-1ab3-468c-943c-4a011f117b7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>&nbsp;million for the year ended December&nbsp;31, 2021. The Company did <span><ix:nonfraction unitref="usd" contextref="ia6a7749193cc45fc901d310757b0a9ff_D20200101-20201231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="fact-identifier-842" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_3db97a04-1c97-4468-a8c9-f9a48116feef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i65d8a19fb4244ecfaa96a4eff824e050_D20190101-20191231" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="fact-identifier-843" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzExNTQ0ODcyMTMzOTg3_a79266fa-2bfe-480e-8dcc-3093a85e8f0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span>t record RSU related expenses for the years ended December 31, 2020 and 2019.  As of December&nbsp;31, 2021, there was $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-844" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5Njk_c67aff2a-a40e-489d-ae65-a75a81234de9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.4</ix:nonfraction></span> million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of <span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="fact-identifier-845" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzIxOTkwMjMyNzQ5NzY_169da346-0358-46d5-b2f0-deab461a4e4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.7</ix:nonnumeric></span> years. The weighted-average grant-date fair value of stock options granted during the year ended December&nbsp;31, 2021, 2020 and 2019 were $<span><ix:nonfraction unitref="usdPerShare" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-846" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTA_969a9284-3480-41de-8c6a-403507a2648e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.16</ix:nonfraction></span></span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-847" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTQ_beb476de-a8eb-4189-8f0b-44e1d2f94987" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.56</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usdPerShare" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-848" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzEwOTk1MTE2Njk4OTg_30313e36-e370-41d6-ad0c-a8b3a2fd9b14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonfraction></span>, respectively. The total intrinsic value of stock options exercised for the years ended December&nbsp;31, 2021, 2020 and 2019 was de minimis.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="fact-identifier-849" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90ZXh0cmVnaW9uOjM4YWZlMjFlYmQ5MzQ0OGFiYmMzMDE0ZDkxZDJmZDMxXzQ5NDc_19a2bfb9-873d-4103-a765-22711de56d68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&nbsp;31, 2021, 2020 and 2019, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="fact-identifier-850" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMS0xLTEtMjc3NDM_65efe2c0-9add-42c6-944a-6828b471a122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.32</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="fact-identifier-851" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItMy0xLTEtMjc3NDM_aac145aa-6d15-47f0-b1a8-9bd22a6e3d8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.87</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="fact-identifier-852" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzItNS0xLTEtMjc3NDM_686a18d6-f807-471c-9c89-1086046fddb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.02</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="ifc1156bb975047729b334bf2e3fa2fc6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="fact-identifier-853" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMS0xLTEtMjc3NDM_2185f3ea-22f8-45c6-ae81-77a4951cfe8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.32</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i8645ab0e887d4a8bbf9664668f155fb6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="fact-identifier-854" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtMy0xLTEtMjc3NDM_61c50b18-69b6-492e-af9d-537d4c21c75c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.87</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i558d72c250fc4f3bb70e9309cb978078_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="fact-identifier-855" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzMtNS0xLTEtMjc3NDM_4400ccfa-7208-4d06-8cd7-6484d8473ec5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.02</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-856" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMS0xLTEtMjc3NDM_8ae8262e-af93-4e14-9f8e-b0f80eacdbb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-857" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtMy0xLTEtMjc3NDM_c51e0daf-bcc2-42f4-ac46-40e824f0502f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.1</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-858" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzQtNS0xLTEtMjc3NDM_0c9f6813-25a6-4e06-b3dc-6b4288c96255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-859" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMS0xLTEtMjc3NDM_ad46d9db-4f64-4db4-a568-7ae41b8394d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.9</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-860" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtMy0xLTEtMjc3NDM_c822a83e-fdad-4b87-a63e-ad694d82bab7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-861" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzUtNS0xLTEtMjc3NDM_39191ac1-e412-4e5c-afdc-94d184d17a64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.1</ix:nonfraction></span>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-862" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMS0xLTEtMjc3NDM_24708e79-e564-4aba-8461-8ed11561df42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74.6</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-863" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtMy0xLTEtMjc3NDM_62e4abfd-6f9e-419e-b0f3-491027340377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71.5</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-864" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzYtNS0xLTEtMjc3NDM_3415844d-410f-40d4-9b84-e0db664eeda2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78.1</ix:nonfraction></span>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i14caf6d5ced74f7dad57b07c2738754a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-865" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMS0xLTEtMjc3NDM_48bb6acb-62b0-4bcb-b470-110abd404332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i174948aaa72c4f719ca1b0528a6ec81d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-866" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctMy0xLTEtMjc3NDM_32887a4c-0702-4a30-afe9-b108b9c01861" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i708320e4fa4c47a9ad97a52b1558bc57_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-867" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTgvZnJhZzozOGFmZTIxZWJkOTM0NDhhYmJjMzAxNGQ5MWQyZmQzMS90YWJsZTpkYTEwMTcyYWRhZGE0ZWFmODdjMTNhNWU1NjA0OGMwNC90YWJsZXJhbmdlOmRhMTAxNzJhZGFkYTRlYWY4N2MxM2E1ZTU2MDQ4YzA0XzctNS0xLTEtMjc3NDM_98d729b7-d032-4a41-b423-79ba1ce5f540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>%</span></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_124"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="fact-identifier-868" continuedat="id037bb6e1d6f49eea4a63c5839ace616" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzI1MzU_1acd523e-d03f-4ae4-8b72-49ebc072b126" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">EMPLOYEE BENEFIT PLANS</ix:nonnumeric></span></span></div><span><ix:continuation id="id037bb6e1d6f49eea4a63c5839ace616" continuedat="i0865547a51b040c5ab940904418c632f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <span><ix:nonfraction unitref="shares" contextref="i3408800d9ca34cbc9107500cccfb1efe_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-870" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3MTI_8a2b1789-e134-492e-93d7-c1991ae1ce3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <span><ix:nonfraction unitref="shares" contextref="i19aa28ed63b64ecf8600a587af11639c_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-871" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3Mzc_f08fafb3-79e5-407a-aec4-e3b044fe6fa8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;million the number of shares of </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i0865547a51b040c5ab940904418c632f" continuedat="if7ef32e3383640afa3cba130cd0ba6d4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <span><ix:nonfraction unitref="number" contextref="i2265e9372ef14f33a95d480831dcfd36_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="fact-identifier-873" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNjA3NTQ_e9b22e89-c96d-4d10-b07f-4e4cee2c956f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the consolidated statements of changes in stockholders' equity (deficit). As of December&nbsp;31, 2021, there were <span><ix:nonfraction unitref="shares" contextref="i256cad603adc478fbe2bb635d926f6d6_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-874" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIxOTkwMjMyNTgyNzI_065af96b-282d-4303-b6cf-3ac6cb798501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;million shares of common stock available for sale under the 2014 ESPP. The Company sold a de minimis number of shares under the ESPP for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <span><ix:nonfraction unitref="number" contextref="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="fact-identifier-875" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE3MTM_e5affa62-7f28-4b8b-b2a0-b737eba59473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100</ix:nonfraction></span>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<span><ix:nonfraction unitref="usd" contextref="ife16e9d2bb9a4a999b0436f355d46b47_D20210101-20211231" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-876" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzE5MTI_8dd89fb0-95ca-4c20-8dec-e499164ff2e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,000</ix:nonfraction></span> per year. The Company contributed a de minimis amount for each of the three years ended December&nbsp;31, 2021, 2020 and 2019, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="if7ef32e3383640afa3cba130cd0ba6d4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <span><ix:nonfraction unitref="number" contextref="i0714416d3dbb41bf905d3f30d60053a9_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="fact-identifier-878" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjQvZnJhZzo2NGJiZmQ0MTI2Yzg0NjA4ODE4NGI5MTRjNWMxOGNiZS90ZXh0cmVnaW9uOjY0YmJmZDQxMjZjODQ2MDg4MTg0YjkxNGM1YzE4Y2JlXzIzMjM_935adc23-ae41-4405-878a-1d3b224b8b66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>% of eligible compensation for its Canadian-based employees to the retirement plan. The Company contributed a de minimis amount for each of the three years ended December&nbsp;31, 2021, 2020 and 2019, respectively.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_127"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="fact-identifier-879" continuedat="i9d6dfe31336d4d0cb61126d6db57e607" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDA_c1e9a30a-afbc-45ba-a0fc-60ac00ae8d67" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">INCOME TAXES </ix:nonnumeric></span></span></div><span><ix:continuation id="i9d6dfe31336d4d0cb61126d6db57e607" continuedat="ie06b98247c834fe3ac6e071b75f415cb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="fact-identifier-881" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTU_56a7f71b-5213-4c34-87e2-c41eea4cf7c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ib2b01c3a7a584c8c83ef29c8a5d2f83b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-882" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMS0xLTEtMjc3NDM_d0b88f1d-b196-40fe-b671-673259e43c64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,757</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2cc2b6152b3a498aa18f90d825cf3988_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-883" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtMy0xLTEtMjc3NDM_5a88f9f5-4570-4f81-9b4f-766d56dd0bcc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,529</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iff556de6a08542a29c8cf9c6757a93ca_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-884" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzMtNS0xLTEtMjc3NDM_fab755ec-12ab-4abb-b378-eea07439def0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,468</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i754f4ed1114d47c585642ec702c9d897_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-885" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMS0xLTEtMjc3NDM_58ac6779-1629-4b0f-bbbf-f1bc84902577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,148</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i95faf853daed44049bbacea1c98c9719_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-886" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtMy0xLTEtMjc3NDM_beb33a98-ba3f-4602-b167-6cbdb0f65479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,577</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4fac383649084445a8d938fea7593c9f_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-887" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzQtNS0xLTEtMjc3NDM_026e35c2-ef0c-456d-aa8a-121cc4502e5b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,032</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Loss Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-888" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMS0xLTEtMjc3NDM_cef87955-0aef-4804-bdb6-9df1892e6f8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,609</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-889" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtMy0xLTEtMjc3NDM_ccaf83a0-53e3-4af2-b20b-e6c0a127e290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,952</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-890" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5YmUxZmJjN2FmOTU0MDExOWEwOTA1NzM4NDY2ZjRhNC90YWJsZXJhbmdlOjliZTFmYmM3YWY5NTQwMTE5YTA5MDU3Mzg0NjZmNGE0XzUtNS0xLTEtMjc3NDM_360e8447-7a24-402a-ba82-2fa2e552165d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,500</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="fact-identifier-891" continuedat="i9dfd9a285a75457b834bbb00e1fe90e8" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NTI_b7c8d363-1535-4b96-9941-83e3f03a010a" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Company's tax benefit (provision) is comprised of the following components (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ie06b98247c834fe3ac6e071b75f415cb" continuedat="ib1263224392d42b092e54e778898fc96" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="text-align:justify"><span><ix:continuation id="i9dfd9a285a75457b834bbb00e1fe90e8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Tax Provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-894" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMS0xLTEtMjc3NDM_8a891cfb-ca83-4865-912b-34b10cba0b7f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-895" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtMy0xLTEtMjc3NDM_84fef57f-e223-4640-94f4-fc93e824732a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-896" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzMtNS0xLTEtMjc3NDM_dc5e317b-7132-4830-9d43-3c130a7280d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-897" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMS0xLTEtMjc3NDM_ddbb4f2a-2192-4625-b2e6-79c88acb4f5f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-898" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtMy0xLTEtMjc3NDM_a15318a3-23bd-4f50-8dde-134ea677e873" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-899" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzQtNS0xLTEtMjc3NDM_97d3c3ec-bbc7-471b-a125-f045072a222c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-900" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMS0xLTEtMjc3NDM_fbd78772-6c1f-416b-971e-cb6f6140baa2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">286</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-901" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtMy0xLTEtMjc3NDM_78a574d5-c94e-49f1-82bd-0d5127ecd8e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,445</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-902" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzUtNS0xLTEtMjc3NDM_d67ab485-e165-4644-b2ca-261232240b68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current (provision)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-903" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMS0xLTEtMjc3NDM_80d62ff3-6801-401b-95e6-56a2180b9197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">286</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-904" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtMy0xLTEtMjc3NDM_69758ab0-aa75-4ac2-b736-930a6d3432ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,445</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-905" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzYtNS0xLTEtMjc3NDM_12ffa86a-70b9-46b8-bb2c-9e9bc071855c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-906" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMS0xLTEtMjc3NDM_e85d1a07-2b1a-40e7-960c-931099bece97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-907" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtMy0xLTEtMjc3NDM_7d92c272-6860-401a-b32b-27ff42bf2b47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-908" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzgtNS0xLTEtMjc3NDM_30a0fd62-b98c-4923-9c95-80aefc1e8c1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-909" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMS0xLTEtMjc3NDM_8def22d1-3a63-43af-9b33-41961b439850" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-910" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktMy0xLTEtMjc3NDM_80199037-1932-431b-97d3-48ce2aa93b7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-911" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzktNS0xLTEtMjc3NDM_09f5d096-5b26-4602-990f-9878adb9c4cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-912" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTEtMS0xLTI3NzQz_7800ab6a-5beb-4011-8f34-26c4d2133a57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,559</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-913" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTMtMS0xLTI3NzQz_0e8b000e-cad0-40fa-b32e-d17ac845c983" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-914" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEwLTUtMS0xLTI3NzQz_ad773e5c-de13-429b-9399-8172e5e03333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred benefit (provision)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-915" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTEtMS0xLTI3NzQz_2b3875ee-08c2-4164-83a7-a22438219db9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,559</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-916" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTMtMS0xLTI3NzQz_36b52200-ad3e-43f9-a193-3400eea39022" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-917" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzExLTUtMS0xLTI3NzQz_1ea73fe4-96f2-4b70-951e-f743f9a2401c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 73pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Benefit (Provision) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-918" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTEtMS0xLTI3NzQz_e0747521-e657-4024-aaa4-d3f11b4f50b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,273</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-919" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTMtMS0xLTI3NzQz_c91fa86c-ec1c-4a96-a62d-d6ef59591251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,445</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-920" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTpmNGY3ZGE0NTExMDI0MzBjOTFiZGRhMDE1ZDI2NDQwYS90YWJsZXJhbmdlOmY0ZjdkYTQ1MTEwMjQzMGM5MWJkZGEwMTVkMjY0NDBhXzEzLTUtMS0xLTI3NzQz_11e4feb4-0c7f-4439-a6df-33a17d11cee9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not record current or deferred income tax or benefit for the year ended December 31, 2019.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="fact-identifier-921" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDU_d9672778-2601-45cd-bd19-4fc992eaf06d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a reconciliation of the statutory United States federal income tax rate to the Company’s effective income tax rate:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended&nbsp;December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal statutory income tax rate</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-922" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMS0xLTEtMjc3NDM_190197df-b2b5-4796-a587-5156eeb161ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-923" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItMy0xLTEtMjc3NDM_10a44062-16ba-4961-8d32-649503ad755d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-924" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzItNS0xLTEtMjc3NDM_5b062622-f62e-4d40-bcd4-41e692564b32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-925" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMS0xLTEtMjc3NDM_64ea8c05-6c46-4a0c-9014-e3c2421e68e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.9</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-926" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtMy0xLTEtMjc3NDM_25aa62fb-84b4-4e5b-95b2-254df64c596a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.2</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-927" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzMtNS0xLTEtMjc3NDM_c8db928a-0a05-47a2-a028-a4804baf3cbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="fact-identifier-928" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMS0xLTEtMjc3NDM_412fe960-fb48-4672-93c9-e0b4c6c04c54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="fact-identifier-929" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtMy0xLTEtMjc3NDM_789763d8-a001-46ba-bc4e-d3f9d094dc2a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.0</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="fact-identifier-930" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzQtNS0xLTEtMjc3NDM_aceb3015-d23f-442d-8909-e34e97f77309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option cancellations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="fact-identifier-931" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMS0xLTEtMjc3NDM_b040c9d6-6445-4847-9bea-58515b221b10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="fact-identifier-932" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtMy0xLTEtMjc3NDM_fd490530-2667-409c-a99c-4f6f468a920c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="fact-identifier-933" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzUtNS0xLTEtMjc3NDM_7e13a3fe-b8d4-45fa-bb63-8d8f1a9ae8db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="fact-identifier-934" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMS0xLTEtMjc3NDM_23135495-964d-41b8-9769-92c774615620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">178.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="fact-identifier-935" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtMy0xLTEtMjc3NDM_edbc5082-c9ea-4f5e-a469-31f611309b06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">14.4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent" scale="-2" id="fact-identifier-936" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzYtNS0xLTEtMjc3NDM_1bc2f351-1e86-4d99-bcf1-1647a83b449d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">18.0</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="fact-identifier-937" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMS0xLTEtMjc3NDM_08aa8c70-65b6-4112-a167-46196ebc9c48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="fact-identifier-938" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctMy0xLTEtMjc3NDM_3f56cc69-599a-47f9-9306-4b6c67b4f9ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" id="fact-identifier-939" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzctNS0xLTEtMjc3NDM_bcd8eef6-c4e0-48e6-a801-92437734fd73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="fact-identifier-940" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMS0xLTEtMjc3NDM_3d9bd497-1917-465b-b6fd-dac07214d9b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="fact-identifier-941" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtMy0xLTEtMjc3NDM_739adad7-61ed-48bd-9fea-3d61807d6b7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="sesn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" format="ixt:fixed-zero" scale="-2" id="fact-identifier-942" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzgtNS0xLTEtMjc3NDM_966ffbce-25db-47ff-9a20-c2e0538a53f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-943" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMS0xLTEtMjc3NDM_098685b1-a2d8-4bf9-9044-6e93e3d50e89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.8</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-944" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktMy0xLTEtMjc3NDM_a928c3c8-3c16-48d8-a249-5d81cf3c79db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.1</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-945" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzktNS0xLTEtMjc3NDM_482f0ea3-fd94-473e-9f2c-96d767bc3f24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="fact-identifier-946" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTEtMS0xLTI3NzQz_044ca513-47c0-482c-a587-6676d1755255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.3</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="fact-identifier-947" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTMtMS0xLTI3NzQz_9812ad41-03ae-4908-b4b9-fa95f5331818" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.9</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="fact-identifier-948" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEwLTUtMS0xLTI3NzQz_2aa965d7-250e-4da7-8892-319fc2cb01c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-949" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTEtMS0xLTI3NzQz_989248c7-8812-4080-9f72-2263528d9252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72.3</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-950" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTMtMS0xLTI3NzQz_5f202e7d-2276-49dd-8f72-c39963d566a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37.7</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-951" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzExLTUtMS0xLTI3NzQz_f71fb798-07df-4b5d-823f-443443cc2483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.9</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Income Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-952" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTEtMS0xLTI3NzQz_53ee16e9-0377-4aa2-b0ee-18aef786c200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">96.1</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i4a6bf5ad46314681b011a2bef9d9cb28_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-953" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTMtMS0xLTI3NzQz_b10c5702-a11d-4bff-8d9c-d6df5218944d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.9</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i3309b00cbba342bfbf23c66423bb27b9_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="fact-identifier-954" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo4N2FhODk5YWIyNGM0Zjk5OThiZDRiZGYyY2E4NTJlOC90YWJsZXJhbmdlOjg3YWE4OTlhYjI0YzRmOTk5OGJkNGJkZjJjYTg1MmU4XzEyLTUtMS0xLTI3NzQz_f0acc336-a0e3-47da-9a62-35f21a7641c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="fact-identifier-955" continuedat="i6d92ae806c3b4deeabc725e927fb8d7b" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1Mzk_02fd80eb-6420-4c13-af65-a657fac522cc" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table sets forth the tax effects of temporary differences that gave rise to significant portions of the Company's deferred tax assets and liabilities (in thousands):</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ib1263224392d42b092e54e778898fc96" continuedat="id29b3ee7b7084e5f94a0c90e8b369c3d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><span><ix:continuation id="i6d92ae806c3b4deeabc725e927fb8d7b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-958" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMS0xLTEtMjc3NDM_41874ceb-eae2-4218-a32e-95c60caec2ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,381</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-959" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtMy0xLTEtMjc3NDM_a7d387fe-ded0-4613-9eaf-9508c6834ae9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,935</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-960" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzMtNS0xLTEtMzMwNDc_899a12a1-de4a-457a-8bbd-22b898f40cca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,727</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R&amp;D credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-961" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMS0xLTEtMjc3NDM_b7b4a9c7-c67e-4116-a6d7-62dd967131d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,316</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-962" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtMy0xLTEtMjc3NDM_3574bfd8-e83a-4127-9334-abf786633bc4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,787</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-963" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzQtNS0xLTEtMzMwNDc_1ea65883-ab00-4298-b2c9-d77229592c13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,385</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-964" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMS0xLTEtMjc3NDM_c5505b89-d677-4611-a567-aa3d05d72077" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,058</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-965" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtMy0xLTEtMjc3NDM_3b5dfabf-c900-470c-907c-e1c153f8369a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,811</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-966" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzUtNS0xLTEtMzMwNDc_9407d777-17a9-4884-b13b-b6662b34c554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,464</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="fact-identifier-967" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMS0xLTEtMjc3NDM_523ffd9a-9132-4ecf-9fd1-0ee590dbf0f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">53</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="fact-identifier-968" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtMy0xLTEtMjc3NDM_ccfaca49-8352-4244-abee-a856494f80d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">70</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="sesn:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="fact-identifier-969" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzYtNS0xLTEtMzMwNDc_e43507d6-7bba-4959-b906-438f698303a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">91</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-970" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMS0xLTEtMjc3NDM_477313b8-6e45-4303-ac3d-c591d64cd756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-971" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctMy0xLTEtMjc3NDM_61ef5f1f-4b57-4b87-80ef-80b57b54767e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-972" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzctNS0xLTEtMzMwNDc_283ad6b9-8772-43f6-8e4e-a3c3bc3fe2e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-973" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMS0xLTEtMjc3NDM_fc760acb-bc0a-4e2e-9ce9-0343ed2f0a05" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,849</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-974" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtMy0xLTEtMjc3NDM_e59a37ce-2adc-4be5-9f1a-f286935dd616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,631</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-975" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzgtNS0xLTEtNTAyNzg_ffbc12e5-d8d3-4995-8a63-d9da7bd2e183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,724</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-976" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTEtMS0xLTI3NzQz_a9bac230-a183-490a-88c0-89452a0c7ec5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,969</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-977" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTMtMS0xLTI3NzQz_534be684-7626-4de0-814e-f598b3a87e02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-978" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEwLTUtMS0xLTMzMDU4_4e60731a-9274-4b17-83f6-4f0711d99018" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-979" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTEtMS0xLTI3NzQz_95d4d839-52c8-4be8-998a-141bae1b4144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,969</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-980" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTMtMS0xLTI3NzQz_ae61da26-5608-419a-aecc-3524673e7391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-981" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEyLTUtMS0xLTUwMjc4_b7ec587a-925d-4823-ae85-c8152750c983" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-982" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTEtMS0xLTI3NzQz_4665cd25-79e6-4131-8c1c-55964adfa678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71,849</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-983" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTMtMS0xLTI3NzQz_21e4ba14-f6d8-4ec5-b7f6-76ac61788979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,631</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-984" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzEzLTUtMS0xLTMzMDY3_02c21fe3-80e9-4065-9b5c-bd2680c86274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,724</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net Deferred Tax Liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-985" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTEtMS0xLTI3NzQz_eebc79b5-61c8-4657-a985-6e3e9d14de50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,969</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-986" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTMtMS0xLTI3NzQz_c464b6f9-efe6-42fe-a56d-15d368c042e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-987" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo2ZGM0NTdkNTBiZjY0NjdmYTA2ZmE2ZGE0YjRjMDRiMC90YWJsZXJhbmdlOjZkYzQ1N2Q1MGJmNjQ2N2ZhMDZmYTZkYTRiNGMwNGIwXzE0LTUtMS0xLTUwMjc4_285c2812-1ee6-4b87-a44d-3846b74a0482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,528</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of the Company's deferred tax assets, management considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOL and R&amp;D credit carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has generated NOLs since its inception, and management believes that it is more likely than not that the Company's deferred tax assets will not be realized. As a result, valuation allowances of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-988" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjQ1_ab6395b8-a28b-4d91-8256-7eb7d0fd0734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71.8</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-989" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjYz_3f12769c-e720-40dc-aace-b94e08354012" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65.6</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i4d96180f8d6e4e14983b270d1c6668aa_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-990" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzE3MDQyNDMwMjQyNjgy_5158db8a-53ee-4a3e-8ed9-1a5aec83554e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57.7</ix:nonfraction></span> million have been established as of December&nbsp;31, 2021, 2020 and 2019, respectively.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-991" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjU4MDA_1e9d7313-0f76-4413-a2dc-f7695627d438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.2</ix:nonfraction></span> million increase in the valuation allowance was attributable to the NOL for the year ended December&nbsp;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability of $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-992" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzIxOTkwMjMyNjYwNTI_cea191ea-b59d-40f3-8a5d-9faa8a503a35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.0</ix:nonfraction></span> million primarily relates to the potential future impairments or amortization associated with IPR&amp;D intangible assets, which is not deductible for tax purposes and cannot be considered as a source of income to realize deferred tax assets. As a result, the Company recorded the deferred tax liability with an offset to goodwill.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="fact-identifier-993" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzQ1NDk_4d0c8547-28ca-4a15-b648-5be74c0f54ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's NOL and R&amp;D and other credit carryforwards in the United States and Canada as of December&nbsp;31, 2021 (in millions):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Beginning in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Through</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal NOL carryforwards - indefinite</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i92b0f304a6e34b6abcd67c26db8d37c6_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-994" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzItMS0xLTEtMjc3NDM_c31aadf1-0c5c-48fd-b2a5-adb50833094d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">101.1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal NOL carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6573654cd29340309dbe2c811248a720_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-995" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzMtMS0xLTEtMjc3NDM_19f9014d-f263-4b14-9a65-acbfcad7ab22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118.9</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State NOL carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibda208642281438089144b87cd645d8d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-996" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzQtMS0xLTEtMjc3NDM_a7d1c543-85f2-4385-b0ae-5b59de8aa431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138.4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal R&amp;D credit carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ied6b0fe41f5b4f79ac97691814a89591_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-997" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzUtMS0xLTEtMjc3NDM_4b4fe745-bfab-4a63-8a9f-d277d1268af3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State R&amp;D credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia696bc1cbc724e098ee3bd580cfb8b6c_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-998" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzYtMS0xLTEtMjc3NDM_840d4a5b-2ab7-492b-967b-3108c426e2f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal non-capital loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id24bd2e4f3be4ae1b8b83df732484432_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-999" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzgtMS0xLTEtMjc3NDM_0ba1f4a2-0f92-4028-a68f-37a4c406b17e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal scientific research and experimental development<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;expense carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5bb901b4a5ff4839828a1c82f4bea528_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-1000" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzktMS0xLTEtMjc3NDM_f4154d1d-5dd4-4304-9477-f47f323d2f29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal and provincial investment tax credit carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i878819bdb7ce45d78433cd5efbbd8d27_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-1001" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90YWJsZTo5Y2I4NjZlOWRmMGI0MTcxOTk5MTVhZWE3NWQ5YTU1OC90YWJsZXJhbmdlOjljYjg2NmU5ZGYwYjQxNzE5OTkxNWFlYTc1ZDlhNTU4XzEwLTEtMS0xLTI3NzQz_75a83bcb-e450-40e8-9e1d-3e46323f406f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="id29b3ee7b7084e5f94a0c90e8b369c3d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Reform Act of 1986 (the "Act'), NOL and R&amp;D credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service, and there are similar provisions in certain state and non-US tax laws. NOL and R&amp;D credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interests of significant shareholders over a three-year period in excess of 50 percent, as defined in Sections 382 and 383 of the Internal Revenue Code, respectively. This could limit the amount of tax attributes that can be utilized to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Management completed a Section 382 study through March 31, 2016 and determined that it is more likely than not that the Company's NOL carryforwards are subject to a material limitation. Accordingly, the Company reduced its NOL carryforward by $<span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-5" name="sesn:OperatingLossCarryforwardsDecrease" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1003" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMjcvZnJhZzo4M2M2YmZmN2NjMDY0MDI5YTUzNThmNGQ0ZjY1NTRkMi90ZXh0cmVnaW9uOjgzYzZiZmY3Y2MwNjQwMjlhNTM1OGY0ZDRmNjU1NGQyXzMxMDA_1ad8ccbf-ee8a-44de-be95-eedf2d2dc2b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.8</ix:nonfraction></span> million. The Company has continued to raise additional equity capital since March 2016 but has not done any additional analysis to determine whether or not ownership changes, as defined in the Act, have occurred, which would result in additional limitations. There could be additional ownership changes in the future that could further limit the amount of NOL carryforwards that the Company can utilize. The Company has not yet conducted a study of its R&amp;D credit carryforwards. Such a study may result in an adjustment to the Company’s R&amp;D credit carryforwards; however, until a study is completed and any adjustment is known, no amount is being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s R&amp;D credit carryforwards, and, if an adjustment is required, it would be offset by an adjustment to the valuation allowance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified.</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's consolidated statements of operations. Due to NOL and R&amp;D credit carryforwards that remain unutilized, income tax returns filed in the United States, certain states within the United States and Canadian tax jurisdictions from the Company's inception through 2020 remain subject to examination by the taxing jurisdictions. There are currently no audits in process in any of the Company's tax filing jurisdictions.</span></div></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_130"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="sesn:LicenseAgreementTextBlock" id="fact-identifier-1004" continuedat="i7fe10af9fd2b46b9b3c69fdc0d909869" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE4NTUx_b4367986-203d-448d-925a-3ee61b44e866" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">LICENSE AGREEMENTS</ix:nonnumeric></span></span></div><span><ix:continuation id="i7fe10af9fd2b46b9b3c69fdc0d909869" continuedat="i1dbfe7e2606e4d6d82567aaf4bf8b568" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the “Zurich License Agreement”). These patents cover some key aspects of Vicineum. Upon the Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company became obligated to pay $<span><ix:nonfraction unitref="usd" contextref="i996be0ab5ebb4bf2948b029b33aae0b8_D20210101-20211231" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1006" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NzA_46b31acb-b551-41cd-80c9-e4b589c121f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span>&nbsp;million in a milestone payment to Zurich. The Company is also obligated to pay up to a <span><ix:nonfraction unitref="number" contextref="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="fact-identifier-1007" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NTM_45f33d60-a3f1-4a64-bb15-2e455f0a33dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4</ix:nonfraction></span>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <span><ix:nonfraction unitref="number" contextref="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="fact-identifier-1008" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2ODg_390dca06-1e02-46f7-ac3a-532899a7f600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span>% or greater, provided that the royalty rate to Zurich may not be less than <span><ix:nonfraction unitref="number" contextref="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="fact-identifier-1009" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc2NDY_7f96f067-e986-469f-a207-09bbcba12dd7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2</ix:nonfraction></span>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<span><ix:nonfraction unitref="usd" contextref="if0ef4a5edb944fbebc48ffa6d09b431c_D20210101-20211231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1010" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyNzc3MDY_1fca1d71-03f0-43d3-b25d-96df5de59886" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="i810bedfc811b413cbc1b773410810321_D20200101-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1011" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5MzA_159be6b0-12fc-4c9e-882a-c7eb53e2758c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span>&nbsp;million related to achievement of a development milestone, (the submission of the Company’s BLA with the FDA in December 2020), in the year ended December 31, 2021 and 2020, respectively, and a regulatory milestone, (the Company’s receipt of the CRL from the FDA in August 2021), in the twelve months ended December&nbsp;31, 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the “Micromet License Agreement”). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of December&nbsp;31, 2021, the Company may be obligated to pay up to €<span><ix:nonfraction unitref="eur" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1012" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODI5ODk_91bada3f-85b0-4bb1-a883-3395c6570f91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.4</ix:nonfraction></span>&nbsp;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<span><ix:nonfraction unitref="usd" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1013" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NzY_ef474ea3-46a2-441b-9387-f6bf8cae4e08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.7</ix:nonfraction></span>&nbsp;million at exchange rates in effect on December&nbsp;31, 2021). The Company is also required to pay up to a </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i1dbfe7e2606e4d6d82567aaf4bf8b568" continuedat="i4e7fcb7d37fb49a7a80e55ddc96cde95" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonfraction unitref="number" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="fact-identifier-1015" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0Mjc_34644c48-842d-4727-b892-ab0ddb8c0cb5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.5</ix:nonfraction></span>% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <span><ix:nonfraction unitref="number" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="fact-identifier-1016" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MTY_cbd306f9-7547-4f23-9930-d2f2b1557ee9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of €<span><ix:nonfraction unitref="eur" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1017" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODg0MDE_553a1f9c-cfc5-4b5b-82a1-355703d884db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000</ix:nonfraction></span> (approximately $<span><ix:nonfraction unitref="usd" contextref="ica6cc9583f244915a31026b7fa7a188c_D20210101-20211231" decimals="0" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1018" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzEwOTk1MTE3MDk5NjM_7b576a14-f2db-4230-a5d5-a031f245fe0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">56,625</ix:nonfraction></span> at exchange rates in effect as of December&nbsp;31, 2021), which can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of €<span><ix:nonfraction unitref="eur" contextref="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1019" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODM5OTU_c94339fd-ea86-4eef-ad34-e707bf3e0cb3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.7</ix:nonfraction></span>&nbsp;million ($<span><ix:nonfraction unitref="usd" contextref="ibb69dbf3ad09468b83efb94fed8f18ec_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1020" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQwMDA_9e9a313e-9350-4c9b-911a-d523c14b02ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span>&nbsp;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of €<span><ix:nonfraction unitref="eur" contextref="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1021" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyMjI_40612604-2ac5-4d7b-9d43-fa6ffa2c521f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.5</ix:nonfraction></span>&nbsp;million ($<span><ix:nonfraction unitref="usd" contextref="i83b573f3cf624b3b8f276a6430373f72_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1022" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODQyNDE_5da66ef8-7f45-47bb-8b32-19762fdc83a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.6</ix:nonfraction></span>&nbsp;million) related to the submission of the MAA to the EMA for Vysyneum™ in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the “XOMA License Agreement”). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $<span><ix:nonfraction unitref="usd" contextref="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1023" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NTM_3e694845-ac2f-4247-a3b1-ab579932aa05" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.25</ix:nonfraction></span>&nbsp;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum’s clinical development pathway. The Company is also required to pay a <span><ix:nonfraction unitref="number" contextref="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="fact-identifier-1024" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4NzM_8bfaec35-cdf7-4363-9107-96c156bc28af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.5</ix:nonfraction></span>% royalty on the net sales for products incorporating XOMA’s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <span><ix:nonfraction unitref="number" contextref="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="fact-identifier-1025" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4OTQ_f12511a0-b228-401f-9391-52c20ce22364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.75</ix:nonfraction></span>% of net sales. In addition, the foregoing royalty rates are reduced by <span><ix:nonfraction unitref="number" contextref="i7e35e96c504045f9b37880d11d241235_D20210101-20211231" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="fact-identifier-1026" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMyODA4ODM_049458ad-37f4-49a4-b5e8-7665b102b1ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the “Roche License Agreement”), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company’s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (“Roche Licensed Product”) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<span><ix:nonfraction unitref="usd" contextref="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1027" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM2ODI_f8eee220-75c9-4a27-81ef-170af996ad4b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.5</ix:nonfraction></span>&nbsp;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<span><ix:nonfraction unitref="usd" contextref="i14ef18e6c97b4c49ab065b69c27b725c_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAdditionalUpFrontFee" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1028" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4MjU_fabeb4df-7636-4d63-a722-adcb141a3065" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">262.5</ix:nonfraction></span>&nbsp;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<span><ix:nonfraction unitref="usd" contextref="i7c28bbf66e0b4945bbdff22096e98ec1_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1029" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3MTE_7a252c73-f3ff-44db-a1c2-8d7006b9c5d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">197.5</ix:nonfraction></span>&nbsp;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<span><ix:nonfraction unitref="usd" contextref="i53830883489044f7a20fd0f2afe3ada7_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1030" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3NDE_ffc96ffa-a69c-4ff0-8d8c-4c468ef8612b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">72.5</ix:nonfraction></span>&nbsp;million in development milestones, the next of which is $<span><ix:nonfraction unitref="usd" contextref="i536ac10f94b7496ebcf21cf333f739f3_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1031" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTY2_0ca4358e-e936-4824-a0ec-e81d2cc1a78e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonfraction></span>&nbsp;million for initiation of the first Phase III clinical trial, (ii) $<span><ix:nonfraction unitref="usd" contextref="i36fc4d06bbde4724b5f3f5d605df0dda_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1032" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM3Njg_7a54c76d-77d0-48b3-bee2-21e200cc783d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>&nbsp;million in regulatory milestones and (iii) $<span><ix:nonfraction unitref="usd" contextref="ibf1e9a4c5180446d85e2e5552350fe42_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1033" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4NTM_c3754d4f-581b-4efc-a62f-47471ace49c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75</ix:nonfraction></span>&nbsp;million in commercialization milestones. Additional amounts of up to $<span><ix:nonfraction unitref="usd" contextref="i672850f3381947678ce8bad19d353cfe_D20210101-20211231" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1034" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzM4NDgyOTA3NjQ2Mzk_1d9ebcd6-a6d7-418f-b633-c36529488477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">65</ix:nonfraction></span>&nbsp;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $<span><ix:nonfraction unitref="usd" contextref="i34be4d2750144c28965180b21ad35c2c_D20160901-20160930" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1035" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM4ODA_3bc8218c-3ed1-48ef-9a1c-e5bda87f81fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">22.5</ix:nonfraction></span>&nbsp;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $<span><ix:nonfraction unitref="usd" contextref="i58f3a5e587554717a5b2e59570cb1b71_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1036" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTc5_5a5e683b-7f7c-4fd2-8b96-ab5a9e55ed1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under ASC 606 and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $<span><ix:nonfraction unitref="usd" contextref="i58f3a5e587554717a5b2e59570cb1b71_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1037" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMTky_d32400c9-510e-481e-9707-846d09e54e0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million with payment terms of <span><ix:nonnumeric contextref="i592275577a9d4f158b7f51ca29978045_D20210101-20211231" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="fact-identifier-1038" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjA3_d008f4a7-2870-47ea-84bc-43dab66ff329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $<span><ix:nonfraction unitref="usd" contextref="i695006bd273747aeb95e43b893e8b867_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1039" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjEz_c5caa3f9-de7f-45c5-9f78-553872bb3834" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20</ix:nonfraction></span>&nbsp;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<span><ix:nonfraction unitref="usd" contextref="i66e168c88e8245ab9cd320085573e00f_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1040" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjI2_2d6ef542-d325-488f-a8df-f4573102205b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20</ix:nonfraction></span>&nbsp;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <span><ix:nonfraction unitref="number" contextref="iced271cdb5d7466d9c7c148965459481_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-1041" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5MzQ_f7c7ca7e-d344-4cb2-944e-4ae2c7d9e5b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.5</ix:nonfraction></span>% to <span><ix:nonfraction unitref="number" contextref="i013a145bc60a457a851dd9b22eab7d0b_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-1042" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5Mjk_74a8684e-bd01-40b9-8799-5e7fee26fe59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15</ix:nonfraction></span>% of net sales of potential future products containing EBI-031 and up to <span><ix:nonfraction unitref="number" contextref="id8f7872b3f9441f786d65989d956951c_I20211231" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="fact-identifier-1043" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMDEwMjA_90106d6a-c665-46a4-ad9e-c35113548237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% of these rates for net </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i4e7fcb7d37fb49a7a80e55ddc96cde95" continuedat="ia7127aa114fb4593aba5377323c48b95" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for <span><ix:nonfraction unitref="period" contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="INF" name="sesn:LicenseAgreementOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-1045" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjQ0_93bb2f11-7a09-42c2-b583-4513ca585c9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">two</ix:nonfraction></span> “option periods” during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (“Initiation”) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<span><ix:nonfraction unitref="usd" contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1046" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTM5NTg_3f71932f-22b9-4526-981f-5e332c251f30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">135</ix:nonfraction></span>&nbsp;million within <span><ix:nonnumeric contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="fact-identifier-1047" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjUx_b3c7ede6-6383-4c4d-b7f7-8daad62b1e27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within <span><ix:nonnumeric contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="fact-identifier-1048" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjYw_242c3d74-1e19-4cca-8266-b82a758863d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days after Roche’s exercise of such buy-out option and receipt of an invoice from the Company, $<span><ix:nonfraction unitref="usd" contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1049" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMzA_1a5643bf-06b9-4f67-a666-1964506b79e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">265</ix:nonfraction></span>&nbsp;million, which amount would be reduced to $<span><ix:nonfraction unitref="usd" contextref="i46b37ca4516a45e3b9c2e2e6dd1b7459_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1050" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwMDM_b404ac80-37e0-409e-8eb7-fccf4ecd4c2a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">220</ix:nonfraction></span>&nbsp;million if none of the Company’s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the “Qilu License Agreement”) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the “Qilu Licensed Product”) for the treatment of NMIBC and other types of cancer (the “Field”) in China, Hong Kong, Macau and Taiwan ("Greater China”). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA”) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<span><ix:nonfraction unitref="usd" contextref="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1051" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwNTY_b2b2ec78-fcb7-4c4b-9075-bd999cfa042f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;million, and milestone payments totaling up to $<span><ix:nonfraction unitref="usd" contextref="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1052" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwODE_d340b8dc-2ba0-46cb-a41b-55e2bac12ae5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">23</ix:nonfraction></span>&nbsp;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <span><ix:nonfraction unitref="number" contextref="icc8b3796e2c04d1c97f36d22c54d2fa0_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="fact-identifier-1053" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQwOTg_59723fe1-4ba2-4974-a0bf-6448075ded86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12</ix:nonfraction></span>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the “Royalty Terms”). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="ia7127aa114fb4593aba5377323c48b95" continuedat="i1895afb208f44db1b944149d86e034f5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party’s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606"), which was adopted effective January 1, 2018. In 2020, the initial transaction price was estimated to be $<span><ix:nonfraction unitref="usd" contextref="ic253a6e3f3ea4d2085234df3e59a15d4_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1055" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxMTc_262e8abf-7d74-4d9f-8e3a-5b4a2fde86c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;million and was based on the up-front fixed consideration of $<span><ix:nonfraction unitref="usd" contextref="i3854b11b1f004bb585ab8a3ed3e68622_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1056" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNDQ_e2d6b05c-2e04-4948-a9f3-e25d67a5e374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span>&nbsp;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $<span><ix:nonfraction unitref="usd" contextref="i028e8f65759541db8dc7760918e71d52_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1057" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQxNzE_0dfaecb2-6764-4ece-b2b7-c2871e090f2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;million of the total $<span><ix:nonfraction unitref="usd" contextref="i028e8f65759541db8dc7760918e71d52_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1058" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMDA_77615bbd-a7e0-4abf-bd69-1f3a942be962" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;million transaction price was considered earned and the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i77d8a2af6cca4ab8b80ffdc3f2434161_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1059" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyMjk_daa2a2d4-348c-4c9d-8ab8-631268a96f18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span>&nbsp;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<span><ix:nonfraction unitref="usd" contextref="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-6" name="sesn:BusinessCombinationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1060" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyODA_29fd2ff7-0b6c-4626-b08b-deacdbe2d1c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span>&nbsp;million milestone payment from Qilu, the first milestone payment out of the $<span><ix:nonfraction unitref="usd" contextref="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-6" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1061" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQyNTY_0b8eab48-f015-4f46-8b49-8262b2aadc4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">23</ix:nonfraction></span>&nbsp;million in potential milestone payments. The Company recorded $<span><ix:nonfraction unitref="usd" contextref="if2ba6584f3c64704a8ac1e4656d7dead_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1062" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzMDU_10a7a7b6-125c-4ae9-be9b-e5e7a90abc2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.8</ix:nonfraction></span>&nbsp;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<span><ix:nonfraction unitref="usd" contextref="i818c0861bdb74095a88cb8cfcda94efa_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1063" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzE3MDQyNDMwMzEzMjc5_d085c774-fa87-4821-ac81-c17aeaa4d9d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.9</ix:nonfraction></span>&nbsp;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<span><ix:nonfraction unitref="usd" contextref="i3fb1bcb7e3874976b1397e8d0fc3b469_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1064" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQzODQ_3f68c78a-7438-4474-9b35-4ad312459c38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>&nbsp;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<span><ix:nonfraction unitref="usd" contextref="i1a168b0aa4c647e1997b38ac0934768d_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1065" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0MDk_8b590708-a3cd-4c21-be67-4305183b45cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million as of December 31, 2020 and was based on <span><ix:nonfraction unitref="number" contextref="i1a168b0aa4c647e1997b38ac0934768d_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="fact-identifier-1066" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0Mjc_9d02c0ad-b085-45fc-95ee-ee39324c1c47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($<span><ix:nonfraction unitref="usd" contextref="i5b79f0dfcd8c4696998a76eff4413ecf_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1067" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzExNTQ0ODcyMTg1NDU2_58c700ad-b375-438e-9f02-93a674990f5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as long-term deferred revenue as of December 31, 2021. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<span><ix:nonfraction unitref="usd" contextref="i0ebdbf98df0844558086fd4461793449_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1068" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0NDU_cebbb13b-dabd-494d-b766-78cd7c9b20a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered.  As of December&nbsp;31, 2021, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.  </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with EİP Eczacıbaşı İlaç Pazarlama A.Ş., (“EIP”) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the “EIP License Agreement). Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $<span><ix:nonfraction unitref="usd" contextref="i34d384e7e18448558f3f9903191a5912_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1069" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ0ODg_c4a654d6-5fda-4377-8a2f-29c943e194c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span>&nbsp;million. The Company is in the process of amending the license agreement to defer payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><ix:continuation id="i1895afb208f44db1b944149d86e034f5" continuedat="ib94d1beaddd54be7963be10e33b83014" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company is eligible to receive additional regulatory and commercial milestone payments of $<span><ix:nonfraction unitref="usd" contextref="i149c70a89b234c42b784e047bac76480_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1071" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MTU_d9dfb2c3-07ea-4102-982a-4a7735b93d36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span>&nbsp;million and is also entitled to receive a <span><ix:nonfraction unitref="number" contextref="i544162f98c2149b991bf17fc6d17e544_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="fact-identifier-1072" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzAvZnJhZzphZDdhZTBjN2M5NmE0Zjk0YjMyMTYyN2VmYjRkYTdmNi90ZXh0cmVnaW9uOmFkN2FlMGM3Yzk2YTRmOTRiMzIxNjI3ZWZiNGRhN2Y2XzIxOTkwMjMzMTQ1MzM_a99e27e9-904f-4d40-9413-d2e5a9cd07ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonfraction></span>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of December&nbsp;31, 2021, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&nbsp;31, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the upfront payment is subject to a refund if certain regulatory approvals in the US are not obtained. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of December&nbsp;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ib94d1beaddd54be7963be10e33b83014" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_133"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="fact-identifier-1074" continuedat="ia08581bf0e1d43ae82d702ea53379b8b" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzE0NTE_7fc057fb-ea4e-42b5-93c7-77cf6deb561d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">RELATED-PARTY TRANSACTIONS</ix:nonnumeric></span></span></div><span><ix:continuation id="ia08581bf0e1d43ae82d702ea53379b8b" continuedat="ieb703b59db7d4ba8a8707b7ce014a0a7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facility in Winnipeg, Manitoba from an affiliate of Leslie L. Dan, a director of the Company until his retirement in July 2019. For each of the years ended December&nbsp;31, 2021, 2020 and 2019, the Company paid $<span><ix:nonfraction unitref="usd" contextref="i289b399c61c441cdbd3ee11d6f7a9ff8_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1076" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_2d4482c9-cc3a-4f5f-b2d0-24a6b7fb81e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="ida0bc936be4b4983b3016c269a7787db_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1077" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_4969f2d5-e078-4922-a550-b6e6a0c2d61f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i9df892e9ea5a49b48fabbf78cf8b871c_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1078" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzI0Nw_f15229b3-cb11-4f07-82e7-0fbcd985751f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.3</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> million of rent, which includes the related operating expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays fees under an intellectual property license agreement to Protoden Technologies Inc. ("Protoden"), a company owned by Clairmark, an affiliate of Mr. Dan. Pursuant to the agreement, the Company has an exclusive, perpetual, irrevocable and non-royalty bearing license, with the right to sublicense, to certain patents and technology to make, use and sell products that utilize such patents and technology. The annual fee is $<span><ix:nonfraction unitref="usd" contextref="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="fact-identifier-1079" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzc0NA_48098db3-4e0f-4e92-b434-ed07703f9957" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million. Upon expiration of the term on December 31, 2024, the licenses granted to the Company will require no further payments to Protoden. For each of the years ended December&nbsp;31, 2021, 2020 and 2019, the Company paid $<span><ix:nonfraction unitref="usd" contextref="i317cc4f85ef44601ac4b99a2c1b802ad_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="fact-identifier-1080" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_2b9f8af3-3047-4374-bef5-2ea7eca26be3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="ic637e93aa17d4ad6a3c0e4e24f9685b5_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="fact-identifier-1081" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_6230ad3d-60dd-42e6-bf4c-1dbb7201dbc7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i41763d631ab94cc3954f93769f016e8a_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="fact-identifier-1082" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzMvZnJhZzplODE2NzI1YjVjNmU0MDc0YTgwM2Y0NTEwOGQzMzkwZi90ZXh0cmVnaW9uOmU4MTY3MjViNWM2ZTQwNzRhODAzZjQ1MTA4ZDMzOTBmXzk0OA_fb358299-49eb-4235-9233-9a3958acedd9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> million under this license agreement.</span></div></ix:continuation></span><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ieb703b59db7d4ba8a8707b7ce014a0a7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Due to his retirement in July 2019, Mr. Dan was not deemed a related party during the twelve-month period ended December 31, 2020 and 2021; as such, only payments made through the nine month period ended September 30, 2019 are considered payments to a related party.</ix:continuation></span> </span></div><div id="if1c5a63ddb584a0db5ee835d7440b255_1190"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="fact-identifier-1084" continuedat="i5777f489b9f64a83a2f24277dcef9ccf" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwMw_6abdc339-b097-4a80-8157-1e37aa4e9629" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonnumeric></span></span></div><span><ix:continuation id="i5777f489b9f64a83a2f24277dcef9ccf" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the “Restructuring Plan”). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restructuring Plan included a reduction in the Company’s workforce by <span><ix:nonfraction unitref="position" contextref="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="fact-identifier-1086" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTM3_547cb409-6bab-4767-a05e-0ddcdd2467be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18</ix:nonfraction></span> positions (or approximately <span><ix:nonfraction unitref="number" contextref="i5cd3b072545f4d7e9f5c483dd4274332_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="fact-identifier-1087" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xMDk5NTExNjI4OTMy_3c663bda-18b4-404c-84bd-7315b29ea92c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35</ix:nonfraction></span>% of the Company’s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="fact-identifier-1088" continuedat="i9a14f078717e454396a0f126fdb64397" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGV4dHJlZ2lvbjoyMTRmMmQ3ZjEyNWQ0ZTMwOTdmNjM5ZWE3ZjMzNTVlNl8xNzA0MjQzMDIzMTgwNA_d3572ad2-a300-4d59-bc3e-edc42f35e014" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following is a summary of accrued restructuring costs related to the Restructuring Plan:</ix:nonnumeric></span></span></div><div><span><ix:continuation id="i9a14f078717e454396a0f126fdb64397" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits costs</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id7ea168da84a45ce835565576cb8541c_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-1090" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8yLTEtMS0xLTMxODAy_1a1efc48-e788-4410-9c6e-470af48bae7f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,792</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract termination costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib3a50664b1a24d31b0f259776c76eef4_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-1091" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV8zLTEtMS0xLTMxODAy_ea1690b4-ab92-447a-a532-c1bbc7fcdb4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,736</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i77fcf675f74847e4ab66d5e451e81521_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="fact-identifier-1092" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV80LTEtMS0xLTMxODAy_7782ab3f-9597-4336-b749-d9a7919117b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-1093" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV81LTEtMS0xLTMxODAy_67d91dff-b38c-460a-84c7-fbcc6a64d01e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,528</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-1094" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV82LTEtMS0xLTMxODAy_9a18663b-4742-416d-a1f5-27beb1f3f5ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,031</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&nbsp;31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8984440967a74e3abe0feaafbe79712a_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-1095" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMTkwL2ZyYWc6MjE0ZjJkN2YxMjVkNGUzMDk3ZjYzOWVhN2YzMzU1ZTYvdGFibGU6NTc3YjYwZGI3M2RiNDBkNDliZjAxMDUyNzQ1NTIzZTkvdGFibGVyYW5nZTo1NzdiNjBkYjczZGI0MGQ0OWJmMDEwNTI3NDU1MjNlOV83LTEtMS0xLTMxODAy_2caf5d69-2d96-44bb-9867-a778112c30d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,497</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs related to the Restructuring Plan were recorded in operating expenses in the Company’s Consolidated Statements of Operations and Comprehensive Loss in the year ended December&nbsp;31, 2021. The Company expects that substantially all of the accrued restructuring costs as of December&nbsp;31, 2021 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div></ix:continuation></span><div id="if1c5a63ddb584a0db5ee835d7440b255_136"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i25915aa2d70c431b82e444bfa97d9d2d_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="fact-identifier-1096" continuedat="i2b7d3841246c49c2ad95b23b87474a50" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzIxMjc_0b9f0752-f471-4c15-bc57-2d175dcb74be" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SUBSEQUENT EVENTS</ix:nonnumeric></span></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br></span></div></div><span><ix:continuation id="i2b7d3841246c49c2ad95b23b87474a50" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, the FDA granted the Company’s request for a Type C Meeting (“Type C Meeting”) to discuss the study protocol for an additional Phase 3 clinical trial that the Company plans to conduct for potential resubmission of a BLA for Vicineum™ for the treatment of BCG-unresponsive NMIBC. The Type C Meeting has been scheduled for March 28, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, the Company received written notice (the “Notice”) from Nasdaq indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice has no effect at this time on the listing of the Company’s common stock (the “Common Stock”), which continues to trade on The Nasdaq Global Market under the symbol “SESN”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is not in compliance by July 25, 2022, the Company may qualify for a second 180 calendar day compliance period. If the Company does not qualify for, or fail to regain, compliance during the second compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to actively monitor the closing bid price of the Company’s common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously announced, the Company’s Board of Directors (the “Board”) initiated an independent internal review conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the “Review”).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Review took place over the course of <span><ix:nonnumeric contextref="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" name="sesn:ReviewPeriod" format="ixt-sec:durwordsen" id="fact-identifier-1098" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTI1_fc9f9379-7ad4-469f-92d0-49252a2fb463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">five months</ix:nonnumeric></span>, involved full cooperation from the Company’s management team, a review of more than <span><ix:nonfraction unitref="document" contextref="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" decimals="INF" name="sesn:NumberOfDocumentsReviewed" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1099" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTMx_f220db26-35c5-4df5-b9af-50c30648ca4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">600,000</ix:nonfraction></span> documents, and <span><ix:nonfraction unitref="interview" contextref="i3f510aea6f994552bf507f53bf801c46_D20220101-20220228" decimals="INF" name="sesn:NumberOfInterviews" scale="0" id="fact-identifier-1100" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVhNjNkZGI1ODRhMGRiNWVlODM1ZDc0NDBiMjU1L3NlYzpmMWM1YTYzZGRiNTg0YTBkYjVlZTgzNWQ3NDQwYjI1NV8xMzYvZnJhZzo3MDI1NzgwNjcwOGE0MjczOWU1NzI1MTQ2NmEwNzM4Yy90ZXh0cmVnaW9uOjcwMjU3ODA2NzA4YTQyNzM5ZTU3MjUxNDY2YTA3MzhjXzE3MDQyNDMwMjc4MTQw_a13451ad-b933-49ed-8664-a08dbfc39f46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">39</ix:nonfraction></span> interviews of current and former employees and consultants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is now complete.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Review, the Board continues to fully support the Company’s current management team and believes no changes or amendments relating to the Company’s prior disclosures to the SEC or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to work cooperatively with the FDA in preparing for an additional Phase 3 clinical trial for Vicineum.</span></div></ix:continuation></span><div style="margin-bottom:6pt;text-align:justify"><span><br></span></div><div style="text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div>

</body>
</html>